0001564590-23-002038 | 10-K | XBRL Viewer | Community Health Systems INC

Print Document View Excel Document

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2022	Feb. 10, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Entity File Number	001-15925
Entity Registrant Name	COMMUNITY HEALTH SYSTEMS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-3893191
Entity Address, Address Line One	4000 Meridian Boulevard
Entity Address, City or Town	Franklin
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37067
City Area Code	615
Local Phone Number	465-7000
Title of 12(b) Security	Common Stock, $.01 par value
Trading Symbol	CYH
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		134,704,003
Entity Central Index Key	0001108109
Amendment Flag	false
Entity Public Float			$ 466,207,299
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
ICFR Auditor Attestation Flag	true
Auditor Firm ID	34
Auditor Name	Deloitte & Touche LLP
Auditor Location	Nashville, Tennessee
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Certain information required for Part III of this annual report is incorporated by reference to portions of the Registrant’s definitive proxy statement for its 2023 annual meeting of stockholders to be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant’s fiscal year ended December 31, 2022.

Consolidated Statements of Income - USD ($) $ in Millions	12 Months Ended
Consolidated Statements of Income - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net operating revenues	$ 12,211	$ 12,368	$ 11,789
Operating costs and expenses:
Salaries and benefits	5,330	5,242	5,411
Supplies	1,975	2,042	1,963
Other operating expenses	3,336	2,958	2,957
Lease cost and rent	317	308	327
Pandemic relief funds	(173)	(148)	(601)
Depreciation and amortization	534	540	558
Impairment and (gain) loss on sale of businesses, net	71	24	48
Total operating costs and expenses	11,390	10,966	10,663
Income from operations	821	1,402	1,126
Interest expense, net of interest income of $2 in 2022 and $3 in both 2021 and 2020	858	885	1,031
(Gain) loss from early extinguishment of debt	(253)	79	(317)
Gain on sale of equity interests in Macon Healthcare, LLC		(39)
Gain from CoreTrust transaction	(119)
Equity in earnings of unconsolidated affiliates	(14)	(22)	(10)
Income before income taxes	349	499	422
Provision for (benefit from) income taxes	170	131	(185)
Net income	179	368	607
Less: Net income attributable to noncontrolling interests	133	138	96
Net income attributable to Community Health Systems, Inc. stockholders	$ 46	$ 230	$ 511
Earnings per share attributable to Community Health Systems,Inc. stockholders:
Basic	$ 0.35	$ 1.82	$ 4.43
Diluted	$ 0.35	$ 1.76	$ 4.39
Weighted-average number of shares outstanding:
Basic	128,808,387	126,754,852	115,491,022
Diluted	130,060,319	130,597,410	116,544,561

Consolidated Statements of Income (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Interest income	$ 2	$ 3	$ 3

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 179	$ 368	$ 607
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax of $0 for the years ended December 31, 2022, 2021 and 2020			(1)
Net change in fair value of available-for-sale debt securities, net of tax of $5 for the year ended December 31, 2022 and $1 for the years ended December 31, 2021 and 2020	(17)	(5)	4
Amortization and recognition of unrecognized pension cost components, net of tax of $3, $0 and $2 for the years ended December 31, 2022, 2021 and 2020, respectively	10	3	(7)
Other comprehensive loss	(7)	(2)	(4)
Comprehensive income	172	366	603
Less: Comprehensive income attributable to noncontrolling interests	133	138	96
Comprehensive income attributable to Community Health Systems, Inc. stockholders	$ 39	$ 228	$ 507

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement Of Income And Comprehensive Income [Abstract]
Net change in fair value of interest rate swaps, tax	$ 0	$ 0	$ 0
Net change in fair value available-for-sale debt securities, tax	5	1	1
Amortization and recognition of unrecognized pension cost components, tax	$ 3	$ 0	$ 2

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 118	$ 507
Patient accounts receivable	2,040	2,062
Supplies	353	355
Prepaid income taxes	99	94
Prepaid expenses and taxes	237	192
Other current assets	235	269
Total current assets	3,082	3,479
Property and equipment
Land and improvements	497	534
Buildings and improvements	6,038	6,050
Equipment and fixtures	3,104	3,173
Property and equipment	9,639	9,757
Less accumulated depreciation and amortization	(4,274)	(4,204)
Property and equipment, net	5,365	5,553
Goodwill	4,166	4,219
Deferred income taxes	49	53
Other assets, net of accumulated amortization of $1,392 and $1,216 at December 31, 2022 and 2021, respectively	2,007	1,913
Total assets	14,669	15,217
Current liabilities:
Current maturities of long-term debt	21	31
Current operating lease liabilities	148	147
Accounts payable	773	830
Accrued liabilities:
Employee compensation	637	655
Accrued interest	189	225
Other	418	476
Total current liabilities	2,186	2,364
Long-term debt	11,614	12,109
Deferred income taxes	354	192
Long-term operating lease liabilities	605	535
Other long-term liabilities	644	827
Total liabilities	15,403	16,027
Redeemable noncontrolling interests in equity of consolidated subsidiaries	541	480
Commitments and contingencies (Note 15)
Community Health Systems, Inc. stockholders’ deficit:
Preferred stock, $.01 par value per share, 100,000,000 shares authorized; none issued
Common stock, $.01 par value per share, 300,000,000 shares authorized; 134,703,717 shares issued and outstanding at December 31, 2022, and 132,146,282 shares issued and outstanding at December 31, 2021	1	1
Additional paid-in capital	2,084	2,118
Accumulated other comprehensive loss	(21)	(14)
Accumulated deficit	(3,431)	(3,477)
Total Community Health Systems, Inc. stockholders’ deficit	(1,367)	(1,372)
Noncontrolling interests in equity of consolidated subsidiaries	92	82
Total stockholders’ deficit	(1,275)	(1,290)
Total liabilities and stockholders’ deficit	$ 14,669	$ 15,217

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Accumulated amortization	$ 1,392	$ 1,216
Preferred stock, par value per share	$ 0.01	$ 0.01
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$ 0.01	$ 0.01
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	134,703,717	132,146,282
Common stock, shares outstanding	134,703,717	132,146,282

Consolidated Statements of Stockholders' Deficit - USD ($) $ in Millions	Total	Redeemable Noncontrolling Interests (Non- Equity)	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Noncontrolling Interest
Equity, beginning balance at Dec. 31, 2019	$ (2,141)		$ 1	$ 2,008	$ (9)	$ (4,218)	$ 77
Redeemable Noncontrolling Interests, beginning balance at Dec. 31, 2019		$ 502
Shares, outstanding, beginning balance at Dec. 31, 2019			117,822,631
Comprehensive income (loss)	545				(4)	511	38
Comprehensive income (loss) attributable to redeemable noncontrolling interest		58
Contributions from noncontrolling interests	15						15
Distributions to noncontrolling interests	(34)						(34)
Distributions to redeemable noncontrolling interests		(82)
Purchase of subsidiary shares from noncontrolling interests	3	(4)		3
Other reclassifications of noncontrolling interests	(9)						(9)
Other reclassifications of redeemable noncontrolling interests		9
Disposition of less-than-wholly owned hospital		(14)
Adjustment to redemption value of redeemable noncontrolling interests	(15)	15		(15)
Cancellation of restricted stock for tax withholdings on vested shares	(1)			(1)
Cancellation of restricted stock for tax withholdings on vested shares, shares			(288,859)
Issuance of common stock in connection with the exercise of stock options, shares			18,166
Income tax payable increase from vesting of restricted shares			333
Section 3(a)(9) exchange	86			86
Section 3(a)(9) exchange, shares			10,000,000
Stock-based compensation	13			13
Stock-based compensation, shares			2,059,846
Equity, ending balance at Dec. 31, 2020	(1,538)		$ 1	2,094	(13)	(3,707)	87
Redeemable Noncontrolling Interests, ending balance at Dec. 31, 2020		484
Shares, outstanding, ending balance at Dec. 31, 2020			129,612,117
Comprehensive income (loss)	266				(2)	230	38
Comprehensive income (loss) attributable to redeemable noncontrolling interest		100
Contributions from redeemable noncontrolling interests		1
Distributions to noncontrolling interests	(39)						(39)
Distributions to redeemable noncontrolling interests		(82)
Purchase of subsidiary shares from noncontrolling interests	13	(32)		17			(4)
Other reclassifications of noncontrolling interests	1				1
Other reclassifications of redeemable noncontrolling interests		1
Noncontrolling interests in acquired entity		2
Disposition of less-than-wholly owned hospital		(7)
Adjustment to redemption value of redeemable noncontrolling interests	(13)	13		(13)
Cancellation of restricted stock for tax withholdings on vested shares	(5)			(5)
Cancellation of restricted stock for tax withholdings on vested shares, shares			(584,379)
Issuance of common stock in connection with the exercise of stock options, shares			65,499
Stock-based compensation	25			25
Stock-based compensation, shares			3,053,045
Equity, ending balance at Dec. 31, 2021	(1,290)		$ 1	2,118	(14)	(3,477)	82
Redeemable Noncontrolling Interests, ending balance at Dec. 31, 2021	480	480
Shares, outstanding, ending balance at Dec. 31, 2021			132,146,282
Comprehensive income (loss)	80				(7)	46	41
Comprehensive income (loss) attributable to redeemable noncontrolling interest		92
Contributions from noncontrolling interests	11						11
Contributions from redeemable noncontrolling interests		2
Distributions to noncontrolling interests	(45)						(45)
Distributions to redeemable noncontrolling interests		(80)
Purchase of subsidiary shares from noncontrolling interests	(6)	1		(6)
Noncontrolling interests in acquired entity	3	6					3
Adjustment to redemption value of redeemable noncontrolling interests	(40)	40		(40)
Cancellation of restricted stock for tax withholdings on vested shares	(8)			(8)
Cancellation of restricted stock for tax withholdings on vested shares, shares			(828,952)
Issuance of common stock in connection with the exercise of stock options, shares			56,500
Stock-based compensation	20			20
Stock-based compensation, shares			3,329,887
Equity, ending balance at Dec. 31, 2022	(1,275)		$ 1	$ 2,084	$ (21)	$ (3,431)	$ 92
Redeemable Noncontrolling Interests, ending balance at Dec. 31, 2022	$ 541	$ 541
Shares, outstanding, ending balance at Dec. 31, 2022			134,703,717

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net income	$ 179	$ 368	$ 607
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	534	540	558
Deferred income taxes	165	170	(187)
Stock-based compensation expense	20	25	13
Impairment and (gain) loss on sale of businesses, net	71	24	48
(Gain) loss from early extinguishment of debt	(253)	79	(317)
Gain on sale of equity interests in Macon Healthcare, LLC		(39)
Gain from CoreTrust transaction	(119)
Other non-cash expenses, net	182	78	131
Changes in operating assets and liabilities, net of effects of acquisitions and divestitures:
Patient accounts receivable	22	(136)	309
Supplies, prepaid expenses and other current assets	(128)	1	(15)
Medicare accelerated payments			1,158
Repayment/derecognition of Medicare accelerated payments		(1,081)	(77)
Pandemic relief funds			104
Accounts payable, accrued liabilities and income taxes	(158)	16	(67)
Other	(215)	(176)	(87)
Net cash provided by (used in) operating activities	300	(131)	2,178
Cash flows from investing activities:
Acquisitions of facilities and other related businesses	(9)	(3)	(1)
Purchases of property and equipment	(415)	(469)	(440)
Proceeds from disposition of hospitals and other ancillary operations	89	17	648
Proceeds from sale of property and equipment	38	10	4
Purchases of available-for-sale debt securities and equity securities	(114)	(171)	(178)
Proceeds from sales of available-for-sale debt securities and equity securities	110	102	194
Purchases of investments in unconsolidated affiliates	(19)	(7)	(1)
Proceeds from sale of equity interests in Macon Healthcare, LLC		110
Distribution of CoreTrust proceeds	121
Increase in other investments	(60)	(113)	(49)
Net cash (used in) provided by investing activities	(259)	(524)	177
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll tax withholding requirements	(8)	(5)	(1)
Deferred financing costs and other debt-related costs	(74)	(313)	(156)
Proceeds from noncontrolling investors in joint ventures	13		15
Redemption of noncontrolling investments in joint ventures	(5)	(19)	(1)
Distributions to noncontrolling investors in joint ventures	(125)	(121)	(116)
Proceeds from sale-leaseback			2
Other borrowings	48	60	53
Issuance of long-term debt	1,535	4,310	4,262
Proceeds from ABL Facility	542		540
Repayments of long-term indebtedness	(2,356)	(4,426)	(5,493)
Net cash used in financing activities	(430)	(514)	(895)
Net change in cash and cash equivalents	(389)	(1,169)	1,460
Cash and cash equivalents at beginning of period	507	1,676	216
Cash and cash equivalents at end of period	118	507	1,676
Supplemental disclosure of cash flow information:
Interest payments	(835)	(778)	(1,039)
Income tax (payments) refunds, net	$ (6)	$ (4)	$ (2)

Basis of Presentation and Significant Accounting Policies

12 Months Ended

Dec. 31, 2022

Organization Consolidation And Presentation Of Financial Statements [Abstract]

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

1. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

Business. Community Health Systems, Inc. is a holding company and operates no business in its own name. On a consolidated basis, Community Health Systems, Inc. and its subsidiaries (collectively the “Company”) own, lease and operate general acute care hospitals as well as outpatient facilities in communities across the country. As of December 31, 2022, the Company’s subsidiaries own or lease 80 affiliated hospitals, with approximately 13,000 beds, and operate more than 1,000 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers. Throughout these notes to the consolidated financial statements, Community Health Systems, Inc. (the “Parent”) and its consolidated subsidiaries are referred to on a collective basis as the “Company.” This drafting style is not meant to indicate that the publicly-traded Parent or any particular subsidiary of the Parent owns or operates any asset, business, or property. The hospitals, operations and businesses described in this filing are owned and operated, and management services provided, by distinct and indirect subsidiaries of Community Health Systems, Inc.

As of December 31, 2022, Indiana, Alabama, Texas and Florida represent the only areas of significant geographic concentration. Net operating revenues generated by the Company’s hospitals in Indiana, as a percentage of consolidated net operating revenues, were 17.3% in 2022, 16.4% in 2021 and 15.0% in 2020. Net operating revenues generated by the Company’s hospitals in Alabama, as a percentage of consolidated net operating revenues, were 13.3% in 2022, 13.0% in 2021 and 12.1% in 2020. Net operating revenues generated by the Company’s hospitals in Texas, as a percentage of consolidated net operating revenues, were 11.7% in 2022, 11.0% in 2021 and 12.2% in 2020. Net operating revenues generated by the Company’s hospitals in Florida, as a percentage of consolidated net operating revenues, were 11.6% in 2022, 12.2% in 2021 and 13.0% in 2020.

Use of Estimates. The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements. Actual results could differ from these estimates under different assumptions or conditions.

Principles of Consolidation. The consolidated financial statements include the accounts of the Parent, its subsidiaries, all of which are controlled by the Parent through majority voting control, and variable interest entities for which the Company is the primary beneficiary. All intercompany accounts, profits and transactions have been eliminated. Noncontrolling interests in less-than-wholly-owned consolidated subsidiaries of the Parent are presented as a component of total equity to distinguish between the interests of the Parent and the interests of the noncontrolling owners. Revenues, expenses and income from these subsidiaries are included in the consolidated amounts as presented in the consolidated statements of income, along with a net income measure that separately presents the amounts attributable to the controlling interests and the amounts attributable to the noncontrolling interests for each of the periods presented. Noncontrolling interests that are redeemable or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company are presented in mezzanine equity in the consolidated balance sheets.

Cost of Revenue. Substantially all of the Company’s operating costs and expenses are “cost of revenue” items. Operating costs that could be classified as general and administrative by the Company would include the Company’s corporate office costs at its Franklin, Tennessee office which were collectively $229 million, $222 million and $190 million for the years ended December 31, 2022, 2021 and 2020, respectively. Included in these corporate office costs is stock-based compensation of $20 million, $25 million and $13 million for the years ended December 31, 2022, 2021 and 2020, respectively. Operating costs for the years ended December 31, 2022 and 2021 reflect increased stock compensation expense and annual cash incentive compensation expense compared to the year ended December 31, 2020.

Cash Equivalents. The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents.

Supplies. Supplies, principally medical supplies, are stated at the lower of cost (first-in, first-out basis) or market.

Marketable Securities. The Company’s marketable securities consist of debt securities that are classified as trading or available-for-sale and equity securities. Available-for-sale debt securities are reported at fair value as determined by quoted market prices, with unrealized gains and losses reported as a separate component of stockholders’ deficit. Trading securities are reported at fair value with unrealized gains and losses included in earnings. Other comprehensive loss, net of tax, included an unrealized loss of $17 million and $5 million during the years ended December 31, 2022 and 2021, respectively, and an unrealized gain of $4 million for the year ended December 31, 2020 related to these available-for-sale debt securities.

Property and Equipment. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the land and improvements (3 to 20 years), buildings and improvements (5 to 40 years) and equipment and fixtures (3 to 18 years). Costs capitalized as construction in progress were $234 million and $225 million at December 31, 2022 and 2021, respectively. Expenditures for renovations and other significant improvements are capitalized; however, maintenance and repairs which do not improve or extend the useful lives of the respective assets are charged to operations as incurred. Interest capitalized related to construction in progress was $9 million, $13 million and $15 million for the years ended December 31, 2022, 2021 and 2020, respectively. Purchases of property and equipment and internal-use software accrued in accounts payable and not yet paid were $87 million and $105 million at December 31, 2022 and 2021, respectively.

The Company also leases certain facilities and equipment under finance leases (see Note 9). Such assets are amortized on a straight-line basis over the lesser of the term of the lease or the remaining useful lives of the applicable assets. During the year ended December 31, 2022, the Company had non-cash investing activity of $38 million related to certain facility and equipment additions that were financed through finance leases and other debt.

Goodwill. Goodwill represents the excess of the fair value of the consideration conveyed in the acquisition over the fair value of net assets acquired. Goodwill arising from business combinations is not amortized. Goodwill is required to be evaluated for impairment at the same time every year and when an event occurs or circumstances change such that it is more likely than not that impairment may exist. The Company performs its annual testing of impairment for goodwill in the fourth quarter of each year. There was no goodwill impairment charge during the years ended December 31, 2022, 2021 and 2020 as a result of the Company’s annual impairment evaluation.

Other Assets. Other assets consist of the insurance recovery receivable from excess insurance carriers related to the Company’s self-insured professional liability and workers’ compensation insurance liability; costs to recruit physicians to the Company’s markets, which are deferred and expensed over the term of the respective physician recruitment contract, generally three years, and included in amortization expense; equity method investments; right-of-use (“ROU”) assets for operating leases; and capitalized internal-use software costs, which are expensed over the expected useful life, which is generally three years for routine software, and included in amortization expense.

Revenue Recognition.

Net Operating Revenues

Net operating revenues are recorded at the transaction price estimated by the Company to reflect the total consideration due from patients and third-party payors in exchange for providing goods and services in patient care. These services are considered to be a single performance obligation and have a duration of less than one year. Revenues are recorded as these goods and services are provided. The transaction price, which involves significant estimates, is determined based on the Company’s standard charges for the goods and services provided, with a reduction recorded for price concessions related to third-party contractual arrangements as well as patient discounts and other patient price concessions. During each of the years ended December 31, 2022, 2021 and 2020, the impact of changes to the inputs used to determine the transaction price was considered immaterial.

Currently, several states utilize supplemental reimbursement programs for the purpose of providing reimbursement to providers that is not specifically tied to an individual’s care, some of which offsets a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from the Centers for Medicare & Medicaid Services (“CMS”) and are funded with a combination of state and federal resources, including, in certain instances, fees or taxes levied on the providers. Under these supplemental programs, the Company recognizes revenue and related expenses in the period in which amounts are estimable and payment is reasonably assured. Reimbursement under these programs is reflected in net operating revenues. Taxes or other program-related costs are reflected in other operating expenses.

The Company’s net operating revenues during the years ended December 31, 2022, 2021 and 2020 have been presented in the following table based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in millions):

	Year Ended December 31,
	2022		2021		2020
Medicare	$	2,547	$	2,650	$	2,813
Medicaid		1,807		1,671		1,578
Medicare Managed Care		1,968		1,861		1,601
Other third-party payors		5,806		6,076		5,799
Self-pay		83		110		(2	)
Total	$	12,211	$	12,368	$	11,789

Patient Accounts Receivable

Patient accounts receivable are recorded at net realizable value based on certain assumptions determined by each payor. For third-party payors including Medicare, Medicaid, and Managed Care, the net realizable value is based on the estimated contractual reimbursement percentage, which is based on current contract prices or historical paid claims data by payor. For self-pay accounts receivable, which includes patients who are uninsured and the patient responsibility portion for patients with insurance, the net realizable value is determined using estimates of historical collection experience without regard to aging category. These estimates are adjusted for estimated conversions of patient responsibility portions, expected recoveries and any anticipated changes in trends.

Patient accounts receivable can be impacted by the effectiveness of the Company’s collection efforts. Additionally, significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect the net realizable value of accounts receivable. The Company also continually reviews the net realizable value of accounts receivable by monitoring historical cash collections as a percentage of trailing net operating revenues, as well as by analyzing current period net operating revenues and admissions by payor classification, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables, the impact of recent acquisitions and dispositions and the impact of current macroeconomic conditions and other events.

Final settlements for some payors and programs are subject to adjustment based on administrative review and audit by third parties. As a result of these final settlements, the Company has recorded amounts due to third-party payors of $101 million and $118 million as of December 31, 2022 and 2021, respectively, and these amounts are included in accrued liabilities-other in the accompanying consolidated balance sheets. Amounts due from third-party payors were $97 million and $114 million as of December 31, 2022 and 2021, respectively, and are included in other current assets in the accompanying consolidated balance sheets. Substantially all Medicare and Medicaid cost reports are final settled through 2018.

Charity Care

In the ordinary course of business, the Company renders services to patients who are financially unable to pay for hospital care. The Company’s policy is to not pursue collections for such amounts; therefore, the related charges for those patients who are financially unable to pay and that otherwise do not qualify for reimbursement from a governmental program are not reported in net operating revenues, and are thus classified as charity care. The Company determines amounts that qualify for charity care based on the patient’s household income relative to the federal poverty level guidelines, as established by the federal government.

These charity care services are estimated to be $1.4 billion, $1.1 billion and $1.0 billion for the years ended December 31, 2022, 2021 and 2020, respectively, representing the value (at the Company’s standard charges) of these charity care services that are excluded from net operating revenues. The estimated cost incurred by the Company to provide these charity care services to patients who are unable to pay was approximately $166 million, $123 million and $122 million for the years ended December 31, 2022, 2021 and 2020, respectively. The estimated cost of these charity care services was determined using a ratio of cost to gross charges and applying that ratio to the gross charges associated with providing care to charity patients for the period. The Company determines amounts that qualify for charity care based on the patient’s household income relative to the federal poverty level guidelines, as established by the federal government. The Company updated its policy during the three months ended March 31, 2022 in a manner which increased the number of accounts qualifying for charity care. This resulted in an increase in charity care services during the year ended December 31, 2022, compared to the same period in 2021.

Leases. Leases are recorded in the consolidated balance sheets through recognition of a liability for the discounted present value of future fixed lease payments and a corresponding ROU asset. The ROU asset recorded at commencement of the lease represents the right to use the underlying asset over the lease term in exchange for the lease payments. Leases with an initial term of 12 months or less that do not have an option to purchase the underlying asset that is deemed reasonably certain to be exercised are not recorded in the consolidated balance sheets; rather, rent expense for these leases is recognized on a straight-line basis over the lease term, or when incurred if a month-to-month lease. When readily determinable, the Company uses the interest rate implicit in a lease to determine the present value of future lease payments. For leases where the implicit rate is not readily determinable, the Company’s incremental borrowing rate is utilized. The Company calculates its incremental borrowing rate on a quarterly basis using a third-party financial model that estimates the rate of interest the Company would have to pay to borrow an amount equal to the total lease payments on a collateralized basis over a term similar to the lease. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.

Physician Income Guarantees. The Company enters into physician recruiting agreements under which it supplements physician income to a minimum amount over a period of time, typically one year, while the physicians establish themselves in the community. As part of the agreements, the physicians are committed to practice in the community for a period of time, typically three years, which extends beyond their income guarantee period. The Company records an asset and liability for the estimated fair value of minimum revenue guarantees on new agreements and the asset is amortized over the life of each respective agreement. Adjustments to the ultimate value of the guarantee paid to physicians are recognized in the period that the change in estimate is identified. As of December 31, 2022 and 2021, the unamortized portion of these physician income guarantees was $12 million and $13 million, respectively, and is recorded in other assets in the consolidated balance sheets.

Concentrations of Credit Risk. The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company’s facilities and are insured under third-party payor agreements. Because of the economic diversity of the Company’s facilities and non-governmental third-party payors, Medicare represents the only significant concentration of credit risk from payors. Accounts receivable, net of contractual allowances, from Medicare was $198 million and $211 million at December 31, 2022 and 2021, respectively, representing 6% and 5% of consolidated net accounts receivable at December 31, 2022 and 2021, respectively.

Accounting for the Impairment or Disposal of Long-Lived Assets. During the year ended December 31, 2022, the Company recorded an impairment charge of approximately $71 million, of which (i) approximately $7 million was recorded to adjust the carrying value of long-lived assets at hospitals and related businesses that were sold at a sales price below carrying value, (ii) approximately $44 million was recorded to reduce the carrying value of closed hospitals to estimated fair value less costs to sell, (iii) approximately $9 million was recorded related to the expiration or planned non-renewal of leases to operate certain hospitals, and (iv) approximately $11 million was recorded to reduce the carrying value of several assets that were either idled, disposed or held-for-sale.

During the year ended December 31, 2021, the Company recorded a net loss on disposal of approximately $24 million, of which (i) approximately $29 million was recorded to adjust the carrying value of long-lived assets at several hospitals that were sold at a sales price below carrying value, (ii) approximately $3 million was recorded related to divestiture related expenses, and (iii) approximately $8 million of gain was recorded related to the disposal of the Company’s majority interest in a surgery center that was sold on January 1, 2021. Approximately $5 million of goodwill was allocated to facilities disposed of during the year ended December 31, 2021.

Income Taxes. The Company accounts for income taxes under the asset and liability method, in which deferred income tax assets and liabilities are recognized for the tax consequences of “temporary differences” by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The effect on deferred taxes of a change in tax rates is recognized in the consolidated statements of income during the period in which the tax rate change becomes law.

Other Comprehensive Loss. Other comprehensive loss is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.

Segment Reporting. A public company is required to report annual and interim financial and descriptive information about its reportable operating segments. Operating segments, as defined, are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Aggregation of similar operating segments into a single reportable operating segment is permitted if the businesses have similar economic characteristics and meet the criteria established by U.S. GAAP. The Company operates a single operating segment represented by hospital operations (which includes the Company's acute care hospitals and related healthcare entities that provide inpatient and outpatient healthcare services).

COVID-19 Pandemic. COVID-19, a disease caused by a novel strain of coronavirus, materially affected the Company’s results of operations during 2020, and continued to affect the Company’s results of operations during the years ended December 31, 2022 and 2021. Federal and state governments have passed legislation, promulgated regulations and taken other administrative actions intended to assist healthcare providers in providing care to COVID-19 and other patients during the public health emergency. Sources of relief include the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), the Paycheck Protection Program and Health Care Enhancement Act (the “PPPHCE Act”), the Consolidated Appropriations Act, 2021 (the “CAA”), and the American Rescue Plan Act of 2021 (the “ARPA”). Together, these stimulus laws authorize over $186 billion in funding to be distributed to hospitals and other healthcare providers through the Public Health and Social Services Emergency Fund (the “PHSSEF”). In addition to the relief funding, the CARES Act provided for an expansion of the Medicare Accelerated and Advance Payment Program whereby inpatient acute care hospitals and other eligible providers were able to request accelerated payment of up to 100% of their Medicare payment amount for a six-month period. Providers are required to repay accelerated payments. Various state and local programs also exist to provide relief, either independently or through distribution of monies received via the CARES Act and other enacted federal legislation. The Company’s accounting policies for the recognition of these stimulus monies are as follows:

Pandemic Relief Funds

The Company received pandemic relief fund payments through various federal, state and local programs of approximately $161 million, $58 million and $705 million during the years ended December 31, 2022, 2021 and 2020, respectively. The recognition of amounts received is conditioned upon the provision of care for individuals with possible or actual cases of COVID-19 after January 31, 2020, certification that payment will be used to prevent, prepare for and respond to coronavirus (such amounts shall reimburse the recipient only for healthcare-related expenses or lost revenues, as defined by the U.S. Department of Health and Human Services Agency (“HHS”), that are attributable to coronavirus), and receipt of the funds. Amounts are recognized as a reduction to operating costs and expenses only to the extent the Company is reasonably assured that underlying conditions have been met. Amounts recognized are denoted by the caption “pandemic relief funds” within the consolidated statements of income.

The Company’s assessment of whether the terms and conditions for amounts received are reasonably assured of having been met is updated each reporting period and considers, among other things, the requirements set forth in the CARES Act and subsequent relief legislation, responses to all applicable frequently asked questions and other interpretive guidance issued by HHS, including the various Post-Payment Notices of Reporting Requirements, the Company’s expenses incurred attributable to the coronavirus, the Company’s results of operations during such period as compared to the Company’s 2020 budget, and the allocation of general and targeted fund distribution payments among subsidiaries of the Company during such period. The HHS guidance, specifically the various Post-Payment Notices of Reporting Requirements and frequently asked questions, set forth the allowable methods for quantifying eligible healthcare related expenses and lost revenues. Only healthcare-related expenses attributable to coronavirus that another source has not reimbursed and is not obligated to reimburse are eligible to be claimed. The use of funds calculation takes into account expenses attributable to each respective entity, which for the Company primarily relate to incremental labor and supply costs, as well as lost revenues. The deadlines for using and required timelines for reporting on the use of funds depend on the dates of receipt of the funds. Approximately $173 million, $148 million and $601 million during the years ended December 31, 2022, 2021 and 2020, respectively, was recognized as pandemic relief funds within the consolidated statements of income.

Amounts received through the PHSSEF or state and local programs that have not yet been recognized or otherwise have not been refunded to HHS or the various state and local agencies as of December 31, 2022, total approximately $2 million and are reflected within accrued liabilities-other in the consolidated balance sheets. Such unrecognized amounts may either be returned or may be recognized in future periods if the underlying conditions for recognition are reasonably assured of having been met. HHS’ interpretation of the underlying terms and conditions of such PHSSEF payments, including auditing and reporting requirements, continues to evolve. Additional guidance or new and amended interpretations of existing guidance on the terms and conditions of such PHSSEF payments may result in changes in the Company’s estimate of amounts for which the terms and conditions are reasonably assured of being met, and any such changes may be material. Additionally, any such changes may result in the Company’s inability to recognize additional PHSSEF payments or may result in the derecognition of amounts previously recognized, which (in any such case) may be material.

Medicare Accelerated Payments

With respect to the Medicare Accelerated and Advanced Payment Program, the Company received Medicare accelerated payments of approximately $1.2 billion in April 2020. No additional Medicare accelerated payments have been received by the Company since such time. In addition, because CMS is no longer accepting new applications for accelerated payments, the Company does not expect to receive additional Medicare accelerated payments. CMS began recouping Medicare accelerated payments in April 2021. As of December 31, 2021, all Medicare accelerated payments received by the Company was recouped or repaid to CMS or assumed by buyers related to hospitals the Company divested. Approximately $1.1 billion and $77 million of Medicare accelerated payments

received by the Company were recouped or repaid to CMS or assumed by buyers related to hospitals the Company divested during the years ended December 31, 2021 and 2020, respectively.

New Accounting Pronouncements. In September 2022, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2022-04, “Liabilities – Supplier Finance Programs (Subtopic 405-50), Disclosure of Supplier Finance Program Obligations.” This ASU provides specific authoritative guidance for disclosure of supplier finance programs including key terms of such programs, amounts outstanding, and where the obligations are presented in the statement of financial position. This ASU is effective for all entities for financial statements issued for annual periods beginning after December 15, 2022, including interim periods, except for the disclosure of rollforward information, which is effective for annual periods beginning after December 15, 2023. Certain components of this guidance must be applied retrospectively while others may be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact that adoption of this ASU will have on its consolidated financial statements.

The Company has evaluated all other recently issued, but not yet effective, ASUs and does not expect the eventual adoption of these ASUs to have a material impact on its consolidated financial position or results of operations.

Accounting for Stock-Based Compensation

12 Months Ended

Dec. 31, 2022

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

ACCOUNTING FOR STOCK-BASED COMPENSATION

2. ACCOUNTING FOR STOCK-BASED COMPENSATION

Stock-based compensation awards have been granted under the Community Health Systems, Inc. Amended and Restated 2009 Stock Option and Award Plan (the “2009 Plan”), which was amended and restated as of March 17, 2021 and approved by the Company’s stockholders at the annual meeting of stockholders held on May 11, 2021.

The 2009 Plan provides for the grant of incentive stock options intended to qualify under Section 422 of the Internal Revenue Code (“IRC”) and for the grant of stock options which do not so qualify, stock appreciation rights, restricted stock, restricted stock units (“RSUs”), performance-based shares or units and other share awards. Persons eligible to receive grants under the 2009 Plan include the Company’s directors, officers, employees and consultants. To date, all options granted under the 2009 Plan have been “nonqualified” stock options for tax purposes. Generally, these options vest in one-third increments on each of the first three anniversaries of the award date and have a 10-year contractual term. As of December 31, 2022, 6,943,882 shares of unissued common stock were reserved for future grants under the 2009 Plan.

The exercise price of all options granted under the 2009 Plan is equal to the fair value of the Company’s common stock on the option grant date.

The following table reflects the impact of total compensation expense related to stock-based equity plans on the reported operating results for the respective periods (in millions):

	Year Ended December 31,
	2022			2021			2020
Effect on income before income taxes	$	(20	)	$	(25	)	$	(13	)
Effect on net income	$	(15	)	$	(20	)	$	(10	)

At December 31, 2022, $34 million of unrecognized stock-based compensation expense related to outstanding unvested stock options, restricted stock and RSUs (the terms of which are summarized below) was expected to be recognized over a weighted-average period of 22 months. Of that amount, $6 million related to outstanding unvested stock options was expected to be recognized over a weighted-average period of 22 months and $28 million related to outstanding unvested restricted stock and RSUs was expected to be recognized over a weighted-average period of 22 months. There were no modifications to awards during the years ended December 31, 2022, 2021 and 2020.

The fair value of stock options was estimated using the Black Scholes option pricing model with the following assumptions and weighted-average fair values during the years ended December 31, 2022, 2021 and 2020:

	Year Ended December 31,
	2022		2021		2020
Expected volatility	84.3% - 87.5%		84.3% - 88.9%		73.5%
Expected dividends		—		—		—
Expected term	3.0 - 6.0 years		3.0 - 6.0 years		6.0 years
Risk-free interest rate	1.5% - 1.6%		0.3% - 0.9%		1.0%

In determining the expected term, the Company examined concentrations of option holdings and historical patterns of option exercises and forfeitures, as well as forward-looking factors, in an effort to determine if there were any discernable employee populations. From this analysis, the Company identified two primary employee populations, one consisting of certain senior executives and the other consisting of substantially all other recipients.

The expected volatility rate was estimated based on historical volatility. In determining expected volatility, the Company also reviewed the market-based implied volatility of actively traded options of its common stock and determined that historical volatility utilized to estimate the expected volatility rate did not differ significantly from the implied volatility.

The expected term computation is based on historical exercise and cancellation patterns and forward-looking factors, where present, for each population identified. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The pre-vesting forfeiture rate is based on historical rates and forward-looking factors for each population identified. The Company adjusts the estimated forfeiture rate to its actual experience.

Options outstanding and exercisable under the 2009 Plan as of December 31, 2022, and changes during each of the years in the three-year period prior to December 31, 2022, were as follows (in millions, except share and per share data):

	Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value as of December 31, 2022
Outstanding at December 31, 2019		1,110,134		$	16.90
Granted		946,500			4.93
Exercised		(18,166	)		4.99
Forfeited and cancelled		(220,943	)		33.52
Outstanding at December 31, 2020		1,817,525			8.77
Granted		749,250			8.81
Exercised		(65,499	)		5.03
Forfeited and cancelled		(199,523	)		33.14
Outstanding at December 31, 2021		2,301,753			6.77
Granted		760,000			10.18
Exercised		(56,500	)		4.97
Forfeited and cancelled		(173,502	)		13.41
Outstanding at December 31, 2022		2,831,751		$	7.32	7.8 years	$	—
Exercisable at December 31, 2022		1,298,412		$	5.64	7.0 years	$	—

The weighted-average grant date fair value of stock options granted during the years ended December 31, 2022, 2021 and 2020, was $7.25, $6.22 and $3.17, respectively. The aggregate intrinsic value (calculated as the number of in-the-money stock options multiplied by the difference between the Company’s closing stock price on the last trading day of the reporting period ($4.32) and the exercise price of the respective stock options) in the table above represents the amount that would have been received by the option holders had all option holders exercised their options on December 31, 2022. This amount changes based on the market value of the Company’s common stock. The aggregate intrinsic value of options exercised during the years ended December 31, 2022, 2021 and 2020 was less than $1 million for all three years. The aggregate intrinsic value of options vested and expected to vest approximates that of the outstanding options.

The Company has also awarded restricted stock under the 2009 Plan to employees of certain subsidiaries. With respect to time-based vesting restricted stock that has been awarded under the 2009 Plan, the restrictions on these shares have generally lapsed in one-third increments on each of the first three anniversaries of the award date. In addition, certain of the restricted stock awards granted to the Company’s senior executives have contained performance objectives required to be met in addition to any time-based vesting requirements. If the applicable performance objectives are not attained, these awards will be forfeited in their entirety. For performance-based awards, the performance objectives are measured cumulatively over a three-year period. If the applicable target performance objective is met at the end of the three-year period, then the restricted stock award subject to such performance objective will vest in full on the third anniversary of the award date. Additionally, for these performance-based awards, based on the level of

achievement for the applicable performance objective within the parameters specified in the award agreement, the number of shares to be issued in connection with the vesting of the award may be adjusted to decrease or increase the number of shares specified in the original award. Notwithstanding the above-mentioned performance objectives and vesting requirements, the restrictions with respect to restricted stock granted under the 2009 Plan may lapse earlier in the event of death, disability or termination of employment by the Company for any reason other than for cause of the holder of the restricted stock, or change in control of the Company. On March 1, 2022, restricted stock awards subject to performance objectives granted on March 1, 2019 vested at 200% of the shares originally granted based on the Company’s cumulative performance compared to objectives for the 2019 through 2021 performance period. Restricted stock awards subject to performance objectives that have not yet been satisfied are not considered outstanding for purposes of determining diluted earnings per share unless the performance objectives have been satisfied on the basis of results through the end of each respective reporting period.

Restricted stock outstanding under the 2009 Plan as of December 31, 2022, and changes during each of the years in the three-year period prior to December 31, 2022, were as follows:

	Shares			Weighted- Average Grant Date Fair Value
Unvested at December 31, 2019		3,857,402		$	5.47
Granted		2,205,500			4.90
Vested		(1,123,329	)		5.84
Forfeited		(383,838	)		8.58
Unvested at December 31, 2020		4,555,735			4.84
Granted		2,929,250			8.16
Vested		(2,312,328	)		4.68
Forfeited		(177,343	)		6.33
Unvested at December 31, 2021		4,995,314			6.30
Granted		3,253,000			8.95
Vested		(2,561,575	)		5.70
Forfeited		(145,674	)		8.89
Unvested at December 31, 2022		5,541,065			8.53

RSUs have been granted to the Company’s non-management directors under the 2009 Plan. Each of the Company’s then serving non-management directors received grants under the 2009 Plan of 17,682 RSUs, 19,296 RSUs and 34,483 RSUs on March 1, 2022, 2021 and 2020, respectively. The March 1, 2022, 2021 and 2020 grants had a fair value of approximately $180,000, $170,000 and $170,000, respectively. On June 1, 2022, a new non-management director received a grant of 17,682 RSUs with a grant date fair value of approximately $88,000. Vesting of these RSUs occurs in one-third increments on each of the first three anniversaries of the award date or upon the director’s earlier cessation of service on the board, other than for cause. Beginning with the 2020 grant, each non-management director may elect, prior to the beginning of the calendar year in which the award is granted, to defer the receipt of shares of the Company’s common stock issuable upon vesting until either his or her (i) separation from service with the Company or (ii) attainment of an age specified in advance by the non-management director. A total of three directors elected to defer the receipt of RSUs granted on March 1, 2022 to a future date, a total of four directors elected to defer the receipt of RSUs granted on March 1, 2021 to a future date, and a total of five directors elected to defer the receipt of RSUs granted on March 1, 2020 to a future date.

RSUs outstanding under the 2009 Plan as of December 31, 2022, and changes during each of the years in the three-year period prior to December 31, 2022, were as follows:

	Shares			Weighted- Average Grant Date Fair Value
Unvested at December 31, 2019		541,576		$	5.13
Granted		310,347			4.93
Vested		(238,184	)		5.47
Forfeited		—			—
Unvested at December 31, 2020		613,739			4.89
Granted		173,664			8.81
Vested		(300,805	)		5.09
Forfeited		—			—
Unvested at December 31, 2021		486,598			6.17
Granted		176,820			9.66
Vested		(151,058	)		5.63
Forfeited		—			—
Unvested at December 31, 2022		512,360			7.54

Acquisitions, Divestitures and Closures

12 Months Ended

Dec. 31, 2022

Acquisitions Divestitures And Closures [Abstract]

ACQUISITIONS, DIVESTITURES AND CLOSURES

3. ACQUISITIONS, DIVESTITURES AND CLOSURES

Acquisitions

The Company accounts for all transactions that represent business combinations using the acquisition method of accounting, where the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquired entity are recognized and measured at their fair values on the date the Company obtains control in the acquiree. Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts. Adjustments to these provisional amounts during the measurement period (defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date) are recorded when identified. Goodwill is determined as the excess of the fair value of the consideration conveyed in the acquisition over the fair value of the net assets acquired.

During the years ended December 31, 2022, 2021 and 2020, one or more subsidiaries of the Company paid approximately $9 million, $3 million and $1 million, respectively, to acquire the operating assets and related businesses of certain physician practices, clinics, ambulatory surgery centers and other ancillary businesses that operate within the communities served by the Company’s affiliated hospitals. In connection with these acquisitions, during the years ended December 31, 2022 and 2021, the Company allocated the purchase price to property and equipment, working capital, noncontrolling interests and goodwill. During the year ended December 31, 2020, the Company allocated the majority of the purchase price to goodwill.

Divestitures

The following table provides a summary of hospitals that the Company divested during the years ended December 31, 2022, 2021 and 2020.

Hospital	Buyer	City, State	Licensed Beds		Effective Date
2022 Divestitures:
AllianceHealth Seminole	SSM Heath Care of Oklahoma, Inc.	Seminole, OK	32		July 1, 2022

2021 Divestitures:
Lea Regional Medical Center	Covenant Health System	Hobbs, NM	84		January 1, 2021
Tennova Healthcare - Tullahoma	Vanderbilt University Medical Center	Tullahoma, TN	135		January 1, 2021
Tennova Healthcare - Shelbyville	Vanderbilt University Medical Center	Shelbyville, TN	60		January 1, 2021
Northwest Mississippi Medical Center	Delta Health System	Clarksdale, MS	181		February 1, 2021
AllianceHealth Midwest	SSM Health Care of Oklahoma, Inc.	Midwest City, OK	255		April 1, 2021

2020 Divestitures:
Berwick Hospital Center	Fayette Holdings, Inc.	Berwick, PA		90	December 1, 2020
Brownwood Regional Medical Center	Hendrick Health System	Brownwood, TX		188	October 27, 2020
Abilene Regional Medical Center	Hendrick Health System	Abilene, TX		231	October 27, 2020
San Angelo Community Medical Center	Shannon Health System	San Angelo, TX		171	October 24, 2020
Bayfront Health St. Petersburg	Orlando Health, Inc.	St. Petersburg, FL		480	October 1, 2020
Hill Regional Hospital	AHRK Holdings, LLC	Hillsboro, TX		25	August 1, 2020
St. Cloud Regional Medical Center	Orlando Health, Inc.	St. Cloud, FL		84	July 1, 2020
Northern Louisiana Medical Center	Allegiance Health Management, Inc.	Ruston, LA		130	July 1, 2020
Shands Live Oak Regional Medical Center	HCA Healthcare, Inc. ("HCA")	Live Oak, FL		25	May 1, 2020
Shands Starke Regional Medical Center	HCA	Starke, FL		49	May 1, 2020
Southside Regional Medical Center	Bon Secours Mercy Health System	Petersburg, VA		300	January 1, 2020
Southampton Memorial Hospital	Bon Secours Mercy Health System	Franklin, VA		105	January 1, 2020
Southern Virginia Regional Medical Center	Bon Secours Mercy Health System	Emporia, VA		80	January 1, 2020

On September 14, 2022, one or more affiliates of the Company entered into a definitive agreement for the sale of substantially all of the assets of Greenbrier Valley Medical Center (122 licensed beds) in Ronceverte, West Virginia, to a subsidiary of Vandalia Health, Inc. This disposition was completed on January 1, 2023, as further described in Note 16 below.

On December 30, 2022, one or more affiliates of the Company entered into a definitive agreement for the sale of substantially all of the assets of Plateau Medical Center (25 licensed beds) in Oak Hill, West Virginia, to a subsidiary of Vandalia Health, Inc. This hospital is classified as held-for-sale as of December 31, 2022.

The following table discloses amounts included in the consolidated balance sheet for hospitals and other assets classified as held-for-sale as of December 31, 2022 (in millions). Other assets, net primarily includes goodwill and the net property and equipment for hospitals held-for-sale. No hospitals were classified as held-for-sale as of December 31, 2021 and no divestitures or potential divestitures meet the criteria for reporting as a discontinued operation as of December 31, 2022, 2021, or 2020.

	December 31,
	2022
Other current assets	$	6
Other assets, net		132
Accrued liabilities		(4	)

On November 30, 2020, one or more subsidiaries of the Company completed the sale of 50% ownership interest in Merit Health Biloxi (153 licensed beds) and its associated healthcare businesses in Biloxi, Mississippi to Memorial Properties, Inc., an affiliate of Memorial Hospital of Gulfport pursuant to the terms of a definitive agreement which was entered into on October 12, 2020. Merit Health Biloxi and its associated healthcare businesses remain consolidated entities of the Company.

Closures

During the three months ended September 30, 2022, the Company completed the closure of Shorepoint Health Venice hospital (312 licensed beds) in Venice, Florida. The Company recorded an impairment charge of approximately $29 million during the year ended December 31, 2022, to adjust the fair value of the long-lived assets of this hospital, including property and equipment and capitalized software costs, based on their estimated fair value.

During the three months ended September 30, 2022, the provision of inpatient services and substantially all outpatient services ceased at First Hospital Wyoming Valley (psychiatric hospital) (149 licensed beds) in Wilkes-Barre, Pennsylvania, resulting in the closure of this facility being substantially complete as of September 30, 2022. The Company completed the closure of First Hospital Wyoming Valley during the three months ended December 31, 2022. The Company recorded an impairment charge of approximately $15 million during the year ended December 31, 2022, to adjust the fair value of the long-lived assets of this hospital, including property and equipment and capitalized software costs, based on their estimated fair value.

Effective September 30, 2020, one or more affiliates of the Company finalized an agreement to terminate the lease and cease operations of Shands Lake Shore Regional Medical Center (99 licensed beds) in Lake City, Florida, including transferring leased assets back to the landlord, the Lake Shore Hospital Authority. The Company recorded an impairment charge of approximately $3 million during the year ended December 31, 2020 in conjunction with exiting the lease to operate this hospital.

Other

On December 31, 2022, the lease for AllianceHealth Clinton (56 licensed beds) in Clinton, Oklahoma, expired and was not renewed. The Company recorded an impairment charge of approximately $1 million during the year ended December 31, 2022 in conjunction with exiting the lease to operate this hospital.

During the three months ended December 31, 2022, the Company notified the lessor of AllianceHealth Woodward (87 licensed beds) in Woodward, Oklahoma that the lease will not be renewed and will therefore expire effective December 1, 2023. The Company recorded an impairment charge of approximately $8 million in conjunction with the determination to exit this lease.

Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2022

Goodwill And Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

4. GOODWILL AND OTHER INTANGIBLE ASSETS

Goodwill

The changes in the carrying amount of goodwill for the years ended December 31, 2022 and 2021 are as follows (in millions):

Balance, beginning balance	2022			2021
Goodwill	$	7,033		$	7,033
Accumulated impairment losses		(2,814	)		(2,814	)
		4,219			4,219
Goodwill acquired as part of acquisitions during current year		11			5
Goodwill allocated to hospitals divested or held-for-sale		(64	)		(5	)

Balance, end of year
Goodwill		6,980			7,033
Accumulated impairment losses		(2,814	)		(2,814	)
	$	4,166		$	4,219

Goodwill is allocated to each identified reporting unit, which is defined as an operating segment or one level below the operating segment (referred to as a component of the entity). Management has determined that the Company’s operating segment meets the criteria to be classified as a reporting unit. At December 31, 2022, after giving effect to the 2022 acquisition and divestiture activity, the Company had approximately $4.2 billion of goodwill recorded.

Goodwill is evaluated for impairment annually and when an event occurs or circumstances change that, more likely than not, reduce the fair value of the reporting unit below its carrying value. The Company performed its last annual goodwill impairment evaluation during the fourth quarter of 2022 using an October 31, 2022 measurement date, which indicated no impairment.

The Company estimates the fair value of the reporting unit using both a discounted cash flow model as well as a market multiple model. The cash flow forecasts are adjusted by an appropriate discount rate based on the Company’s estimate of a market participant’s weighted-average cost of capital. These models are both based on the Company’s best estimate of future revenues and operating costs and are reconciled to the Company’s consolidated market capitalization, with consideration of the amount a potential acquirer would be required to pay, in the form of a control premium, in order to gain sufficient ownership to set policies, direct operations and control management decisions.

The determination of fair value in the Company’s goodwill impairment analysis is based on an estimate of fair value for the reporting unit utilizing known and estimated inputs at the evaluation date. Some of those inputs include, but are not limited to, the most recent price of the Company’s common stock and fair value of long-term debt, the Company’s recent financial results, estimates of future revenue and expense growth, estimated market multiples, expected capital expenditures, income tax rates, costs of invested capital and a discount rate.

Future estimates of fair value could be adversely affected if the actual outcome of one or more of the assumptions described above changes materially in the future, including as a result of any decline in the Company’s stock price and the fair value of its long-term debt, an increase in the volatility of the Company’s stock price and the fair value of its long-term debt, lower-than-expected hospital volumes and/or net operating revenues, higher market interest rates, increased operating costs or other adverse impacts on the Company’s financial results. Such changes impacting the calculation of fair value could result in a material impairment charge in the future.

The determination of fair value of the Company’s hospital operations reporting unit as part of its goodwill impairment measurement represents a Level 3 fair value measurement in the fair value hierarchy due to its use of internal projections and unobservable measurement inputs.

Intangible Assets

No intangible assets other than goodwill were acquired during the years ended December 31, 2022 and 2021. The gross carrying amount of the Company’s other intangible assets subject to amortization was $4 million and $1 million at December 31, 2022 and 2021, respectively, and the net carrying amount was $2 million and less than $1 million at December 31, 2022 and 2021, respectively. The carrying amount of the Company’s other intangible assets not subject to amortization was $50 million and $54 million at December 31, 2022 and 2021, respectively. Other intangible assets are included in other assets, net on the Company’s consolidated balance sheets. Substantially all of the Company’s intangible assets are contract-based intangible assets related to operating licenses, management contracts, or non-compete agreements entered into in connection with prior acquisitions.

The weighted-average remaining amortization period for the intangible assets subject to amortization is approximately three years. There are no expected residual values related to these intangible assets. Amortization expense on these intangible assets was $1 million during the year ended December 31, 2022, and less than $1 million during both of the years ended December 31, 2021 and 2020. Amortization expense on intangible assets is estimated to be less than $1 million in 2023, 2024 and 2025.

The gross carrying amount of capitalized software for internal use was approximately $968 million and $992 million at December 31, 2022 and 2021, respectively, and the net carrying amount was approximately $170 million and $215 million at December 31, 2022 and 2021, respectively. The estimated amortization period for capitalized internal-use software is generally three years. There is no expected residual value for capitalized internal-use software. At December 31, 2022, there were approximately $82 million of capitalized costs for internal-use software that is currently in the development stage and will begin amortization once the software project is complete and ready for its intended use. Amortization expense on capitalized internal-use software was $85 million, $108 million and $123 million during the years ended December 31, 2022, 2021 and 2020, respectively. Amortization expense on capitalized internal-use software is estimated to be $66 million in 2023, $43 million in 2024, $26 million in 2025, $20 million in 2026, $8 million in 2027 and $7 million thereafter.

Income Taxes

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

INCOME TAXES

5. INCOME TAXES

The provision for (benefit from) income taxes consists of the following (in millions):

	Year Ended December 31,
	2022			2021			2020
Current:
Federal	$	—		$	(46	)	$	(1	)
State		5			6			3
		5			(40	)		2
Deferred:
Federal		166			161			(162	)
State		(1	)		10			(25	)
		165			171			(187	)
Total provision for (benefit from) income taxes for income	$	170		$	131		$	(185	)

The following table reconciles the differences between the statutory federal income tax rate and the effective tax rate (dollars in millions):

	Year Ended December 31,
	2022						2021						2020
	Amount			%			Amount			%			Amount			%
Provision for (benefit from) income taxes at statutory federal rate	$	73			21.0	%	$	105			21.0	%	$	89			21.0	%
State income taxes, net of federal income tax benefit		3			0.8			44			8.7			(15	)		(3.6	)
Net income attributable to noncontrolling interests		(28	)		(8.0	)		(29	)		(5.8	)		(20	)		(4.7	)
Change in valuation allowance		122			34.9			33			6.8			(267	)		(63.2	)
Nondeductible goodwill		—			—			—			—			41			9.8
Amended return adjustments		—			—			(22	)		(4.4	)		—			—
Nondeductible loss on divestiture		—			—			—			—			(15	)		(3.4	)
Other		—			—			—			—			2			0.3
Provision for (benefit from) income taxes and effective tax rate for income	$	170			48.7	%	$	131			26.3	%	$	(185	)		(43.8	)%

The Company’s effective tax rates were 48.7%, 26.3% and (43.8)% for the years ended December 31, 2022, 2021 and 2020, respectively. The increase in the Company’s effective tax rate for the year ended December 31, 2022, when compared to the year ended December 31, 2021, was primarily due to an increase in non-deductible interest for 2022 compared to 2021, compounded by an adverse change in the IRC Section 163(j) limit for deductible interest expense beginning in 2022. The increase in the Company’s effective tax rate for the year ended December 31, 2021, when compared to the year ended December 31, 2020, was primarily due to a decrease in the valuation allowance in 2020 as a result of an increase to the deductible interest expense allowed for 2019 and 2020 under the CARES Act; the CARES Act related benefits for deductibility of interest recognized in 2020 did not reoccur in 2021.

Deferred income taxes are based on the estimated future tax effects of differences between the financial statement and tax bases of assets and liabilities under the provisions of the enacted tax laws. Deferred income taxes as of December 31, 2022 and 2021 consist of (in millions):

	December 31,
	2022					2021
	Assets			Liabilities		Assets			Liabilities
Net operating loss and credit carryforwards	$	553		$	—	$	833		$	—
Property and equipment		—			323		—			343
Self-insurance liabilities		30			—		49			—
Prepaid expenses		—			31		—			30
Intangibles		—			148		—			144
Investments in unconsolidated affiliates		—			58		—			58
Other liabilities		—			9		—			9
Long-term debt and interest		41			—		48			—
Accounts receivable		16			—		22			—
IRC Section 163(j) interest limitation		448			—		329			—
Accrued vacation		19			—		22			—
Accrued bonus		19			—		31			—
Other comprehensive income		6			—		5			—
Right-of-use assets		—			148		—			137
Right-of-use liability		156			—		142			—
Stock-based compensation		5			—		4			—
Deferred compensation		51			—		64			—
IRC Section 481(a) adjustments		—			122		—			191
Other		19			—		38			—
Total		1,363			839		1,587			912
Valuation allowance		(829	)		—		(814	)		—
Total deferred income taxes	$	534		$	839	$	773		$	912

The Company believes that the net deferred tax assets will ultimately be realized, except as noted below. Its conclusion is based on its estimate of future taxable income and the expected timing of temporary difference reversals. The Company has gross federal net operating loss carryforwards of approximately $68 million and state net operating loss carryforwards of approximately $9.6 billion, which expire from 2023 through 2042. The Company’s tax affected federal and state net operating loss and credit carryforwards are approximately $21 million and $532 million, respectively. A valuation allowance of approximately $829 million has been recognized for state net operating loss carryforwards, state credit carryforwards and federal and state deferred tax assets that the Company does not expect to be able to realize. With respect to the deferred tax liability pertaining to intangibles, as included above, goodwill purchased in connection with certain of the Company’s business acquisitions is amortizable for income tax reporting purposes. However, for financial reporting purposes, there is no corresponding amortization allowed with respect to such purchased goodwill.

The valuation allowance for federal and state jurisdictions where the Company concluded that the associated deferred tax assets would not be realized increased by $122 million and decreased by $108 million, respectively, for the year ended December 31, 2022, and increased by $64 million and decreased by $31 million, respectively, for the year ended December 31, 2021.

The total amount of unrecognized benefit that would affect the effective tax rate, if recognized, was $2 million as of December 31, 2022. A total of less than $1 million of interest and penalties is included in the amount of the liability for uncertain tax positions at December 31, 2022. It is the Company’s policy to recognize interest and penalties related to unrecognized benefits in its consolidated statements of income as income tax expense.

It is possible the amount of unrecognized tax benefit could change in the next 12 months as a result of a lapse of the statute of limitations and settlements with taxing authorities; however, the Company does not anticipate the change will have a material impact on the Company’s consolidated results of operations or consolidated financial position.

The following is a tabular reconciliation of the total amount of unrecognized tax benefit for the years ended December 31, 2022, 2021 and 2020 (in millions):

	Year Ended December 31,
	2022		2021			2020
Unrecognized tax benefit, beginning of year	$	42	$	45		$	26
Gross increases — tax positions in current period		8		5			19
Reductions — tax positions in prior period		—		(8	)		—
Unrecognized tax benefit, end of year	$	50	$	42		$	45

The Company’s income tax return for the 2014, 2015 and 2018 tax years remain under examination by the Internal Revenue Service. The Company believes the result of this examination will not be material to its consolidated results of operations or consolidated financial position. The Company has extended the federal statute of limitations through December 31, 2023 for Community Health Systems, Inc. for the tax period ended December 31, 2018.

Cash paid for income taxes, net of refunds received, was $6 million, $4 million and $2 million during the years ended December 31, 2022, 2021 and 2020, respectively.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Long-Term Debt

12 Months Ended

Dec. 31, 2022

Long Term Debt And Capital Lease Obligations [Abstract]

LONG-TERM DEBT

6. LONG-TERM DEBT

Long-term debt, net of unamortized debt issuance costs and discounts or premiums, consists of the following (in millions):

	December 31,
	2022			2021
6⅝% Senior Secured Notes due 2025	$	—		$	1,462
8% Senior Secured Notes due 2026		2,101			2,101
8% Senior Secured Notes due 2027		700			700
5⅝% Senior Secured Notes due 2027		1,900			1,900
6⅞% Senior Notes due 2028		756			767
6% Senior Secured Notes due 2029		900			900
5¼% Senior Secured Notes due 2030		1,535			—
4¾% Senior Secured Notes due 2031		1,058			1,095
6⅞% Junior-Priority Secured Notes due 2029		1,386			1,775
6⅛% Junior-Priority Secured Notes due 2030		1,232			1,440
ABL Facility		53			—
Finance lease and financing obligations		380			398
Other		36			37
Less: Unamortized deferred debt issuance costs and note discount		(402	)		(435	)
Total debt		11,635			12,140
Less: Current maturities		(21	)		(31	)
Total long-term debt	$	11,614		$	12,109

6⅝% Senior Notes due 2025

On February 4, 2022, CHS/Community Health Systems, Inc. (“CHS”) completed a private offering of $1.535 billion aggregate principal amount of 5¼% Senior Secured Notes due May 15, 2030 (the “5¼% Senior Secured Notes due 2030”). The proceeds of the offering were used to redeem the 6⅝% Senior Secured Notes due 2025 on February 4, 2022, and to pay related fees and expenses.

The 6⅝% Senior Secured Notes due 2025 bore interest at a rate of 6.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year, commencing on August 15, 2020. The 6⅝% Senior Secured Notes were scheduled to mature on February 15, 2025. The 6⅝% Senior Secured Notes due 2025 were unconditionally guaranteed on a senior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under the Company’s asset-based loan facility (“ABL Facility”), any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS. The 6⅝% Senior Secured Notes due 2025 and the related guarantees were secured by shared (i) first-priority liens on the Non-ABL Priority Collateral and (ii) second-priority liens on the ABL Priority Collateral that secured on a first-priority

basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 6⅝% Senior Secured Notes due 2025.

8% Senior Secured Notes due 2026

On March 6, 2019, CHS completed a private offering of $1.601 billion aggregate principal amount of the 8% Senior Secured Notes due March 15, 2026 (the “8% Senior Secured Notes due 2026”). The net proceeds from this issuance were used to finance the repayment of approximately $1.557 billion aggregate principal amount of CHS’ then outstanding Term H Facility and related fees and expenses. On November 19, 2019, CHS completed a tack-on offering of $500 million aggregate principal amount of the additional 2026 Notes, increasing the total aggregate principal amount of the 8% Senior Secured Notes due 2026 to $2.101 billion. CHS used the proceeds from the additional 2026 Notes to repay amounts outstanding under the ABL Facility, redeem all $121 million aggregate principal amount of CHS’ then outstanding 7⅛% Senior Notes due 2020 and repay borrowings outstanding under the ABL Facility. The additional 2026 Notes have identical terms, other than issue date, issue price and the date from which interest initially accrued, as the 8% Senior Secured Notes due 2026 issued on March 6, 2019. The 8% Senior Secured Notes due 2026 bear interest at a rate of 8.000% per annum, payable semi-annually in arrears on March 15 and September 15 of each year. Interest on the 8% Senior Secured Notes due 2026 accrues from the initial issuance date of the 8% Senior Secured Notes due 2026. Interest is calculated on the basis of a 360-day year comprised of 12 30-day months. The 8% Senior Secured Notes due 2026 are scheduled to mature on March 15, 2026.

The 8% Senior Secured Notes due 2026 are unconditionally guaranteed on a senior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS᾿ outstanding senior notes) and certain other long-term debt of CHS.

The 8% Senior Secured Notes due 2026 and the related guarantees are secured by shared (i) first-priority liens on the Non-ABL Priority Collateral and (ii) second-priority liens on the ABL Priority Collateral that secures on a first-priority basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 8% Senior Secured Notes due 2026.

Prior to March 15, 2022, CHS may redeem some or all of the 8% Senior Secured Notes due 2026 at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 8% Senior Secured Notes due 2026. In addition, at any time prior to March 15, 2022, CHS may redeem up to 40% of the aggregate principal amount of the 8% Senior Secured Notes due 2026 with the proceeds from certain equity offerings at the redemption price of 108.000%, plus accrued and unpaid interest, if any, to, but excluding, the applicable redemption date.

After March 15, 2022, CHS is entitled, at its option, to redeem all or a portion of the 8% Senior Secured Notes due 2026 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
March 15, 2022 to March 14, 2023		104.000	%
March 15, 2023 to March 14, 2024		102.000	%
March 15, 2024 to March 14, 2026		100.000	%

8% Senior Secured Notes due 2027

On November 19, 2019, CHS issued approximately $700 million aggregate principal amount of the 8% Senior Secured Notes due December 15, 2027 (the “8% Senior Secured Notes due 2027”) in connection with the 2019 Exchange Offer. No cash proceeds were received from the 2019 Exchange Offer. The 8% Senior Secured Notes due 2027 bear interest at a rate of 8.000% per annum, payable semi-annually in arrears on June 15 and December 15 of each year. Interest on the 8% Senior Secured Notes due 2027 accrues from the initial issuance date of the 8% Senior Secured Notes due 2027. Interest is calculated on the basis of a 360-day year comprised of 12 30-day months. The 8% Senior Secured Notes due 2027 are scheduled to mature on December 15, 2027. The 8% Senior Secured Notes due 2027 are unconditionally guaranteed on a senior-priority secured basis by the Company and each of CHS’ current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS᾿outstanding senior notes) and certain other long-term debt of CHS.

The 8% Senior Secured Notes due 2027 and the related guarantees are secured by shared (i) first-priority liens on the Non-ABL Priority Collateral and (ii) second-priority liens on the ABL Priority Collateral that secures on a first-priority basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 8% Senior Secured Notes due 2027.

CHS is entitled, at its option, to redeem all or a portion of the 8% Senior Secured Notes due 2027 at any time prior to December 15, 2022, upon not less than 15 nor more than 60 days’ notice, at a price equal to 100% of the principal amount of the 8% Senior Secured Notes due 2027 redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 8% Senior Secured Notes due 2027. In addition, CHS may redeem up to 40% of the aggregate principal amount of the 8% Senior Secured Notes due 2027 at any time prior to December 15, 2022 using the net proceeds from certain equity offerings at the redemption price of 108.000% of the principal amount of the 8% Senior Secured Notes due 2027 redeemed, plus accrued and unpaid interest, if any.

CHS may redeem some or all of the 8% Senior Secured Notes due 2027 at any time on or after December 15, 2022 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
December 15, 2022 to December 14, 2023		104.000	%
December 15, 2023 to December 14, 2024		102.000	%
December 15, 2024 to December 14, 2027		100.000	%

5⅝% Senior Secured Notes due 2027

On December 28, 2020, CHS completed a private offering of $1.9 billion aggregate principal amount of 5⅝% Senior Secured Notes due March 15, 2027 (the “5⅝% Senior Secured Notes due 2027”). The proceeds of the offering were used to repurchase approximately $2.579 billion of the outstanding principal amount of 6¼% Senior Secured Notes due 2023 that were validly tendered and accepted for purchase pursuant to the early tender deadline of a tender offer that launched on December 11, 2020, and to pay related fees. The remaining principal value of 6¼% Senior Secured Notes due 2023 that were not validly tendered as of the early tender deadline were redeemed or repurchased via the completion of the tender offer on January 11, 2021 or redemption on January, 28, 2021. The 5⅝% Senior Secured Notes due 2027, which mature on March 15, 2027, bear interest at a rate of 5⅝% per year payable semi-annually in arrears on March 15 and September 15 of each year, commencing on September 15, 2021. The 5⅝% Senior Secured Notes due 2027 are unconditionally guaranteed on a senior-priority secured basis by the Company and each of CHS’ current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS.

The 5⅝% Senior Secured Notes due 2027 and the related guarantees are secured by shared (i) first-priority liens on the Non-ABL Priority Collateral and (ii) second-priority liens on the ABL Priority Collateral that secures on a first-priority basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 5⅝% Senior Secured Notes due 2027.

CHS is entitled, at its option, to redeem all or a portion of the 5⅝% Senior Secured Notes due 2027 at any time prior to December 15, 2023, upon not less than 15 nor more than 60 days’ notice, at a price equal to 100% of the principal amount of the 5⅝% Senior Secured Notes due 2027 redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 5⅝% Senior Secured Notes due 2027. In addition, CHS may redeem up to 40% of the aggregate principal amount of the 5⅝% Senior Secured Notes due 2027 at any time prior to December 15, 2023 using the net proceeds from certain equity offerings at the redemption price of 105.625% of the principal amount of the 5⅝% Senior Secured Notes due 2027 redeemed, plus accrued and unpaid interest, if any.

At any time and from time to time on or after December 15, 2023, CHS may redeem the 5⅝% Senior Secured Notes due 2027 in whole or in part, upon not less than 15 no more than 60 days’ prior written notice at a redemption price equal to the percentage of principal amount set forth below plus accrued and unpaid interest, if any, on the 5⅝% Senior Secured Notes due 2027 redeemed, to, but excluding, the applicable date of redemption, if redeemed during the 12 month period beginning on December 15 of the years indicated below:

Period	Redemption Price
December 15, 2023 to December 14, 2024		102.813	%
December 15, 2024 to December 14, 2025		101.406	%
December 15, 2025 to December 14, 2027		100.000	%

6⅞% Senior Notes due 2028

On November 19, 2019, CHS issued approximately $1.7 billion aggregate principal amount of the 6⅞% Senior Notes due April 1, 2028 (“the 6⅞% Senior Notes due 2028”) in connection with the 2019 Exchange Offer. No cash proceeds were received in the 2019 Exchange Offer. The 6⅞% Senior Notes due 2028 bear interest at a rate of 6.875% per annum, payable semi-annually in arrears on April 1 and October 1 of each year. Interest on the 6⅞% Senior 2028 Notes accrues from the initial issuance date of the 6⅞% Senior Notes due 2028. Interest is calculated on the basis of a 360-day year comprised of 12 30-day months. The 6⅞% Senior Notes due 2028 are scheduled to mature on April 1, 2028.

The 6⅞% Senior Notes due 2028 are unconditionally guaranteed on a senior-priority unsecured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS᾿ outstanding senior notes) and certain other long-term debt of CHS.

CHS is entitled, at its option, to redeem all or a portion of the 6⅞% Senior Notes due 2028 at any time prior to April 1, 2023, upon not less than 15 nor more than 60 days’ notice, at a price equal to 100% of the principal amount of the 6⅞% Senior Notes due 2028 redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 6⅞% Senior Notes due 2028. In addition, the Issuer may redeem up to 40% of the aggregate principal amount of the 6⅞% Senior Notes due 2028 at any time prior to April 1, 2023 using the net proceeds from certain equity offerings at the redemption price of 106.875% of the principal amount of the 6⅞% Senior Notes due 2028 redeemed, plus accrued and unpaid interest, if any.

CHS may redeem some or all of the 6⅞% Senior Notes due 2028 at any time on or after April 1, 2023 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
April 1, 2023 to March 31, 2024		103.438	%
April 1, 2024 to March 31, 2025		101.719	%
April 1, 2025 to March 31, 2028		100.000	%

On December 7, 2020, CHS entered into a privately negotiated agreement with a multi-asset investment manager who has certain funds and accounts which are holders of the 6⅞% Senior Notes due 2028. Pursuant to the agreement, the Company exchanged $700 million aggregate principal amount of the 6⅞% Senior Notes due 2028 for an aggregate consideration of $400 million of cash and 10 million newly issued shares of the Company’s common stock. The exchange transaction was completed on December 9, 2020 and the shares of common stock issued in the exchange were not, and are not required to be, registered under the Securities Act of 1933 pursuant to an exemption from registration provisions via Section 3(a)(9) of the Securities Act of 1933. A gain from early extinguishment of debt of approximately $205 million was recognized associated with this exchange.

During the year ended December 31, 2020, the Company extinguished $226 million in principal of the 6⅞% Senior Notes due 2028 through open market repurchases and approximately $7 million via a tender offer that commenced on October 30, 2020 and expired on November 30, 2020.

6% Senior Secured Notes due 2029

On December 28, 2020, CHS completed a private offering of $900 million aggregate principal amount of 6% Senior Secured Notes due January 15, 2029 (the “6% Senior Secured Notes due 2029”). The proceeds of the offering were used, together with proceeds from the 5⅝% Senior Secured Notes due 2027 described above, to repurchase approximately $2.579 billion of the outstanding principal amount of 6¼% Senior Secured Notes due 2023 that were validly tendered and accepted for purchase pursuant to the early tender deadline of a tender offer that launched on December 11, 2020, and to pay related fees. The remaining principal value of 6¼% Senior Secured Notes due 2023 that were not validly tendered as of the early tender deadline were redeemed or repurchased via the completion of the tender offer on January 11, 2021 or redemption on January, 28, 2021. The 6% Senior Secured Notes due 2029, which mature on January 15, 2029, bear interest at a rate of 6% per year payable semi-annually in arrears on January 15 and July 15 of each year, commencing on July 15, 2021. The 6% Senior Secured Notes due 2029 are unconditionally guaranteed on a senior-priority secured basis by each of CHS’ current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS.

The 6% Senior Secured Notes due 2029 and the related guarantees are secured by shared (i) first-priority liens on the Non-ABL Priority Collateral and (ii) second-priority liens on the ABL Priority Collateral that secures on a first-priority basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 6% Senior Secured Notes due 2029.

CHS is entitled, at its option, to redeem all or a portion of the 6% Senior Secured Notes due 2029 at any time prior to January 15, 2024, upon not less than 15 nor more than 60 days’ notice, at a price equal to 100% of the principal amount of the 6% Senior Secured Notes due 2029 redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 6% Senior Secured Notes due 2029. In addition, CHS may redeem up to 40% of the aggregate principal amount of the 6% Senior Secured Notes due 2029 at any time prior to January 15, 2024 using the net proceeds from certain equity offerings at the redemption price of 106.000% of the principal amount of the 6% Senior Secured Notes due 2029 redeemed, plus accrued and unpaid interest, if any.

At any time and from time to time on or after January 15, 2024, CHS may redeem the 6% Senior Secured Notes due 2029 in whole or in part, upon not less than 15 nor more than 60 days’ prior written notice at a redemption price equal to the percentage of principal amount set forth below plus accrued and unpaid interest, if any, on the 6% Senior Secured Notes due 2029 redeemed, to, but excluding, the applicable date of redemption, if redeemed during the 12 month period beginning on January 15 of the years indicated below:

Period	Redemption Price
January 15, 2024 to January 14, 2025		103.000	%
January 15, 2025 to January 14, 2026		101.500	%
January 15, 2026 to January14, 2029		100.000	%

5¼% Senior Secured Notes due 2030

On February 4, 2022, CHS completed a private offering of $1.535 billion aggregate principal amount of 5¼% Senior Secured Notes due May 15, 2030 (the “5¼% Senior Secured Notes due 2030”). The proceeds of the offering were used to redeem the 6⅝% Senior Secured Notes due 2025 on February 4, 2022, and to pay related fees and expenses. The 5¼% Senior Secured Notes due 2030 bear interest at a rate of 5.250% per year payable semi-annually in arrears on May 15 and November 15, commencing on November 15, 2022. The 5¼% Senior Secured Notes due 2030 are unconditionally guaranteed on a senior-priority secured basis by each of CHS’ current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS.

The 5¼% Senior Secured Notes due 2030 and the related guarantees are secured by shared (i) first-priority liens on the Non-ABL Priority Collateral and (ii) second-priority liens on the ABL Priority Collateral that secures on a first-priority basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 5¼% Senior Secured Notes due 2030.

CHS is entitled, at its option, to redeem all or a portion of the 5¼% Senior Secured Notes due 2030 at any time prior to May 15, 2025, upon not less than 10 nor more than 60 days’ notice, at a price equal to 100% of the principal amount of the 5¼% Senior Secured Notes due 2030 redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 5¼% Senior Secured Notes due 2030.

CHS may redeem up to 40% of the aggregate principal amount of the 5¼% Senior Secured Notes due 2030 at any time prior to May 15, 2025 using the net proceeds from certain equity offerings at a redemption price of 105.250% of the principal amount of the 5¼% Senior Secured Notes due 2030 redeemed, plus accrued and unpaid interest, if any. In addition, any time prior to May 15, 2025, but not more than once during each 12 month period, CHS may redeem up to 10% of the original aggregate principal amount of the 5¼% Senior Secured Notes due 2030 at a redemption price equal to 103% of the principal amount of the 5¼% Senior Secured Notes due 2030 to be redeemed, plus accrued and unpaid interest, if any.

At any time and from time to time on or after May 15, 2025, CHS may redeem the 5¼% Senior Secured Notes due 2030 in whole or in part, upon not less than 10 nor more than 60 days’ prior written notice at a redemption price equal to the percentage of principal amount set forth below plus accrued and unpaid interest, if any, on the 5¼% Senior Secured Notes due 2030 redeemed, to, but excluding, the applicable date of redemption, if redeemed during the 12 month period beginning on May 15 of the years indicated below:

Period	Redemption Price
May 15, 2025 to May 14, 2026		102.625	%
May 15, 2026 to May 14, 2027		101.313	%
May 15, 2027 to May 14, 2030		100.000	%

4¾% Senior Secured Notes due 2031

On February 9, 2021, CHS completed a private offering of $1.095 billion aggregate principal amount of 4¾% Senior Secured Notes due February 15, 2031 (the “4¾% Senior Secured Notes due 2031”). The proceeds of the offering, together with cash on hand, were used to redeem the 8⅝% Senior Secured Notes due 2024 on February 9, 2021, and to pay related fees and expenses. The 4¾% Senior Secured Notes due 2031 bear interest at a rate of 4.750% per year payable semi-annually in arrears on February 15 and August 15, commencing on August 15, 2021. The 4¾% Senior Secured Notes due 2031 are unconditionally guaranteed on a senior-priority secured basis by each of CHS’ current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS.

The 4¾% Senior Secured Notes due 2031 and the related guarantees are secured by shared (i) first-priority liens on the Non-ABL Priority Collateral and (ii) second-priority liens on the ABL Priority Collateral that secures on a first-priority basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 4¾% Senior Secured Notes due 2031.

CHS is entitled, at its option, to redeem all or a portion of the 4¾% Senior Secured Notes due 2031 at any time prior to February 15, 2026, upon not less than 15 nor more than 60 days’ notice, at a price equal to 100% of the principal amount of the 4¾% Senior Secured Notes due 2031 redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 4¾% Senior Secured Notes due 2031.

CHS may redeem up to 40% of the aggregate principal amount of the 4¾% Senior Secured Notes due 2031 at any time prior to February 15, 2024 using the net proceeds from certain equity offerings at a redemption price of 104.750% of the principal amount of the 4¾% Senior Secured Notes due 2031 redeemed, plus accrued and unpaid interest, if any. In addition, any time prior to February 15, 2026, but not more than once during each 12 month period, CHS may redeem up to 10% of the original aggregate principal amount of the 4¾% Senior Secured Notes due 2031 at a redemption price equal to 103% of the principal amount of the 4¾% Senior Secured Notes due 2031 to be redeemed, plus accrued and unpaid interest, if any.

At any time and from time to time on or after February 15, 2026, CHS may redeem the 4¾% Senior Secured Notes due 2031 in whole or in part, upon not less than 15 nor more than 60 days’ prior written notice at a redemption price equal to the percentage of principal amount set forth below plus accrued and unpaid interest, if any, on the 4¾% Senior Secured Notes due 2031 redeemed, to, but excluding, the applicable date of redemption, if redeemed during the 12 month period beginning on February 15 of the years indicated below:

Period	Redemption Price
February 15, 2026 to February 14, 2027		102.375	%
February 15, 2027 to February 14, 2028		101.583	%
February 15, 2028 to February 14, 2029		100.792	%
February 15, 2029 to February 14, 2031		100.000	%

6⅞% Junior-Priority Secured Notes due 2029

On February 2, 2021, CHS completed a private offering of $1.775 billion aggregate principal amount of 6⅞% Junior-Priority Secured Notes due April 15, 2029 (the “6⅞% Junior-Priority Secured Notes due 2029”). The proceeds of the offering, together with cash on hand, were used to redeem the 9⅞% Junior-Priority Secured Notes due 2023 in February 2021 and to pay related fees and expenses. The 6⅞% Junior-Priority Secured Notes due 2029 bear interest at a rate of 6.875% per year payable semi-annually in arrears on April 15 and October 15 of each year, commencing on October 15, 2021. The 6⅞% Junior-Priority Secured Notes due 2029 are unconditionally guaranteed on a junior-priority secured basis by the Company and each of the current and future domestic subsidiaries of CHS that provide guarantees under CHS’ ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS.

The 6⅞% Junior-Priority Secured Notes due 2029 and the related guarantees are secured by shared (i) second-priority liens on the Non-ABL Priority Collateral that secures on a first-priority basis CHS’ senior-priority secured notes and (ii) third-priority liens on the

ABL-Priority Collateral that secures on a first-priority basis the ABL Facility (and also secures on a second-priority basis CHS’ senior-priority secured notes), in each case subject to permitted liens described in the indenture governing the 6⅞% Junior-Priority Secured Notes due 2029.

At any time and from time to time prior to April 15, 2024, CHS may redeem the 6⅞% Junior-Priority Secured Notes due 2029 in whole or in part, at its option, upon not less than 15 nor more than 60 days’ prior written notice at a redemption price equal to 100% of the principal amount of the 6⅞% Junior-Priority Secured Notes due 2029 to be redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 6⅞% Junior-Priority Secured Notes due 2029. In addition, CHS may redeem up to 40% of the aggregate principal amount of the 6⅞% Junior-Priority Secured Notes due 2029 at any time prior to April 15, 2024 using the net proceeds from certain equity offerings at a redemption price of 106.875% of the principal amount of the 6⅞% Junior-Priority Secured Notes due 2029 redeemed, plus accrued and unpaid interest, if any.

At any time and from time to time on or after April 15, 2024, CHS may redeem the 6⅞% Junior-Priority Secured Notes due 2029 in whole or in part, upon not less than 15 nor more than 60 days’ prior written notice at a redemption price equal to the percentage of principal amount set forth below plus accrued and unpaid interest, if any, on the 6⅞% Junior-Priority Secured Notes due 2029 redeemed, to, but excluding, the applicable date of redemption, if redeemed during the 12 month period beginning on April 15 of the years indicated below:

Period	Redemption Price
April 15, 2024 to April 14, 2025		103.438	%
April 15, 2025 to April 14, 2026		101.719	%
April 15, 2026 to April 14, 2029		100.000	%

6⅛% Junior-Priority Secured Notes due 2030

On May 19, 2021, CHS completed a private offering of $1.440 billion aggregate principal amount of 6⅛% Junior-Priority Secured Notes due April 1, 2030 (the “6⅛% Junior-Priority Secured Notes due 2030”). The proceeds of the offering, together with cash on hand, were used to redeem the 8⅛% Junior-Priority Secured Notes due 2024 on May 19, 2021, and to pay related fees and expenses. The 6⅛% Junior-Priority Secured Notes due 2030 bear interest at a rate of 6.125% per year payable semi-annually in arrears on April 1 and October 1, commencing on October 1, 2021. The 6⅛% Junior-Priority Secured Notes due 2030 are unconditionally guaranteed on a junior-priority secured basis by each of CHS’ current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS.

The 6⅛% Junior-Priority Secured Notes due 2030 and the related guarantees are secured by shared (i) second-priority liens on the Non-ABL Priority Collateral and (ii) third-priority liens on the ABL Priority Collateral that secures on a first-priority basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 6⅛% Junior-Priority Secured Notes due 2030.

CHS is entitled, at its option, to redeem all or a portion of the 6⅛% Junior-Priority Secured Notes due 2030 at any time prior to April 1, 2025, upon not less than 15 nor more than 60 days’ notice, at a price equal to 100% of the principal amount of the 6⅛% Junior-Priority Secured Notes due 2030 redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 6⅛% Junior-Priority Secured Notes due 2030.

CHS may redeem up to 40% of the aggregate principal amount of the 6⅛% Junior-Priority Secured Notes due 2030 at any time prior to May 15, 2024 using the net proceeds from certain equity offerings at a redemption price of 106.125% of the principal amount of the 6⅛% Junior-Priority Secured Notes due 2030 redeemed, plus accrued and unpaid interest, if any.

At any time and from time to time on or after April 1, 2025, CHS may redeem the 6⅛% Junior-Priority Secured Notes due 2030 in whole or in part, upon not less than 15 nor more than 60 days’ prior written notice at a redemption price equal to the percentage of principal amount set forth below plus accrued and unpaid interest, if any, on the 6⅛% Junior-Priority Secured Notes due 2030 redeemed, to, but excluding, the applicable date of redemption, if redeemed during the 12 month period beginning on April 1 of the years indicated below:

Period	Redemption Price
April 1, 2025 to March 31, 2026		103.063	%
April 1, 2026 to March 31, 2027		101.531	%
April 1, 2027 to March 31, 2030		100.000	%

During the year ended December 31, 2022, the Company extinguished a portion of certain series of its outstanding notes through open market and privately negotiated repurchases, as follows (in millions):

	Principal Amount
6⅞% Senior Notes due 2028	$	11
4¾% Senior Secured Notes due 2031		37
6⅞% Junior-Priority Secured Notes due 2029		389
6⅛% Junior-Priority Secured Notes due 2030		208
Total principal amount of debt extinguished	$	645

Financing and repayment transactions discussed above resulted in a pre-tax and after-tax gain from early extinguishment of debt of $253 million and $208 million, respectively, for the year ended December 31, 2022, a pre-tax and after-tax loss from early extinguishment of $79 million and $116 million, respectively, for the year ended December 31, 2021, and a pre-tax and after-tax gain from early extinguishment of $317 million and $352 million, respectively, for the year ended December 31, 2020.

ABL Facility

On November 22, 2021, the Company and CHS entered into an amendment and restatement agreement (the “Amendment”) to refinance and replace the asset-based loan (ABL) credit agreement (the “ABL Credit Agreement” and, as amended by the Amendment, the “Amended and Restated ABL Credit Agreement”), dated as of April 3, 2018, with JPMorgan Chase Bank, N.A., as administrative agent, and the lenders and other agents party thereto. Pursuant to the Amended and Restated ABL Credit Agreement, the lenders have extended to CHS a revolving asset-based loan facility in the maximum aggregate principal amount of $1.0 billion, subject to borrowing base capacity. The ABL Facility includes borrowing capacity available for letters of credit of $200 million. CHS and all domestic subsidiaries of CHS that guarantee CHS’ other outstanding senior and senior secured indebtedness guarantee the obligations of CHS under the ABL Facility. Subject to certain exceptions, all obligations under the ABL Facility and the related guarantees are secured by a perfected first-priority security interest in substantially all of the receivables, deposit, collection and other accounts and contract rights, books, records and other instruments related to the foregoing of the Company, CHS and the guarantors, as well as a perfected junior-priority security interest in substantially all of the other assets of the Company, CHS and the guarantors, subject to customary exceptions and intercreditor arrangements. At December 31, 2022, the Company had outstanding borrowings of $53 million and approximately $852 million of additional borrowing capacity (after taking into consideration the $83 million of outstanding letters of credit) under the ABL Facility. The issued letters of credit were primarily in support of potential insurance-related claims and certain bonds.

Borrowings under the ABL Facility bear interest at a rate per annum equal to an applicable percentage, plus, at the borrower’s option, either (a) a base rate or (b) the Federal Reserve’s secured overnight financing rate (“SOFR”). The applicable margin under the ABL Facility is determined based on excess availability as a percentage of the maximum commitment amount under the ABL Facility at a rate per annum of 0.75%, 1.00% and 1.25% for loans based on the base rate and 1.75%, 2.00% and 2.25% for loans based on SOFR. The applicable commitment fee rate under the ABL Facility is determined based on average utilization as a percentage of the maximum commitment amount under the ABL Facility at a rate per annum of either 0.25% or 0.375% times the unused portion of the ABL Facility.

Principal amounts outstanding under the ABL Facility will be due and payable in full on November 22, 2026. The ABL Facility includes a 91-day springing maturity applicable if more than $350 million in the aggregate principal amount of the 6⅝% Senior Secured Notes due 2025, 8% Senior Secured Notes due 2026 or 5⅝% Senior Secured Notes due 2027 or any indebtedness incurred to refinance the foregoing are scheduled to mature or similarly become due on a date prior to November 22, 2026. In such event, principal amounts outstanding under the ABL Facility will be accelerated and all amounts outstanding under the ABL Facility will become immediately due and payable.

The ABL Facility contains customary representations and warranties, subject to limitations and exceptions, and customary covenants restricting the Company’s ability, subject to certain exceptions, to, among other things (1) declare dividends, make

distributions or redeem or repurchase capital stock, (2) prepay, redeem or repurchase other debt, (3) incur liens or grant negative pledges, (4) make loans and investments and enter into acquisitions and joint ventures, (5) incur additional indebtedness or provide certain guarantees, (6) engage in mergers, acquisitions and asset sales, (7) conduct transactions with affiliates, (8) alter the nature of the Company’s, CHS’ or the guarantors’ businesses, (9) grant certain guarantees with respect to physician practices, (10) engage in sale and leaseback transactions or (11) change the Company’s fiscal year. The Company is also required to comply with a consolidated fixed coverage ratio, upon certain triggering events described below, and various affirmative covenants. The consolidated fixed coverage ratio is calculated as the ratio of (x) consolidated EBITDA (as defined in the ABL Facility) less capital expenditures to (y) the sum of consolidated interest expense (as defined in the ABL Facility), scheduled principal payments, income taxes and restricted payments made in cash or in permitted investments. For purposes of calculating the consolidated fixed charge coverage ratio, the calculation of consolidated EBITDA as defined in the ABL Facility is a trailing 12-month calculation that begins with the Company’s consolidated net income, with certain adjustments for interest, taxes, depreciation and amortization, net income attributable to noncontrolling interests, stock compensation expense, restructuring costs, and the financial impact of other non-cash or non-recurring items recorded during any such 12-month period. The consolidated fixed charge coverage ratio is a required covenant only in periods where the total borrowings outstanding under the ABL Facility reduce the amount available in the facility to less than the greater of (i) $95 million or (ii) 10% of the calculated borrowing base. As a result, in the event the Company has less than $95 million available under the ABL Facility, the Company would need to comply with the consolidated fixed charge coverage ratio. At December 31, 2022, the Company is not subject to the consolidated fixed charge coverage ratio as such triggering event had not occurred during the year ended December 31, 2022.

In addition, in the event the amount of borrowings and letters of credit outstanding at any time under the ABL Facility exceeds the borrowing base at such time, the Company will be required to, first, repay outstanding borrowings and, second, replace or cash collateralize outstanding letters of credit, in an aggregate amount sufficient to eliminate such excess.

Events of default under the ABL Facility include, but are not limited to, (1) CHS’ failure to pay principal, interest, fees or other amounts under the ABL Facility Agreement when due (taking into account any applicable grace period), (2) any representation or warranty proving to have been materially incorrect when made, (3) covenant defaults subject, with respect to certain covenants, to an available cure and applicable grace periods, (4) bankruptcy and insolvency events, (5) a cross default to certain other debt, (6) certain undischarged judgments (not paid within an applicable grace period), (7) a change of control (as defined), (8) certain ERISA-related defaults and (9) the invalidity or impairment of specified security interests, guarantees or subordination provisions in favor of the ABL agent or lenders under the ABL Facility.

As of December 31, 2022, the scheduled maturities of long-term debt outstanding, including finance lease and financing obligations for each of the next four years and thereafter are as follows (in millions):

Year Ending December 31,	Amount
2023	$	21
2024		15
2025		10
2026		2,163
2027		2,609
Thereafter		7,219
Total maturities		12,037
Less: Deferred debt issuance costs		(391	)
Less: Unamortized note discount		(11	)
Total long-term debt	$	11,635

The Company paid interest of $835 million, $778 million and approximately $1.0 billion on borrowings during the years ended December 31, 2022, 2021 and 2020, respectively.

Fair Value of Financial Instruments

12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

FAIR VALUE OF FINANCIAL INSTRUMENTS

7. FAIR VALUE OF FINANCIAL INSTRUMENTS

The fair value of financial instruments has been estimated by the Company using available market information as of December 31, 2022 and 2021, and valuation methodologies considered appropriate. The estimates presented in the table below are not necessarily indicative of amounts the Company could realize in a current market exchange (in millions):

	December 31, 2022				December 31, 2021
	Carrying		Estimated Fair		Carrying		Estimated Fair
	Amount		Value		Amount		Value
Assets:
Cash and cash equivalents	$	118	$	118	$	507	$	507
Investments in equity securities		107		107		144		144
Available-for-sale debt securities		179		179		178		178
Trading securities		5		5		13		13
Liabilities:
6⅝% Senior Secured Notes due 2025		—		—		1,434		1,517
8% Senior Secured Notes due 2026		2,083		1,917		2,078		2,210
8% Senior Secured Notes due 2027		693		631		692		758
5⅝% Senior Secured Notes due 2027		1,833		1,633		1,819		2,011
6⅞% Senior Notes due 2028		749		389		759		758
6% Senior Secured Notes due 2029		865		751		860		966
5¼% Senior Secured Notes due 2030		1,448		1,166		—		—
4¾% Senior Secured Notes due 2031		1,053		766		1,090		1,108
6⅞% Junior-Priority Secured Notes due 2029		1,282		720		1,625		1,823
6⅛% Junior-Priority Secured Notes due 2030		1,164		615		1,352		1,431
ABL Facility and other debt		85		85		32		32

The carrying value of the Company’s long-term debt in the above table is presented net of unamortized deferred debt issuance costs. The estimated fair value is determined using the methodologies discussed below in accordance with accounting standards related to the determination of fair value based on the U.S. GAAP fair value hierarchy as discussed in Note 8. The estimated fair value for financial instruments with a fair value that does not equal its carrying value is considered a Level 1 valuation. The Company utilizes the market approach and obtains indicative pricing through publicly available subscription services such as Bloomberg to determine fair values where relevant.

Cash and cash equivalents. The carrying amount approximates fair value due to the short-term maturity of these instruments (less than three months).

Investments in equity securities. Estimated fair value is based on closing price as quoted in public markets.

Available-for-sale debt securities. Estimated fair value is based on closing price as quoted in public markets or other various valuation techniques.

Trading securities. Estimated fair value is based on closing price as quoted in public markets.

Senior Notes, Senior Secured Notes and Junior-Priority Secured Notes. Estimated fair value is based on the closing market price for these notes.

ABL Facility and other debt. The carrying amount of the ABL Facility and all other debt approximates fair value due to the nature of these obligations.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Fair Value

12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

FAIR VALUE

8. FAIR VALUE

Fair Value Hierarchy

Fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering

market participant assumptions in fair value measurements, the Company utilizes the U.S. GAAP fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumption about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

The inputs used to measure fair value are classified into the following fair value hierarchy:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes values determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting the Company’s own assumptions.

In instances where the determination of the fair value hierarchy measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment of factors specific to the asset or liability. Transfers between levels within the fair value hierarchy are recognized by the Company on the date of the change in circumstances that requires such transfer. There were no transfers between levels during the years ended December 31, 2022 or 2021.

The following table sets forth, by level within the fair value hierarchy, the financial assets recorded at fair value on a recurring basis as of December 31, 2022 and 2021 (in millions):

	December 31, 2022		Level 1		Level 2		Level 3
Investments in equity securities	$	107	$	107	$	—	$	—
Available-for-sale debt securities		179		—		179		—
Trading securities		5		—		5		—
Total assets	$	291	$	107	$	184	$	—

	December 31, 2021		Level 1		Level 2		Level 3
Investments in equity securities	$	144	$	144	$	—	$	—
Available-for-sale debt securities		178		—		178		—
Trading securities		13		—		13		—
Total assets	$	335	$	144	$	191	$	—

Investments in Equity Securities, Available-for-Sale Debt Securities and Trading Securities

Investments in equity securities classified as Level 1 are measured using quoted market prices. Level 2 available-for-sale debt securities and trading securities primarily consisted of bonds and notes issued by the United States government and its agencies and domestic and foreign corporations. The estimated fair values of these securities are determined using various valuation techniques, including a multi-dimensional relational model that incorporates standard observable inputs and assumptions such as benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids/offers and other pertinent reference data.

Supplemental information regarding the Company’s available-for-sale debt securities (all of which had no withdrawal restrictions) is set forth in the table below (in millions):

			Gross		Gross			Estimated
	Amortized		Unrealized		Unrealized			Fair
	Cost		Gains		Losses			Values
As of December 31, 2022:
Government	$	107	$	—	$	(11	)	$	96
Corporate		69		—		(9	)		60
Mortgage and asset-backed securities		25		—		(2	)		23
Total available-for-sale debt securities	$	201	$	—	$	(22	)	$	179

			Gross		Gross			Estimated
	Amortized		Unrealized		Unrealized			Fair
	Cost		Gains		Losses			Values
As of December 31, 2021:
Government	$	83	$	1	$	(1	)	$	83
Corporate		62		—		(1	)		61
Mortgage and asset-backed securities		34		—		—			34
Total available-for-sale debt securities	$	179	$	1	$	(2	)	$	178

As of December 31, 2022 and 2021, investments with aggregate estimated fair values of approximately $169 million (348 investments) and $125 million (281 investments), respectively, generated the gross unrealized losses disclosed in the above table. At each reporting date, the Company performs an evaluation of impaired securities to determine if the unrealized losses are other-than-temporary. This evaluation considers a number of factors including, but not limited to, the length of time and extent to which the fair value has been less than cost, and management’s ability and intent to hold the securities until fair value recovers. Based on the results of this evaluation, management concluded that as of December 31, 2022, there were no other-than-temporary losses related to available-for-sale debt securities. The recent declines in value of the securities and/or length of time they have been below cost, as well as the Company’s ability and intent to hold the securities for a reasonable period of time sufficient for a projected recovery of fair value, have caused management to conclude that the securities, that have generated gross unrealized losses, were not other-than-temporarily impaired. Management will continue to monitor and evaluate the recoverability of the Company’s available-for-sale debt securities.

The contractual maturities of debt-based securities held by the Company as of December 31, 2022 and 2021, excluding mutual fund holdings, are set forth in the table below (in millions). Expected maturities will differ from contractual maturities because the issuers of the debt securities may have the right to prepay their obligations without prepayment penalties.

	December 31, 2022				December 31, 2021
	Amortized		Estimated		Amortized		Estimated
	Cost		Fair Values		Cost		Fair Values
Within 1 year	$	13	$	13	$	8	$	8
After 1 year and through year 5		74		70		61		61
After 5 years and through year 10		56		48		49		49
After 10 years		58		48		61		60

Gross realized gains and losses on sales of available-for-sale debt securities are summarized in the table below (in millions):

	Year Ended December 31,
	2022			2021			2020
Realized gains	$	—		$	1		$	2
Realized losses		(2	)		(1	)		(1	)

Other investment income, which includes interest and dividends, related to all investment securities was $6 million, $5 million and $6 million for the years ended December 31, 2022, 2021 and 2020, respectively.

Net gains and losses recognized during the years ended December 31, 2022, 2021 and 2020 for investments in equity securities, which are broken out between investments sold during the year and investments held at the end of the year, are summarized in the table below (in millions):

	Year Ended December 31,
	2022			2021		2020
Net (losses) and gains recognized during the year on equity securities	$	(28	)	$	20	$	9
Less: Net (losses) and gains recognized during the year on equity securities sold during the year		(2	)		13		14
Unrealized (losses) and gains recognized during the year on equity securities held at the end of year	$	(26	)	$	7	$	(5	)

Leases

12 Months Ended

Dec. 31, 2022

Leases [Abstract]

LEASES

9. LEASES

The Company utilizes operating and finance leases for the use of certain hospitals, medical office buildings, and medical equipment. All lease agreements generally require the Company to pay maintenance, repairs, property taxes and insurance costs, which are variable amounts based on actual costs incurred during each applicable period. Such costs are not included in the determination of the ROU asset or lease liability. Variable lease cost also includes escalating rent payments that are not fixed at commencement but are based on an index that is determined in future periods over the lease term based on changes in the Consumer Price Index or other measures of cost inflation. Most leases include one or more options to renew the lease at the end of the initial term, with renewal terms that generally extend the lease at the then market rate of rental payment. Certain leases also include an option to buy the underlying asset at or a short time prior to the termination of the lease. All such options are at the Company’s discretion and are evaluated at the commencement of the lease, with only those that are reasonably certain of exercise included in determining the appropriate lease term.

The components of lease cost and rent expense for the years ended December 31, 2022, 2021 and 2020 are as follows (in millions):

	Year Ended December 31,
Lease Cost	2022			2021			2020
Operating lease cost:
Operating lease cost	$	211		$	196		$	203
Short-term rent expense		87			92			104
Variable lease cost		24			25			26
Sublease income		(5	)		(5	)		(6	)
Total operating lease cost	$	317		$	308		$	327
Finance lease cost:
Amortization of ROU assets	$	13		$	9		$	10
Interest on finance lease liabilities		15			9			8
Total finance lease cost	$	28		$	18		$	18

Supplemental balance sheet information related to leases was as follows (in millions):

	Balance Sheet Classification	December 31, 2022			December 31, 2021
Operating Leases:
Operating Lease ROU Assets	Other assets, net	$	738		$	668

Finance Leases:
Finance Lease ROU Assets	Property and equipment
	Land and improvements	$	—		$	8
	Buildings and improvements		261			289
	Equipment and fixtures		12			17
	Property and equipment		273			314
	Less accumulated depreciation and amortization		(56	)		(54	)
	Property and equipment, net	$	217		$	260

Current finance lease liabilities	Current maturities of long-term debt	$	3		$	8
Long-term finance lease liabilities	Long-term debt		220			233

Supplemental cash flow information related to leases for the years ended December 31, 2022, 2021 and 2020 are as follows (in millions):

	Year Ended December 31,
Cash flow information	2022			2021			2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases (1)	$	204		$	197		$	188
Operating cash flows from finance leases		15			9			8
Financing cash flows from finance leases		9			4			7
ROU assets obtained in exchange for new finance lease liabilities		42			166			22
ROU assets obtained in exchange for new operating lease liabilities		195			143			150
Weighted-average remaining lease term:
Operating leases	8 years			6 years			7 years
Finance leases	31 years			30 years			19 years
Weighted-average discount rate:
Operating leases		8.0	%		8.1	%		9.0	%
Finance leases		6.4	%		6.3	%		8.4	%

(1)	Included in the change in other operating assets and liabilities in the consolidated statements of cash flows.

Commitments relating to noncancellable operating and finance leases and financing obligations for each of the next five years and thereafter are as follows (in millions):

							Financing
Year Ending December 31,	Operating			Finance			Obligations
2023	$	205		$	16		$	13
2024		157			16			13
2025		126			15			13
2026		102			16			13
2027		76			16			14
Thereafter		385			488			75
Total minimum future payments		1,051			567			141
Less: Imputed interest		(298	)		(344	)		16
Total liabilities		753			223			157
Less: Current portion		(148	)		(3	)		(3	)
Long-term liabilities	$	605		$	220		$	154

As of December 31, 2022, there were approximately $28 million of assets underlying approved but pending leases that have not yet commenced, primarily for leases of various real-estate and medical equipment.

Employee Benefit Plans

12 Months Ended

Dec. 31, 2022

Compensation And Retirement Disclosure [Abstract]

Employee Benefit Plans

10. EMPLOYEE BENEFIT PLANS

The Company maintains various benefit plans, including defined contribution plans, defined benefit plans and deferred compensation plans, for which certain of the Company’s subsidiaries are the plan sponsors. The CHS/Community Health Systems, Inc. Retirement Savings Plan is a defined contribution plan that covers the majority of the Company’s employees. Employees at locations whose employment is covered by collective bargaining agreements are generally eligible to participate in the CHS/Community Health Systems, Inc. Standard 401(k) Plan. Total expense to the Company under the 401(k) plans was $70 million, $65 million and $74 million for the years ended December 31, 2022, 2021 and 2020, respectively, and is recorded in salaries and benefits expense in the consolidated statements of income.

The Company maintains unfunded deferred compensation plans that allow participants to defer receipt of a portion of their compensation. The liability for the deferred compensation plans was $127 million and $175 million as of December 31, 2022 and 2021, respectively, and is included in other long-term liabilities in the consolidated balance sheets. Assets designated to pay benefits under these plans are discussed below.

The Company provides an unfunded Supplemental Executive Retirement Plan (“SERP”) for certain members of its executive management. The Company uses a December 31 measurement date for the benefit obligations and a January 1 measurement date for its net periodic costs for the SERP. Variances from actuarially assumed rates will result in increases or decreases in benefit obligations and net periodic cost in future periods. Benefits expense under the SERP was $11 million for both of the years ended December 31, 2022 and 2021 and $7 million for the year ended December 31, 2020. The accrued benefit liability for the SERP totaled $91 million and $99 million at December 31, 2022 and 2021, respectively. The weighted-average assumptions used in determining net periodic cost for both of the years ended December 31, 2022 and 2021 were discount rates of 2.7% and an annual salary increase of 3.0%.

During 2021, certain members of executive management of the Company that were participants in the SERP retired and met the requirements for payout of their SERP retirement benefit. The SERP payout provisions require payment to the participant in an actuarially determined lump sum amount six months after the participant retires from the Company. There were no settlement losses during the years ended December 31, 2022, 2021 and 2020.

As of December 31, 2022, the Company had assets of $181 million in a non-qualified plan trust generally designated to pay benefits of the deferred compensation plans and the SERP, consisting of equity securities of $46 million and company-owned life insurance contracts of $135 million. As of December 31, 2021, the Company had assets of $248 million in a non-qualified plan trust generally designated to pay benefits of the deferred compensation plans and the SERP, consisting of equity securities of $81 million and company-owned life insurance contracts of $167 million.

The Company maintains the CHS/Community Health Systems, Inc. Retirement Income Plan (“Pension Plan”), which is a defined benefit, non-contributory pension plan that covers certain employees at three of its formerly owned hospitals. The Pension Plan provides benefits to covered individuals satisfying certain age and service requirements. Employer contributions to the Pension Plan

are in accordance with the minimum funding requirements of the Employee Retirement Income Security Act of 1974, as amended. The Company does not expect to make contributions to the Pension Plan in 2023.

In September 2021, the lifetime obligation of the Pension Plan with respect to certain participants was transferred to a third-party insurer via an irrevocable annuity contract. The third-party insurer began paying benefits to the participants as of November 1, 2021. This action resulted in a partial plan settlement and recognition of a less than $1 million settlement charge during the year ended December 31, 2021.

The Company uses a December 31 measurement date for the benefit obligations and a January 1 measurement date for its net periodic costs for the Pension Plan. Variances from actuarially assumed rates will result in increases or decreases in benefit obligations, net periodic cost and funding requirements in future periods. Benefits expense under the Pension Plan was less than $1 million for each of the years ended December 31, 2022, 2021 and 2020, inclusive of the aforementioned partial plan settlement during the year ended December 31, 2021. The accrued benefit liability for the Pension Plan totaled $2 million and less than $1 million at December 31, 2022 and 2021, respectively, and is included in other long-term liabilities in the consolidated balance sheets. The weighted-average assumptions used for determining the net periodic cost for the years ended December 31, 2022 and 2021 were discount rates of 2.8% and 2.5%, respectively, and the expected long-term rates of return on assets of 4.3% and 5.5%, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI https://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

Stockholders' Deficit

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

STOCKHOLDERS' DEFICIT

11. STOCKHOLDERS’ DEFICIT

Authorized capital shares of the Company include 400,000,000 shares of capital stock consisting of 300,000,000 shares of common stock and 100,000,000 shares of preferred stock. Each of the aforementioned classes of capital stock has a par value of $0.01 per share. Shares of preferred stock, none of which were outstanding as of December 31, 2022, may be issued in one or more series having such rights, preferences and other provisions as determined by the Board of Directors without approval by the holders of common stock.

The Company is a holding company which operates through its subsidiaries. The Company’s ABL Facility and the indentures governing each series of the Company’s outstanding notes contain various covenants under which the assets of the subsidiaries of the Company are subject to certain restrictions relating to, among other matters, dividends and distributions, as referenced in the paragraph below.

The ABL Facility and the indentures governing each series of the Company’s outstanding notes restrict the Company’s subsidiaries from, among other matters, paying dividends and making distributions to the Company, which thereby limits the Company’s ability to pay dividends and/or repurchase stock. As of December 31, 2022, under the most restrictive test in these agreements (and subject to certain exceptions), the Company has approximately $300 million of capacity to pay permitted dividends and/or repurchase shares of stock or make other restricted payments.

The following schedule discloses the effects of changes in the Company’s ownership interest in its less-than-wholly-owned subsidiaries on Community Health Systems, Inc. stockholders’ deficit (in millions):

	Year Ended December 31,
	2022			2021		2020
Net income attributable to Community Health Systems,
Inc. stockholders	$	46		$	230	$	511
Transfers to the noncontrolling interests:
Net (decrease) increase in Community Health
Systems, Inc. paid-in-capital for
purchase of subsidiary partnership interests		(6	)		17		3
Net transfers to the noncontrolling interests		(6	)		17		3
Change to Community Health Systems, Inc.
stockholders’ deficit from net income attributable to
Community Health Systems, Inc. stockholders
and transfers to noncontrolling interests	$	40		$	247	$	514

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

Earnings Per Share

12 Months Ended

Dec. 31, 2022

Earnings Per Share [Abstract]

Earnings Per Share

12. EARNINGS PER SHARE

The following table sets forth the components of the denominator for the computation of basic and diluted earnings per share for net income attributable to Community Health Systems, Inc. stockholders:

	Year Ended December 31,
	2022		2021		2020
Weighted-average number of shares outstanding — basic		128,808,387		126,754,852		115,491,022
Effect of dilutive securities:
Restricted stock awards		842,055		2,803,938		905,903
Employee stock options		278,057		726,130		122,785
Other equity-based awards		131,820		312,490		24,851
Weighted-average number of shares outstanding — diluted		130,060,319		130,597,410		116,544,561

	Year Ended December 31,
	2022		2021		2020
Dilutive securities outstanding not included in the computation of earnings per share because their effect is antidilutive:
Employee stock options and restricted stock awards		4,406,764		774,981		2,821,511

Equity Investments

12 Months Ended

Dec. 31, 2022

Equity Method Investments And Joint Ventures [Abstract]

Equity Investments

13. EQUITY INVESTMENTS

On July 30, 2021, the Company sold its unconsolidated equity interests in Macon Healthcare, LLC, a joint venture with certain subsidiaries of HCA representing two hospitals in Macon, Georgia, in which the Company held a 38% interest. The Company received $110 million in cash in connection with the sale of its equity interests and, as a result, recognized a pre-tax gain of approximately $39 million on the sale of equity interests in Macon Healthcare, LLC during the year ended December 31, 2021.

On December 31, 2016, the Company sold 80% of its ownership interest in the legal entity that owned and operated its home care agency business. As part of the divestiture of its controlling interest in the home care agency business, the Company recorded an equity method investment representing its remaining 20% ownership. Since December 31, 2016 and primarily in conjunction with the divestiture of hospitals, the Company has divested its remaining 20% ownership in certain home care agency businesses.

In March 2005, the Company began purchasing items, primarily medical supplies, medical equipment and pharmaceuticals, under an agreement with HealthTrust Purchasing Group, L.P. (“HealthTrust”), a group purchasing organization in which the Company is a noncontrolling partner. Effective October 1, 2022, HealthTrust completed the sale of a majority interest in CoreTrust Holdings, LLC (“CoreTrust”) to a third party. Proceeds for the sale of interest in CoreTrust were distributed to members of HealthTrust and the Company received approximately $121 million in connection with such distribution during the year ended December 31, 2022. A gain of approximately $119 million was recognized associated with this transaction as included in the line item “Gain from CoreTrust transaction” within the consolidated statements of income. As of December 31, 2022, the Company had a 13.3% ownership interest in HealthTrust.

The Company’s investment in all of its unconsolidated affiliates was $155 million and $129 million at December 31, 2022 and 2021, respectively, and is included in other assets, net in the accompanying consolidated balance sheets. Included in the Company’s results of operations is the Company’s equity in pre-tax earnings from its investments in unconsolidated affiliates, which was $14 million, $22 million and $10 million for the years ended December 31, 2022, 2021 and 2020, respectively.

Comprehensive Loss

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

Comprehensive Loss

14. COMPREHENSIVE LOSS

The following tables present information about items reclassified out of accumulated other comprehensive loss (“AOCL”) by component for the years ended December 31, 2022 and 2021 (in millions, net of tax):

	Change in
	Fair Value of			Change in
	Available-for-Sale			Unrecognized
	Debt			Pension Cost
	Securities (1)			Components			AOCL (1)
Balance as of December 31, 2021	$	(2	)	$	(12	)	$	(14	)
Other comprehensive (loss)
income before reclassifications		(16	)		10			(6	)
Amounts reclassified from
AOCL		(1	)		—			(1	)
Net current-period other
comprehensive (loss) income		(17	)		10			(7	)
Balance as of December 31, 2022	$	(19	)	$	(2	)	$	(21	)

__________________________

(1) Totals may not add due to rounding.

	Change in
	Fair Value of			Change in
	Available-for-Sale			Unrecognized
	Debt			Pension Cost
	Securities (1)			Components			AOCL (1)
Balance as of December 31, 2020	$	2		$	(15	)	$	(13	)
Other comprehensive (loss)
income before reclassifications		(1	)		1			—
Amounts reclassified from
AOCL		(4	)		2			(2	)
Net current-period other
comprehensive (loss) income		(5	)		3			(2	)
Balance as of December 31, 2021	$	(2	)	$	(12	)	$	(14	)

__________________________

(1) Totals may not add due to rounding.

The following tables present a subtotal for each significant reclassification to net income out of AOCL and the line item affected in the accompanying consolidated statements of income for the years ended December 31, 2022 and 2021 (in millions):

	Amount reclassified
	from AOCL			Affected line item in the
	Year Ended			statement where net
Details about AOCL components	December 31, 2022			income is presented
Amortization of defined benefit pension items
Prior service costs	$	(1	)	Salaries and benefits
Settlement losses recognized		—		Salaries and benefits
		(1	)	Total before tax
		—		Tax benefit
	$	(1	)	Net of tax

	Amount reclassified
	from AOCL			Affected line item in the
	Year Ended			statement where net
Details about AOCL components	December 31, 2021			income is presented
Amortization of defined benefit pension items
Prior service costs	$	(2	)	Salaries and benefits
		(2	)	Total before tax
		—		Tax benefit
	$	(2	)	Net of tax

Commitments and Contingencies

12 Months Ended

Dec. 31, 2022

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

15. COMMITMENTS AND CONTINGENCIES

Construction and Other Capital Commitments. Pursuant to a hospital purchase agreement from the Company’s March 1, 2016 acquisition of Northwest Health – Starke, formerly known as Starke Hospital, the Company is committed to build a replacement facility in Knox, Indiana. Under the terms of such agreement, the construction of the replacement facility for Northwest Health - Starke is required to be completed within five years of the date the Company entered into a new lease with Starke County, Indiana, the hospital lessor, or in the event the Company does not enter into a new lease with Starke County, construction shall be completed by September 30, 2026. The Company has not entered into a new lease with the lessor for Northwest Health - Starke and currently anticipates completing construction of the Northwest Health - Starke replacement facility in 2026.

Physician Recruiting Commitments. As part of its physician recruitment strategy, the Company provides income guarantee agreements to certain physicians who agree to relocate to its communities and commit to remain in practice there. Under such agreements, the Company is required to make payments to the physicians in excess of the amounts they earned in their practice up to the amount of the income guarantee. These income guarantee periods are typically for 12 months. Such payments are recoverable by the Company from physicians who do not fulfill their commitment period, which is typically three years, to the respective community. At December 31, 2022, the maximum potential amount of future payments under these guarantees in excess of the liability recorded is $6 million.

Professional Liability Claims. As part of the Company’s business of providing healthcare services, it is subject to legal actions alleging liability on its part. The Company accrues for losses resulting from such liability claims, as well as loss adjustment expenses that are out-of-pocket and directly related to such liability claims. These direct out-of-pocket expenses include fees of outside counsel and experts. The Company does not accrue for costs that are part of corporate overhead, such as the costs of in-house legal and risk management departments. The losses resulting from professional liability claims primarily consist of estimates for known claims, as well as estimates for incurred but not reported claims. The estimates are based on specific claim facts, historical claim reporting and payment patterns, the nature and level of hospital operations, and actuarially determined projections. The actuarially determined projections are based on the Company’s actual claim data, including historic reporting and payment patterns that have been gathered over the life of the Company. As discussed below, since the Company purchases excess insurance on a claims-made basis that transfers risk to third-party insurers, the estimated liability for professional and general liability claims does include an amount for the losses covered by this excess insurance. The Company also records a receivable for the expected reimbursement of losses covered by excess insurance. Since the Company believes that the amount and timing of its future claims payments are reliably determinable, it discounts the amount accrued for losses resulting from professional liability claims.

The net present value of the projected payments was discounted using weighted-average interest rates of 3.8% in 2022 and 1.8% in both 2021 and 2020. This liability is adjusted for new claims information in the period such information becomes known. The Company’s estimated liability for professional and general liability claims was $467 million and $533 million as of December 31, 2022 and 2021, respectively. The estimated undiscounted claims liability was $516 million and $564 million as of December 31, 2022 and 2021, respectively. The current portion of the liability for professional and general liability claims was $159 million and $162 million as of December 31, 2022 and 2021, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets, with the long-term portion recorded in other long-term liabilities. Professional liability expense includes the losses resulting from professional liability claims and loss adjustment expense, as well as excess insurance premiums, and is presented within other operating expenses in the accompanying consolidated statements of income.

The Company’s processes for obtaining and analyzing claims and incident data are standardized across all of its businesses and have been consistent for many years. The Company monitors the outcomes of the medical care services that it provides and for each reported claim, the Company obtains various information concerning the facts and circumstances related to that claim. In addition, the Company routinely monitors current key statistics and volume indicators in its assessment of utilizing historical trends. The average lag period between claim occurrence and payment of a final settlement is between three and four years, although the facts and circumstances of individual claims could result in the timing of such payments being different from this average. Since claims are paid promptly after settlement with the claimant is reached, settled claims represent approximately 7% or less of the total liability at the end of any period.

For purposes of estimating its individual claim accruals, the Company utilizes specific claim information, including the nature of the claim, the expected claim amount, the year in which the claim occurred and the laws of the jurisdiction in which the claim occurred. Once the case accruals for known claims are determined, information is stratified by loss layers and retentions, accident years, reported years and geography. Several actuarial methods are used against this data to produce estimates of ultimate paid losses and reserves for incurred but not reported claims. Each of these methods uses company-specific historical claims data and other information. This company-specific data includes information regarding the Company’s business, including historical paid losses and loss adjustment expenses, historical and current case loss reserves, actual and projected hospital statistical data, a variety of hospital census information, employed physician information, professional liability retentions for each policy year, geographic information and other data.

Based on these analyses, the Company determines its estimate of the professional liability claims. The determination of management’s estimate, including the preparation of the reserve analysis that supports such estimate, involves subjective judgment of management. Changes in reserve data or the trends and factors that influence reserve data may signal fundamental shifts in the Company’s future claim development patterns or may simply reflect single-period anomalies. Even if a change reflects a fundamental shift, the full extent of the change may not become evident until years later. Moreover, since the Company’s methods and models use different types of data and the Company selects its liability from the results of all of these methods, it typically cannot quantify the precise impact of such factors on its estimates of the liability. Due to the Company’s standardized and consistent processes for handling claims and the long history and depth of company-specific data, the Company’s methodologies have produced reliably determinable estimates of ultimate paid losses. Management considers any changes in the amount and pattern of its historical paid losses up through the most recent reporting period to identify any fundamental shifts or trends in claim development experience in determining the estimate of professional liability claims. However, due to the subjective nature of this estimate and the impact that previously unforeseen shifts in actual claim experience can have, future estimates of professional liability could be adversely impacted when actual paid losses develop unexpectedly based on assumptions and settlement events that were not previously known or anticipated.

During the year ended December 31, 2020, the Company incurred expenses in the amount of approximately $50 million related to the settlement of a professional liability claim for which the Company’s third-party insurers’ obligation to provide coverage to the Company in connection with the underlying loss was being litigated. In the ordinary course of business, the Company’s expense with respect to professional liability claims, which is actuarially determined, is limited to amounts not covered by third-party insurance policies, which typically provide coverage for professional liability claims. The subject of the litigation for the recovery of the full amount of the $50 million settlement was whether the claim was covered under the subject policies. This litigation was settled during the three months ended December 31, 2021, and in connection with this settlement, approximately $22 million was recovered from various third-party insurers related to their obligation to provide coverage for the professional liability claim. During the year ended December 31, 2022, the Company experienced an increase in the amounts paid or expected to be paid to settle outstanding professional liability claims related to divested locations, compared to the same period in the prior year and to previous actuarially determined estimates. This resulted in a change in estimate of $15 million during the three months and year ended December 31, 2022. There were no other significant changes in the Company’s estimate of the reserve for professional liability claims during the years ended December 31, 2022 and 2021.

The Company is primarily self-insured for professional liability claims; however, the Company obtains excess insurance that transfers the risk of loss to a third-party insurer for claims in excess of the Company’s self-insured retentions. The Company’s excess insurance is underwritten on a claims-made basis. For claims reported prior to June 1, 2002, substantially all of the Company’s professional and general liability risks were subject to a less than $1 million per occurrence self-insured retention and for claims reported from June 1, 2002 through June 1, 2003, these self-insured retentions were $2 million per occurrence. Substantially all claims reported after June 1, 2003 and before June 1, 2005 are self-insured up to $4 million per claim. Substantially all claims reported on or after June 1, 2005 and before June 1, 2014 are self-insured up to $5 million per claim. Substantially all claims reported on or after June 1, 2014 and before June 1, 2018 are self-insured up to $10 million per claim. Substantially all claims reported on or after June 1, 2018 are self-insured up to $15 million per claim. Management, on occasion, has selectively increased the insured risk at certain hospitals based upon insurance pricing and other factors and may continue that practice in the future.

Excess insurance for all hospitals has been purchased through commercial insurance companies and generally covers the Company for liabilities in excess of the self-insured retentions. The excess coverage consists of multiple layers of insurance, the sum of which totals up to $95 million per occurrence and in the aggregate for claims reported on or after June 1, 2003, up to $145 million per occurrence and in the aggregate for claims reported on or after January 1, 2008, up to $195 million per occurrence and in the aggregate for claims reported on or after June 1, 2010, and up to at least $216 million per occurrence and in the aggregate for claims reported on or after June 1, 2015. In addition, for integrated professional liability claims, there is an additional $50 million of excess coverage for claims reported on or after June 1, 2014 and an additional $75 million of excess coverage for claims reported on or after June 1, 2015 through June 1, 2020. The $75 million in integrated occurrence coverage will also apply to claims reported between June 1, 2020 and June 1, 2023 for events that occurred prior to June 1, 2020 but which were not previously known or reported. For certain policy years prior to June 1, 2014, if the first aggregate layer of excess coverage becomes fully utilized, then the self-insured retention will increase to $10 million per claim for any subsequent claims in that policy year until the Company’s total aggregate coverage is met. Beginning June 1, 2018, this drop-down provision in the excess policies attaches over the $15 million per claim self-insured retention.

Effective June 1, 2014, the hospitals acquired from HMA were insured on a claims-made basis as described above and through commercial insurance companies as described above for substantially all claims reported on or after June 1, 2014 except for physician-related claims with an occurrence date prior to June 1, 2014. Prior to June 1, 2014, the former HMA hospitals obtained insurance coverage through a wholly-owned captive insurance subsidiary and a risk retention group subsidiary (“Insurance Subsidiaries”) that are domiciled in the Cayman Islands and South Carolina, respectively. The Insurance Subsidiaries provided (i) claims-made coverage to all of the former HMA hospitals and (ii) occurrence-basis coverage to most of the physicians employed by the former HMA hospitals. The employed physicians not covered by the Insurance Subsidiaries generally maintained claims-made policies with unrelated third-party insurance companies. To mitigate the exposure of the program covering the former HMA hospitals and other healthcare facilities, the Insurance Subsidiaries bought claims-made reinsurance policies from unrelated third parties for claims above self-retention levels of $10 million or $15 million per claim, depending on the policy year.

Legal Matters. The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters, including the matters described herein, will have a material adverse effect on the consolidated financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in pending legal, regulatory and governmental matters, some of which are beyond the Company’s control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to the Company’s results of operations or cash flows for any particular reporting period.

With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the possible loss or range of loss. However, the Company is unable to estimate a possible loss or range of loss in some instances based on the significant uncertainties involved in, and/or the preliminary nature of, certain legal, regulatory and governmental matters.

In connection with the spin-off of Quorum Health Corporation (“QHC”), the Company agreed to indemnify QHC for certain liabilities relating to outcomes or events occurring prior to April 29, 2016, the closing date of the spin-off, including (i) certain claims and proceedings that were known to be outstanding at or prior to the consummation of the spin-off and involved multiple facilities and (ii) certain claims, proceedings and investigations by governmental authorities or private plaintiffs related to activities occurring at or related to QHC’s healthcare facilities prior to the closing date of the spin-off, but only to the extent, in the case of clause (ii), that such claims are covered by insurance policies maintained by the Company, including professional liability and employer practices. Notwithstanding the foregoing, the Company is not required to indemnify QHC in respect of any claims or proceedings arising out of or related to the business operations of Quorum Health Resources, LLC at any time or QHC’s compliance with the corporate integrity agreement. Subsequent to the spin-off of QHC, the Office of the Inspector General provided the Company with written assurance that it would look solely at QHC for compliance for its facilities under the Company’s corporate integrity agreement; however, the Office of the Inspector General declined to enter into a separate corporate integrity agreement with QHC.

Summary of Recorded Amounts

The table below presents a reconciliation of the beginning and ending liability balances (in millions) during the years ended December 31, 2022 and 2021, with respect to the Company’s determination of the contingencies of the Company in respect of which an accrual has been recorded. The liability as of December 31, 2022 is comprised of individually insignificant amounts for various matters.

	Probable
	Contingencies
Balance as of December 31, 2020	$	11
Expense		11
Reserve for insured claim		(1	)
Cash payments		(1	)
Balance as of December 31, 2021		20
Expense		8
Cash payments		(17	)
Balance as of December 31, 2022	$	11

In accordance with applicable accounting guidance, the Company establishes a liability for litigation, regulatory and governmental matters for which, based on information currently available, the Company believes that a negative outcome is known or is probable and the amount of the loss is reasonably estimable. For all such matters (whether or not discussed in this contingencies footnote), such amounts have been recorded in other accrued liabilities in the consolidated balance sheets and are included in the table above. Due to the uncertainties and difficulty in predicting the ultimate resolution of these contingencies, the actual amount could differ from the estimated amount reflected as a liability in the consolidated balance sheets.

Subsequent Events

12 Months Ended

Dec. 31, 2022

Subsequent Events [Abstract]

Subsequent Events

16. SUBSEQUENT EVENTS

The Company has evaluated all material events occurring subsequent to the balance sheet date for events requiring disclosure or recognition in the consolidated financial statements.

On January 1, 2023, one or more affiliates of the Company completed the sale of substantially all of the assets of Greenbrier Valley Medical Center (122 licensed beds) in Ronceverte, West Virginia, to a subsidiary of Vandalia Health, Inc. pursuant to the terms of a definitive agreement, as amended, which was entered into on September 14, 2022. The net proceeds from this sale of approximately $85 million were received at a preliminary closing on December 30, 2022.

A third-party vendor, Fortra, LLC, who provides a secure file transfer software platform utilized by the Company, experienced a security breach whereby protected health information (as defined by the Health Insurance Portability and Accountability Act) and personal information of certain patients of the Company’s facilities were exposed to Fortra’s attacker. Upon receiving notification of the security breach, the Company promptly launched an investigation. The Company has incurred, and may incur in the future, expenses and losses related to this incident, some of which may not be covered by its cyber/privacy liability insurance policies. The Company will ensure that appropriate notification is provided to affected patients and regulatory agencies as required by federal and state law. Because of the preliminary nature of the investigation into this incident, an estimate of total costs, including remediation expenses and other potential liabilities, cannot be made.

Condensed Financial Information of Parent

12 Months Ended

Dec. 31, 2022

Condensed Financial Information Of Parent Company Only Disclosure [Abstract]

Condensed Financial Information of Parent

17. CONDENSED FINANCIAL INFORMATION OF PARENT

Parent Company Only
Condensed Balance Sheets
(In millions)
	December 31,
	2022			2021
ASSETS
Prepaid income taxes	$	99		$	94
Total current assets		99			94
Deferred income taxes		49			53
Other assets, net		—			—
Total assets	$	148		$	147
LIABILITIES AND STOCKHOLDERS' DEFICIT
Intercompany payable	$	1,159		$	1,326
Deferred income taxes		354			192
Other long-term liabilities		2			1
Total liabilities		1,515			1,519
Community Health Systems, Inc. stockholders’ deficit:
Preferred stock		—			—
Common stock		1			1
Additional paid-in capital		2,084			2,118
Accumulated other comprehensive loss		(21	)		(14	)
Accumulated deficit		(3,431	)		(3,477	)
Total Community Health Systems, Inc. stockholders’ deficit		(1,367	)		(1,372	)
Total liabilities and stockholders' deficit	$	148		$	147

See note to condensed financial statements of Parent.

Parent Company Only
Condensed Statements of Income
(In millions)
	Year Ended December 31,
	2022			2021			2020
Net operating revenues	$	—		$	—		$	—
Operating costs and expenses:
Salaries and benefits		—			—			—
Supplies		—			—			—
Other operating expenses		—			—			—
Lease cost and rent		—			—			—
Pandemic relief funds		—			—			—
Depreciation and amortization		—			—			—
Impairment and (gain) loss on sale of businesses, net		—			—			—
Total operating costs and expenses		—			—			—
Income from operations		—			—			—
Interest expense, net		—			—			—
(Gain) loss from early extinguishment of debt		—			—			—
Equity in earnings of unconsolidated affiliates		(46	)		(230	)		(511	)
Income before income taxes		46			230			511
Provision for (benefit from) income taxes		—			—			—
Net income		46			230			511
Less: Net income attributable to noncontrolling interests		—			—			—
Net income attributable to Community Health Systems, Inc. stockholders	$	46		$	230		$	511

See note to condensed financial statements of Parent.

Parent Company Only
Condensed Statements of Comprehensive Income
(In millions)
	Year Ended December 31,
	2022			2021			2020
				(In millions)
Net income	$	46		$	230		$	511
Equity in other comprehensive (loss) income of affiliates, net of income taxes:
Net change in fair value of interest rate swaps, net of tax		—			—			(1	)
Net change in fair value of available-for-sale debt securities, net of tax		(17	)		(5	)		4
Amortization and recognition of unrecognized pension cost components, net of tax		10			3			(7	)
Other comprehensive loss		(7	)		(2	)		(4	)
Comprehensive income		39			228			507
Less: Comprehensive income attributable to noncontrolling interests		—			—			—
Comprehensive income attributable to Community Health Systems, Inc. stockholders	$	39		$	228		$	507

See note to condensed financial statements of Parent.

Parent Company Only
Condensed Statements of Cash Flows
(In millions)
	Year Ended December 31,
	2022			2021			2020
Cash flows from operating activities:
Net cash used in operating activities	$	(13	)	$	(11	)	$	(12	)
Cash flows from investing activities:
Net cash provided by (used in) investing activities		—			—			—
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll tax withholding requirements		(8	)		(5	)		(1	)
Changes in intercompany balances with affiliates, net		21			16			13
Net cash provided by financing activities		13			11			12
Net change in cash and cash equivalents		—			—			—
Cash and cash equivalents at beginning of period		—			—			—
Cash and cash equivalents at end of period	$	—		$	—		$	—

See note to condensed financial statements of Parent.

Basis of Presentation

The Parent is a holding company and operates no business in its own name; all of the Company’s business operations are conducted through subsidiaries of the Parent. The Company’s outstanding indebtedness restricts the ability of subsidiaries to dividend or otherwise provide funds to the Parent. Accordingly, these financial statements have been presented on a “parent-only” basis. Under parent-only presentation, the Parent’s investments in its consolidated subsidiaries are presented under the equity method of accounting. These parent-only financial statements should be read in conjunction with consolidated financial statements of Community Health Systems, Inc.

Basis of Presentation and Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2022

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Basis of Accounting

Use of Estimates

Principles of Consolidation

Cost of Revenue

Cash Equivalents

Cash Equivalents. The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents.

Supplies

Supplies. Supplies, principally medical supplies, are stated at the lower of cost (first-in, first-out basis) or market.

Marketable Securities

Property and Equipment

Goodwill

Other Assets

Revenue Recognition

Revenue Recognition.

Net Operating Revenues

	Year Ended December 31,
	2022		2021		2020
Medicare	$	2,547	$	2,650	$	2,813
Medicaid		1,807		1,671		1,578
Medicare Managed Care		1,968		1,861		1,601
Other third-party payors		5,806		6,076		5,799
Self-pay		83		110		(2	)
Total	$	12,211	$	12,368	$	11,789

Patient Accounts Receivable

Charity Care

Leases

Leases. Leases are recorded in the consolidated balance sheets through recognition of a liability for the discounted present value of future fixed lease payments and a corresponding ROU asset. The ROU asset recorded at commencement of the lease represents the right to use the underlying asset over the lease term in exchange for the lease payments. Leases with an initial term of 12 months or less that do not have an option to purchase the underlying asset that is deemed reasonably certain to be exercised are not recorded in the consolidated balance sheets; rather, rent expense for these leases is recognized on a straight-line basis over the lease term, or when incurred if a month-to-month lease. Whenreadily determinable, the Company uses the interest rate implicit in a lease to determine the present value of future lease payments. For leases where the implicit rate is not readily determinable, the Company’s incremental borrowing rate is utilized. The Company calculates its incremental borrowing rate on a quarterly basis using a third-party financial model that estimates the rate of interest the Company would have to pay to borrow an amount equal to the total lease payments on a collateralized basis over a term similar to the lease. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.

Physician Income Guarantees

Concentrations of Credit Risk

Accounting for the Impairment or Disposal of Long-Lived Assets

Income Taxes

Comprehensive Loss

Other Comprehensive Loss. Other comprehensive loss is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.

Segment Reporting

COVID-19 Pandemic

Pandemic Relief Funds

Medicare Accelerated Payments

received by the Company were recouped or repaid to CMS or assumed by buyers related to hospitals the Company divested during the years ended December 31, 2021 and 2020, respectively.

New Accounting Pronouncements

Acquisitions

Fair Value of Financial Instruments

Cash and cash equivalents. The carrying amount approximates fair value due to the short-term maturity of these instruments (less than three months).

Investments in equity securities. Estimated fair value is based on closing price as quoted in public markets.

Available-for-sale debt securities. Estimated fair value is based on closing price as quoted in public markets or other various valuation techniques.

Trading securities. Estimated fair value is based on closing price as quoted in public markets.

Senior Notes, Senior Secured Notes and Junior-Priority Secured Notes. Estimated fair value is based on the closing market price for these notes.

ABL Facility and other debt. The carrying amount of the ABL Facility and all other debt approximates fair value due to the nature of these obligations.

Fair Value

The inputs used to measure fair value are classified into the following fair value hierarchy:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Legal Matters

Basis of Presentation and Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2022

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Net Operating Revenues

	Year Ended December 31,
	2022		2021		2020
Medicare	$	2,547	$	2,650	$	2,813
Medicaid		1,807		1,671		1,578
Medicare Managed Care		1,968		1,861		1,601
Other third-party payors		5,806		6,076		5,799
Self-pay		83		110		(2	)
Total	$	12,211	$	12,368	$	11,789

Accounting for Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Share-based Compensation Expense

The following table reflects the impact of total compensation expense related to stock-based equity plans on the reported operating results for the respective periods (in millions):

	Year Ended December 31,
	2022			2021			2020
Effect on income before income taxes	$	(20	)	$	(25	)	$	(13	)
Effect on net income	$	(15	)	$	(20	)	$	(10	)

Schedule of Share-based Payment Awards, Stock Options, Valuation Assumptions

	Year Ended December 31,
	2022		2021		2020
Expected volatility	84.3% - 87.5%		84.3% - 88.9%		73.5%
Expected dividends		—		—		—
Expected term	3.0 - 6.0 years		3.0 - 6.0 years		6.0 years
Risk-free interest rate	1.5% - 1.6%		0.3% - 0.9%		1.0%

Schedule of Share-based Compensation, Stock Options, Activity

	Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value as of December 31, 2022
Outstanding at December 31, 2019		1,110,134		$	16.90
Granted		946,500			4.93
Exercised		(18,166	)		4.99
Forfeited and cancelled		(220,943	)		33.52
Outstanding at December 31, 2020		1,817,525			8.77
Granted		749,250			8.81
Exercised		(65,499	)		5.03
Forfeited and cancelled		(199,523	)		33.14
Outstanding at December 31, 2021		2,301,753			6.77
Granted		760,000			10.18
Exercised		(56,500	)		4.97
Forfeited and cancelled		(173,502	)		13.41
Outstanding at December 31, 2022		2,831,751		$	7.32	7.8 years	$	—
Exercisable at December 31, 2022		1,298,412		$	5.64	7.0 years	$	—

Schedule of Share-based Compensation, Restricted Stock, Activity

Restricted stock outstanding under the 2009 Plan as of December 31, 2022, and changes during each of the years in the three-year period prior to December 31, 2022, were as follows:

	Shares			Weighted- Average Grant Date Fair Value
Unvested at December 31, 2019		3,857,402		$	5.47
Granted		2,205,500			4.90
Vested		(1,123,329	)		5.84
Forfeited		(383,838	)		8.58
Unvested at December 31, 2020		4,555,735			4.84
Granted		2,929,250			8.16
Vested		(2,312,328	)		4.68
Forfeited		(177,343	)		6.33
Unvested at December 31, 2021		4,995,314			6.30
Granted		3,253,000			8.95
Vested		(2,561,575	)		5.70
Forfeited		(145,674	)		8.89
Unvested at December 31, 2022		5,541,065			8.53

Schedule of Share-based Compensation, Restricted Stock Units, Activity

RSUs outstanding under the 2009 Plan as of December 31, 2022, and changes during each of the years in the three-year period prior to December 31, 2022, were as follows:

	Shares			Weighted- Average Grant Date Fair Value
Unvested at December 31, 2019		541,576		$	5.13
Granted		310,347			4.93
Vested		(238,184	)		5.47
Forfeited		—			—
Unvested at December 31, 2020		613,739			4.89
Granted		173,664			8.81
Vested		(300,805	)		5.09
Forfeited		—			—
Unvested at December 31, 2021		486,598			6.17
Granted		176,820			9.66
Vested		(151,058	)		5.63
Forfeited		—			—
Unvested at December 31, 2022		512,360			7.54

Acquisitions, Divestitures and Closures (Tables)

12 Months Ended

Dec. 31, 2022

Acquisitions Divestitures And Closures [Abstract]

Schedule of Divestitures

The following table provides a summary of hospitals that the Company divested during the years ended December 31, 2022, 2021 and 2020.

Hospital	Buyer	City, State	Licensed Beds		Effective Date
2022 Divestitures:
AllianceHealth Seminole	SSM Heath Care of Oklahoma, Inc.	Seminole, OK	32		July 1, 2022

2021 Divestitures:
Lea Regional Medical Center	Covenant Health System	Hobbs, NM	84		January 1, 2021
Tennova Healthcare - Tullahoma	Vanderbilt University Medical Center	Tullahoma, TN	135		January 1, 2021
Tennova Healthcare - Shelbyville	Vanderbilt University Medical Center	Shelbyville, TN	60		January 1, 2021
Northwest Mississippi Medical Center	Delta Health System	Clarksdale, MS	181		February 1, 2021
AllianceHealth Midwest	SSM Health Care of Oklahoma, Inc.	Midwest City, OK	255		April 1, 2021

2020 Divestitures:
Berwick Hospital Center	Fayette Holdings, Inc.	Berwick, PA		90	December 1, 2020
Brownwood Regional Medical Center	Hendrick Health System	Brownwood, TX		188	October 27, 2020
Abilene Regional Medical Center	Hendrick Health System	Abilene, TX		231	October 27, 2020
San Angelo Community Medical Center	Shannon Health System	San Angelo, TX		171	October 24, 2020
Bayfront Health St. Petersburg	Orlando Health, Inc.	St. Petersburg, FL		480	October 1, 2020
Hill Regional Hospital	AHRK Holdings, LLC	Hillsboro, TX		25	August 1, 2020
St. Cloud Regional Medical Center	Orlando Health, Inc.	St. Cloud, FL		84	July 1, 2020
Northern Louisiana Medical Center	Allegiance Health Management, Inc.	Ruston, LA		130	July 1, 2020
Shands Live Oak Regional Medical Center	HCA Healthcare, Inc. ("HCA")	Live Oak, FL		25	May 1, 2020
Shands Starke Regional Medical Center	HCA	Starke, FL		49	May 1, 2020
Southside Regional Medical Center	Bon Secours Mercy Health System	Petersburg, VA		300	January 1, 2020
Southampton Memorial Hospital	Bon Secours Mercy Health System	Franklin, VA		105	January 1, 2020
Southern Virginia Regional Medical Center	Bon Secours Mercy Health System	Emporia, VA		80	January 1, 2020

Schedule of Balance Sheet Items Classified as Held for Sale

	December 31,
	2022
Other current assets	$	6
Other assets, net		132
Accrued liabilities		(4	)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2022

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The changes in the carrying amount of goodwill for the years ended December 31, 2022 and 2021 are as follows (in millions):

Balance, beginning balance	2022			2021
Goodwill	$	7,033		$	7,033
Accumulated impairment losses		(2,814	)		(2,814	)
		4,219			4,219
Goodwill acquired as part of acquisitions during current year		11			5
Goodwill allocated to hospitals divested or held-for-sale		(64	)		(5	)

Balance, end of year
Goodwill		6,980			7,033
Accumulated impairment losses		(2,814	)		(2,814	)
	$	4,166		$	4,219

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

+ Details

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Schedule of Provision for (Benefit from) Income Taxes

The provision for (benefit from) income taxes consists of the following (in millions):

	Year Ended December 31,
	2022			2021			2020
Current:
Federal	$	—		$	(46	)	$	(1	)
State		5			6			3
		5			(40	)		2
Deferred:
Federal		166			161			(162	)
State		(1	)		10			(25	)
		165			171			(187	)
Total provision for (benefit from) income taxes for income	$	170		$	131		$	(185	)

Schedule of Reconciliation between the Statutory Federal Income Tax Rate and the Effective Tax Rate

The following table reconciles the differences between the statutory federal income tax rate and the effective tax rate (dollars in millions):

	Year Ended December 31,
	2022						2021						2020
	Amount			%			Amount			%			Amount			%
Provision for (benefit from) income taxes at statutory federal rate	$	73			21.0	%	$	105			21.0	%	$	89			21.0	%
State income taxes, net of federal income tax benefit		3			0.8			44			8.7			(15	)		(3.6	)
Net income attributable to noncontrolling interests		(28	)		(8.0	)		(29	)		(5.8	)		(20	)		(4.7	)
Change in valuation allowance		122			34.9			33			6.8			(267	)		(63.2	)
Nondeductible goodwill		—			—			—			—			41			9.8
Amended return adjustments		—			—			(22	)		(4.4	)		—			—
Nondeductible loss on divestiture		—			—			—			—			(15	)		(3.4	)
Other		—			—			—			—			2			0.3
Provision for (benefit from) income taxes and effective tax rate for income	$	170			48.7	%	$	131			26.3	%	$	(185	)		(43.8	)%

Schedule of Components of Deferred Income Taxes

	December 31,
	2022					2021
	Assets			Liabilities		Assets			Liabilities
Net operating loss and credit carryforwards	$	553		$	—	$	833		$	—
Property and equipment		—			323		—			343
Self-insurance liabilities		30			—		49			—
Prepaid expenses		—			31		—			30
Intangibles		—			148		—			144
Investments in unconsolidated affiliates		—			58		—			58
Other liabilities		—			9		—			9
Long-term debt and interest		41			—		48			—
Accounts receivable		16			—		22			—
IRC Section 163(j) interest limitation		448			—		329			—
Accrued vacation		19			—		22			—
Accrued bonus		19			—		31			—
Other comprehensive income		6			—		5			—
Right-of-use assets		—			148		—			137
Right-of-use liability		156			—		142			—
Stock-based compensation		5			—		4			—
Deferred compensation		51			—		64			—
IRC Section 481(a) adjustments		—			122		—			191
Other		19			—		38			—
Total		1,363			839		1,587			912
Valuation allowance		(829	)		—		(814	)		—
Total deferred income taxes	$	534		$	839	$	773		$	912

Schedule of Reconciliation of the Total Amount of Unrecognized Tax Benefit

The following is a tabular reconciliation of the total amount of unrecognized tax benefit for the years ended December 31, 2022, 2021 and 2020 (in millions):

	Year Ended December 31,
	2022		2021			2020
Unrecognized tax benefit, beginning of year	$	42	$	45		$	26
Gross increases — tax positions in current period		8		5			19
Reductions — tax positions in prior period		—		(8	)		—
Unrecognized tax benefit, end of year	$	50	$	42		$	45

Long-Term Debt (Tables)

12 Months Ended

Dec. 31, 2022

Debt Instrument [Line Items]

Schedule of Debt

Long-term debt, net of unamortized debt issuance costs and discounts or premiums, consists of the following (in millions):

	December 31,
	2022			2021
6⅝% Senior Secured Notes due 2025	$	—		$	1,462
8% Senior Secured Notes due 2026		2,101			2,101
8% Senior Secured Notes due 2027		700			700
5⅝% Senior Secured Notes due 2027		1,900			1,900
6⅞% Senior Notes due 2028		756			767
6% Senior Secured Notes due 2029		900			900
5¼% Senior Secured Notes due 2030		1,535			—
4¾% Senior Secured Notes due 2031		1,058			1,095
6⅞% Junior-Priority Secured Notes due 2029		1,386			1,775
6⅛% Junior-Priority Secured Notes due 2030		1,232			1,440
ABL Facility		53			—
Finance lease and financing obligations		380			398
Other		36			37
Less: Unamortized deferred debt issuance costs and note discount		(402	)		(435	)
Total debt		11,635			12,140
Less: Current maturities		(21	)		(31	)
Total long-term debt	$	11,614		$	12,109

Summary of Extinguished Portion of Certain Series of Outstanding Notes

	Principal Amount
6⅞% Senior Notes due 2028	$	11
4¾% Senior Secured Notes due 2031		37
6⅞% Junior-Priority Secured Notes due 2029		389
6⅛% Junior-Priority Secured Notes due 2030		208
Total principal amount of debt extinguished	$	645

Schedule of Maturities of Long-term Debt

Year Ending December 31,	Amount
2023	$	21
2024		15
2025		10
2026		2,163
2027		2,609
Thereafter		7,219
Total maturities		12,037
Less: Deferred debt issuance costs		(391	)
Less: Unamortized note discount		(11	)
Total long-term debt	$	11,635

Senior Secured Notes at 8%, Due 2026 | Senior Secured Notes

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
March 15, 2022 to March 14, 2023		104.000	%
March 15, 2023 to March 14, 2024		102.000	%
March 15, 2024 to March 14, 2026		100.000	%

Senior Secured Notes at 8% Due 2027 | Senior Secured Notes

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
December 15, 2022 to December 14, 2023		104.000	%
December 15, 2023 to December 14, 2024		102.000	%
December 15, 2024 to December 14, 2027		100.000	%

5⅝% Senior Secured Notes due 2027 | Senior Secured Notes

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
December 15, 2023 to December 14, 2024		102.813	%
December 15, 2024 to December 14, 2025		101.406	%
December 15, 2025 to December 14, 2027		100.000	%

Senior Notes at 6.875% Due 2028 | Senior Notes

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
April 1, 2023 to March 31, 2024		103.438	%
April 1, 2024 to March 31, 2025		101.719	%
April 1, 2025 to March 31, 2028		100.000	%

6% Senior Secured Notes due 2029 | Senior Secured Notes

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
January 15, 2024 to January 14, 2025		103.000	%
January 15, 2025 to January 14, 2026		101.500	%
January 15, 2026 to January14, 2029		100.000	%

Senior Secured Notes 5.250%, Due 2030 | Senior Secured Notes

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
May 15, 2025 to May 14, 2026		102.625	%
May 15, 2026 to May 14, 2027		101.313	%
May 15, 2027 to May 14, 2030		100.000	%

Senior Secured Notes at 4.75% due 2031 | Senior Secured Notes

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
February 15, 2026 to February 14, 2027		102.375	%
February 15, 2027 to February 14, 2028		101.583	%
February 15, 2028 to February 14, 2029		100.792	%
February 15, 2029 to February 14, 2031		100.000	%

Junior-Priority Secured Notes at 6.875% Due 2029 | Senior Secured Notes

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
April 15, 2024 to April 14, 2025		103.438	%
April 15, 2025 to April 14, 2026		101.719	%
April 15, 2026 to April 14, 2029		100.000	%

Junior-Priority Secured Notes at 6.125% Due 2030 | Senior Secured Notes

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
April 1, 2025 to March 31, 2026		103.063	%
April 1, 2026 to March 31, 2027		101.531	%
April 1, 2027 to March 31, 2030		100.000	%

Fair Value of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

Schedule of Estimated Fair Value of Financial Instruments, by Balance Sheet Grouping

	December 31, 2022				December 31, 2021
	Carrying		Estimated Fair		Carrying		Estimated Fair
	Amount		Value		Amount		Value
Assets:
Cash and cash equivalents	$	118	$	118	$	507	$	507
Investments in equity securities		107		107		144		144
Available-for-sale debt securities		179		179		178		178
Trading securities		5		5		13		13
Liabilities:
6⅝% Senior Secured Notes due 2025		—		—		1,434		1,517
8% Senior Secured Notes due 2026		2,083		1,917		2,078		2,210
8% Senior Secured Notes due 2027		693		631		692		758
5⅝% Senior Secured Notes due 2027		1,833		1,633		1,819		2,011
6⅞% Senior Notes due 2028		749		389		759		758
6% Senior Secured Notes due 2029		865		751		860		966
5¼% Senior Secured Notes due 2030		1,448		1,166		—		—
4¾% Senior Secured Notes due 2031		1,053		766		1,090		1,108
6⅞% Junior-Priority Secured Notes due 2029		1,282		720		1,625		1,823
6⅛% Junior-Priority Secured Notes due 2030		1,164		615		1,352		1,431
ABL Facility and other debt		85		85		32		32

Fair Value (Tables)

12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets Measured on Recurring Basis

The following table sets forth, by level within the fair value hierarchy, the financial assets recorded at fair value on a recurring basis as of December 31, 2022 and 2021 (in millions):

	December 31, 2022		Level 1		Level 2		Level 3
Investments in equity securities	$	107	$	107	$	—	$	—
Available-for-sale debt securities		179		—		179		—
Trading securities		5		—		5		—
Total assets	$	291	$	107	$	184	$	—

	December 31, 2021		Level 1		Level 2		Level 3
Investments in equity securities	$	144	$	144	$	—	$	—
Available-for-sale debt securities		178		—		178		—
Trading securities		13		—		13		—
Total assets	$	335	$	144	$	191	$	—

Supplemental Information Regarding Available-for-Sale Debt Securities

Supplemental information regarding the Company’s available-for-sale debt securities (all of which had no withdrawal restrictions) is set forth in the table below (in millions):

			Gross		Gross			Estimated
	Amortized		Unrealized		Unrealized			Fair
	Cost		Gains		Losses			Values
As of December 31, 2022:
Government	$	107	$	—	$	(11	)	$	96
Corporate		69		—		(9	)		60
Mortgage and asset-backed securities		25		—		(2	)		23
Total available-for-sale debt securities	$	201	$	—	$	(22	)	$	179

			Gross		Gross			Estimated
	Amortized		Unrealized		Unrealized			Fair
	Cost		Gains		Losses			Values
As of December 31, 2021:
Government	$	83	$	1	$	(1	)	$	83
Corporate		62		—		(1	)		61
Mortgage and asset-backed securities		34		—		—			34
Total available-for-sale debt securities	$	179	$	1	$	(2	)	$	178

Contractual Maturities of Debt Securities

	December 31, 2022				December 31, 2021
	Amortized		Estimated		Amortized		Estimated
	Cost		Fair Values		Cost		Fair Values
Within 1 year	$	13	$	13	$	8	$	8
After 1 year and through year 5		74		70		61		61
After 5 years and through year 10		56		48		49		49
After 10 years		58		48		61		60

Gross Realized Gains and Losses and Investment Income on Available-for-Sale Debt Securities

Gross realized gains and losses on sales of available-for-sale debt securities are summarized in the table below (in millions):

	Year Ended December 31,
	2022			2021			2020
Realized gains	$	—		$	1		$	2
Realized losses		(2	)		(1	)		(1	)

Net Gains and Losses Recognized for Investments in Equity Securities

	Year Ended December 31,
	2022			2021		2020
Net (losses) and gains recognized during the year on equity securities	$	(28	)	$	20	$	9
Less: Net (losses) and gains recognized during the year on equity securities sold during the year		(2	)		13		14
Unrealized (losses) and gains recognized during the year on equity securities held at the end of year	$	(26	)	$	7	$	(5	)

Leases (Tables)

12 Months Ended

Dec. 31, 2022

Leases [Abstract]

Components of Lease Cost and Rent Expense

The components of lease cost and rent expense for the years ended December 31, 2022, 2021 and 2020 are as follows (in millions):

	Year Ended December 31,
Lease Cost	2022			2021			2020
Operating lease cost:
Operating lease cost	$	211		$	196		$	203
Short-term rent expense		87			92			104
Variable lease cost		24			25			26
Sublease income		(5	)		(5	)		(6	)
Total operating lease cost	$	317		$	308		$	327
Finance lease cost:
Amortization of ROU assets	$	13		$	9		$	10
Interest on finance lease liabilities		15			9			8
Total finance lease cost	$	28		$	18		$	18

Supplemental Balance Sheet Information Related to Leases

Supplemental balance sheet information related to leases was as follows (in millions):

	Balance Sheet Classification	December 31, 2022			December 31, 2021
Operating Leases:
Operating Lease ROU Assets	Other assets, net	$	738		$	668

Finance Leases:
Finance Lease ROU Assets	Property and equipment
	Land and improvements	$	—		$	8
	Buildings and improvements		261			289
	Equipment and fixtures		12			17
	Property and equipment		273			314
	Less accumulated depreciation and amortization		(56	)		(54	)
	Property and equipment, net	$	217		$	260

Current finance lease liabilities	Current maturities of long-term debt	$	3		$	8
Long-term finance lease liabilities	Long-term debt		220			233

Supplemental Cash Flow and Other Information Related to Leases

Supplemental cash flow information related to leases for the years ended December 31, 2022, 2021 and 2020 are as follows (in millions):

	Year Ended December 31,
Cash flow information	2022			2021			2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases (1)	$	204		$	197		$	188
Operating cash flows from finance leases		15			9			8
Financing cash flows from finance leases		9			4			7
ROU assets obtained in exchange for new finance lease liabilities		42			166			22
ROU assets obtained in exchange for new operating lease liabilities		195			143			150
Weighted-average remaining lease term:
Operating leases	8 years			6 years			7 years
Finance leases	31 years			30 years			19 years
Weighted-average discount rate:
Operating leases		8.0	%		8.1	%		9.0	%
Finance leases		6.4	%		6.3	%		8.4	%

(1)	Included in the change in other operating assets and liabilities in the consolidated statements of cash flows.

Commitments Relating To Noncancellable Operating And Finance Leases And Financing Obligations

Commitments relating to noncancellable operating and finance leases and financing obligations for each of the next five years and thereafter are as follows (in millions):

							Financing
Year Ending December 31,	Operating			Finance			Obligations
2023	$	205		$	16		$	13
2024		157			16			13
2025		126			15			13
2026		102			16			13
2027		76			16			14
Thereafter		385			488			75
Total minimum future payments		1,051			567			141
Less: Imputed interest		(298	)		(344	)		16
Total liabilities		753			223			157
Less: Current portion		(148	)		(3	)		(3	)
Long-term liabilities	$	605		$	220		$	154

Stockholders' Deficit (Tables)

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

Schedule of Impact of Noncontrolling Interest to Stockholders' Deficit

	Year Ended December 31,
	2022			2021		2020
Net income attributable to Community Health Systems,
Inc. stockholders	$	46		$	230	$	511
Transfers to the noncontrolling interests:
Net (decrease) increase in Community Health
Systems, Inc. paid-in-capital for
purchase of subsidiary partnership interests		(6	)		17		3
Net transfers to the noncontrolling interests		(6	)		17		3
Change to Community Health Systems, Inc.
stockholders’ deficit from net income attributable to
Community Health Systems, Inc. stockholders
and transfers to noncontrolling interests	$	40		$	247	$	514

Earnings Per Share (Tables)

12 Months Ended

Dec. 31, 2022

Earnings Per Share [Abstract]

Schedule of Components of Denominator for Computation of Basic and Diluted Earnings Per Share

	Year Ended December 31,
	2022		2021		2020
Weighted-average number of shares outstanding — basic		128,808,387		126,754,852		115,491,022
Effect of dilutive securities:
Restricted stock awards		842,055		2,803,938		905,903
Employee stock options		278,057		726,130		122,785
Other equity-based awards		131,820		312,490		24,851
Weighted-average number of shares outstanding — diluted		130,060,319		130,597,410		116,544,561

Schedule of Antidilutive Securities

	Year Ended December 31,
	2022		2021		2020
Dilutive securities outstanding not included in the computation of earnings per share because their effect is antidilutive:
Employee stock options and restricted stock awards		4,406,764		774,981		2,821,511

Comprehensive Loss (Tables)

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

Schedule of Changes in Accumulated Other Comprehensive Income (Loss) ("AOCL") by Component

	Change in
	Fair Value of			Change in
	Available-for-Sale			Unrecognized
	Debt			Pension Cost
	Securities (1)			Components			AOCL (1)
Balance as of December 31, 2021	$	(2	)	$	(12	)	$	(14	)
Other comprehensive (loss)
income before reclassifications		(16	)		10			(6	)
Amounts reclassified from
AOCL		(1	)		—			(1	)
Net current-period other
comprehensive (loss) income		(17	)		10			(7	)
Balance as of December 31, 2022	$	(19	)	$	(2	)	$	(21	)

__________________________

(1) Totals may not add due to rounding.

	Change in
	Fair Value of			Change in
	Available-for-Sale			Unrecognized
	Debt			Pension Cost
	Securities (1)			Components			AOCL (1)
Balance as of December 31, 2020	$	2		$	(15	)	$	(13	)
Other comprehensive (loss)
income before reclassifications		(1	)		1			—
Amounts reclassified from
AOCL		(4	)		2			(2	)
Net current-period other
comprehensive (loss) income		(5	)		3			(2	)
Balance as of December 31, 2021	$	(2	)	$	(12	)	$	(14	)

__________________________

(1) Totals may not add due to rounding.

Schedule of Amounts Reclassified Out of AOCL (Loss)

	Amount reclassified
	from AOCL			Affected line item in the
	Year Ended			statement where net
Details about AOCL components	December 31, 2022			income is presented
Amortization of defined benefit pension items
Prior service costs	$	(1	)	Salaries and benefits
Settlement losses recognized		—		Salaries and benefits
		(1	)	Total before tax
		—		Tax benefit
	$	(1	)	Net of tax

	Amount reclassified
	from AOCL			Affected line item in the
	Year Ended			statement where net
Details about AOCL components	December 31, 2021			income is presented
Amortization of defined benefit pension items
Prior service costs	$	(2	)	Salaries and benefits
		(2	)	Total before tax
		—		Tax benefit
	$	(2	)	Net of tax

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2022

Commitments And Contingencies Disclosure [Abstract]

Schedule of Reconciliation of the Beginning and Ending Liability Balances in Connection with Probable Contingencies

	Probable
	Contingencies
Balance as of December 31, 2020	$	11
Expense		11
Reserve for insured claim		(1	)
Cash payments		(1	)
Balance as of December 31, 2021		20
Expense		8
Cash payments		(17	)
Balance as of December 31, 2022	$	11

Condensed Financial Information of Parent (Tables)

12 Months Ended

Dec. 31, 2022

Condensed Financial Information Of Parent Company Only Disclosure [Abstract]

Condensed Balance Sheets

Parent Company Only
Condensed Balance Sheets
(In millions)
	December 31,
	2022			2021
ASSETS
Prepaid income taxes	$	99		$	94
Total current assets		99			94
Deferred income taxes		49			53
Other assets, net		—			—
Total assets	$	148		$	147
LIABILITIES AND STOCKHOLDERS' DEFICIT
Intercompany payable	$	1,159		$	1,326
Deferred income taxes		354			192
Other long-term liabilities		2			1
Total liabilities		1,515			1,519
Community Health Systems, Inc. stockholders’ deficit:
Preferred stock		—			—
Common stock		1			1
Additional paid-in capital		2,084			2,118
Accumulated other comprehensive loss		(21	)		(14	)
Accumulated deficit		(3,431	)		(3,477	)
Total Community Health Systems, Inc. stockholders’ deficit		(1,367	)		(1,372	)
Total liabilities and stockholders' deficit	$	148		$	147

See note to condensed financial statements of Parent.

Condensed Statements of Income

Parent Company Only
Condensed Statements of Income
(In millions)
	Year Ended December 31,
	2022			2021			2020
Net operating revenues	$	—		$	—		$	—
Operating costs and expenses:
Salaries and benefits		—			—			—
Supplies		—			—			—
Other operating expenses		—			—			—
Lease cost and rent		—			—			—
Pandemic relief funds		—			—			—
Depreciation and amortization		—			—			—
Impairment and (gain) loss on sale of businesses, net		—			—			—
Total operating costs and expenses		—			—			—
Income from operations		—			—			—
Interest expense, net		—			—			—
(Gain) loss from early extinguishment of debt		—			—			—
Equity in earnings of unconsolidated affiliates		(46	)		(230	)		(511	)
Income before income taxes		46			230			511
Provision for (benefit from) income taxes		—			—			—
Net income		46			230			511
Less: Net income attributable to noncontrolling interests		—			—			—
Net income attributable to Community Health Systems, Inc. stockholders	$	46		$	230		$	511

See note to condensed financial statements of Parent.

Condensed Statements of Comprehensive Income

Parent Company Only
Condensed Statements of Comprehensive Income
(In millions)
	Year Ended December 31,
	2022			2021			2020
				(In millions)
Net income	$	46		$	230		$	511
Equity in other comprehensive (loss) income of affiliates, net of income taxes:
Net change in fair value of interest rate swaps, net of tax		—			—			(1	)
Net change in fair value of available-for-sale debt securities, net of tax		(17	)		(5	)		4
Amortization and recognition of unrecognized pension cost components, net of tax		10			3			(7	)
Other comprehensive loss		(7	)		(2	)		(4	)
Comprehensive income		39			228			507
Less: Comprehensive income attributable to noncontrolling interests		—			—			—
Comprehensive income attributable to Community Health Systems, Inc. stockholders	$	39		$	228		$	507

See note to condensed financial statements of Parent.

Condensed Statement of Cash Flows

Parent Company Only
Condensed Statements of Cash Flows
(In millions)
	Year Ended December 31,
	2022			2021			2020
Cash flows from operating activities:
Net cash used in operating activities	$	(13	)	$	(11	)	$	(12	)
Cash flows from investing activities:
Net cash provided by (used in) investing activities		—			—			—
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll tax withholding requirements		(8	)		(5	)		(1	)
Changes in intercompany balances with affiliates, net		21			16			13
Net cash provided by financing activities		13			11			12
Net change in cash and cash equivalents		—			—			—
Cash and cash equivalents at beginning of period		—			—			—
Cash and cash equivalents at end of period	$	—		$	—		$	—

See note to condensed financial statements of Parent.

Basis of Presentation and Significant Accounting Policies - Additional Information (Details)	1 Months Ended	12 Months Ended
	Apr. 30, 2020 USD ($)	Dec. 31, 2022 USD ($) Hospital Item	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Business Description [Abstract]
Number of affiliated hospitals owned and leased by subsidiaries \| Hospital		80
Number of beds \| Item		13,000
Number of sites of care operates \| Item		1,000
Cost of Revenue, Policy [Abstract]
Corporate Office Costs		$ 229,000,000	$ 222,000,000	$ 190,000,000
Stock-based compensation expense		20,000,000	25,000,000	13,000,000
Marketable Securities, Policy [Abstract]
Net change in fair value of available-for-sale debt securities, net of tax of $5 for the year ended December 31, 2022 and $1 for the years ended December 31, 2021 and 2020		(17,000,000)	(5,000,000)	4,000,000
Property and Equipment, Policy [Abstract]
Construction in Progress, Gross		234,000,000	225,000,000
Interest Costs Capitalized		9,000,000	13,000,000	15,000,000
Purchases of property and equipment and internal-use software accrued in accounts payable		87,000,000	105,000,000
Goodwill, Policy [Abstract]
Impairment of goodwill		0	0	0
Third Party Reimbursement [Abstract]
Amounts due to third party payors		101,000,000	118,000,000
Amounts due from third party payors		97,000,000	114,000,000
Net Operating Revenues, Policy [Abstract]
Charity care services charges excluded from net operating revenues		1,400,000,000	1,100,000,000	1,000,000,000.0
Value of charity care services at the Company's standard charges included in contractual allowances		166,000,000	123,000,000	122,000,000
Concentration of Credit Risk, Policy [Abstract]
Accounts receivable, net of contractual allowances		2,040,000,000	2,062,000,000
Accounting for the Impairment or Disposal of Long-Lived Assets
Gain (loss) on disposition of business			(24,000,000)
Impairment of long-lived assets sold		71,000,000
Amount related to closure of hospitals		44,000,000
Amount related to expiration or planned non-renewal of leases		9,000,000
Amount related to several assets idled disposed or held for sale		$ 11,000,000
New Accounting Pronouncements, Policy [Abstract]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]		true
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]		true
CARES Act
Medicare Accelerated Payments [Abstract]
Medicare accelerated payments received under the Cares Act	$ 1,200,000,000
Medicare accelerated payments, recouped subject to the aforementioned repayment terms			1,100,000,000	77,000,000
CARES Act \| Paycheck Protection Program, Health Care Enhancement Act And the American Rescue Plan Act of 2021
COVID-19 Pandemic [Abstract]
Percentage of maximum accelerated payment		100.00%
Medicare accelerated and advance payment program period		6 months
Public Health and Social Services Emergency Fund (the "PHSSEF") \| CARES Act \| Paycheck Protection Program, Health Care Enhancement Act And the American Rescue Plan Act of 2021
COVID-19 Pandemic [Abstract]
CARES Act and PPPHCE Act of 2020 Aid, amount		$ 186,000,000,000
C A R E S Act And P P P H C E Act Funds [Abstract]
Accelerated Payments Received Returned Under Cares Act		161,000,000	58,000,000	705,000,000
Public Health and Social Services Emergency Fund (the "PHSSEF") \| CARES Act \| Paycheck Protection Program And Health Care Enhancement Act \| Accrued Liabilities - Other
C A R E S Act And P P P H C E Act Funds [Abstract]
Payments through the PHSSEF and various state and local programs				2,000,000
Public Health and Social Services Emergency Fund (the "PHSSEF") \| CARES Act \| Paycheck Protection Program And Health Care Enhancement Act \| Operating Costs and Expenses
C A R E S Act And P P P H C E Act Funds [Abstract]
Payments through the PHSSEF and various state and local programs		173,000,000	148,000,000	$ 601,000,000
Adjustment for Carrying Value of Other Long-Lived Assets at Underperforming Hospitals
Accounting for the Impairment or Disposal of Long-Lived Assets
Impairment of long-lived assets held for sale		7,000,000
Hospitals Sold Or Deemed Held For Sale \| Certain Hospitals
Accounting for the Impairment or Disposal of Long-Lived Assets
Gain (loss) on disposition of business			(3,000,000)
Adjustment for Carrying Value of Other Long-Lived Assets at Underperforming Hospitals
Accounting for the Impairment or Disposal of Long-Lived Assets
Gain (loss) on disposition of business			29,000,000
Hospitals Closed
Accounting for the Impairment or Disposal of Long-Lived Assets
Gain (loss) on disposition of business			8,000,000
Shared Service Center
Accounting for the Impairment or Disposal of Long-Lived Assets
Gain (loss) on disposition of business			5,000,000
Medicare
Concentration of Credit Risk, Policy [Abstract]
Accounts receivable, net of contractual allowances		$ 198,000,000	$ 211,000,000
Accounts receivable net of contractual allowances, percent		6.00%	5.00%
Physician Recruitment Contracts
Other Assets, Policy [Abstract]
Term of Physician Recruitment Contract		3 years
Physician Income Guarantees, Policy [Abstract]
Physicians recruitment agreement period		1 year
Term of Physician Recruitment Contract		3 years
Unamortized portion of physician income guarantees		$ 12,000,000	$ 13,000,000
Capitalized Internal Use Software, Significant System Conversions
Other Assets, Policy [Abstract]
Finite-Lived Intangible Assets, Weighted-Average Useful Life		3 years
Capitalized Internal Use Software Except Significant System Conversions
Other Assets, Policy [Abstract]
Finite-Lived Intangible Assets, Weighted-Average Useful Life		3 years
Land Improvements \| Minimum
Property and Equipment, Policy [Abstract]
Property, Plant and Equipment, Useful Life		3 years
Land Improvements \| Maximum
Property and Equipment, Policy [Abstract]
Property, Plant and Equipment, Useful Life		20 years
Building and Building Improvements \| Minimum
Property and Equipment, Policy [Abstract]
Property, Plant and Equipment, Useful Life		5 years
Building and Building Improvements \| Maximum
Property and Equipment, Policy [Abstract]
Property, Plant and Equipment, Useful Life		40 years
Equipment and Fixtures \| Minimum
Property and Equipment, Policy [Abstract]
Property, Plant and Equipment, Useful Life		3 years
Equipment and Fixtures \| Maximum
Property and Equipment, Policy [Abstract]
Property, Plant and Equipment, Useful Life		18 years
Certain Facility
Property and Equipment, Policy [Abstract]
Non-cash investing activity through capital leases		$ 38,000,000
Geographic Concentration Risk \| Indiana \| Sales Revenue, Net
Business Description [Abstract]
Concentration Risk, Percentage		17.30%	16.40%	15.00%
Geographic Concentration Risk \| Florida \| Sales Revenue, Net
Business Description [Abstract]
Concentration Risk, Percentage		11.60%	12.20%	13.00%
Geographic Concentration Risk \| Texas \| Sales Revenue, Net
Business Description [Abstract]
Concentration Risk, Percentage		11.70%	11.00%	12.20%
Geographic Concentration Risk \| Alabama \| Sales Revenue, Net
Business Description [Abstract]
Concentration Risk, Percentage		13.30%	13.00%	12.10%

Basis of Presentation and Significant Accounting Policies - Schedule of Net Operating Revenues (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues	$ 12,211	$ 12,368	$ 11,789
Medicare
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues	2,547	2,650	2,813
Medicaid
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues	1,807	1,671	1,578
Medicare Managed Care
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues	1,968	1,861	1,601
Other Third-party Payors
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues	5,806	6,076	5,799
Self-Pay
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues	$ 83	$ 110	$ (2)

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

Accounting for Stock-Based Compensation - Additional Information (Details)					12 Months Ended
	Jun. 01, 2022 USD ($) shares	Mar. 01, 2022 USD ($) Director shares	Mar. 01, 2021 USD ($) Director shares	Mar. 01, 2020 USD ($) Director shares	Dec. 31, 2022 USD ($) Item $ / shares shares	Dec. 31, 2021 USD ($) Item $ / shares shares	Dec. 31, 2020 USD ($) Item $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee service share-based compensation, unrecognized compensation costs on nonvested awards					$ 34,000,000
Employee service share-based compensation total compensation cost not yet recognized, period for recognition					22 months
Employee service share-based compensation, nonvested awards, modifications to awards \| Item					0	0	0
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value of options exercised					$ 1,000,000	$ 1,000,000	$ 1,000,000
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee service share-based compensation total compensation cost not yet recognized, period for recognition					22 months
Employee service share-based compensation, unrecognized compensation costs on nonvested stock options					$ 6,000,000
Weighted-average grant date fair value of stock options \| $ / shares					$ 7.25	$ 6.22	$ 3.17
Share Price \| $ / shares					$ 4.32
Restricted Stock and RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee service share-based compensation total compensation cost not yet recognized, period for recognition					22 months
Employee service share-based compensation, unrecognized compensation costs on nonvested awards other than options					$ 28,000,000
Restricted Stock, Performance-Based Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by payment award, performance objective measurement period					3 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, number of grants \| shares					176,820	173,664	310,347
Number of directors elected to defer the receipt of RSUs granted \| Director		3	4	5
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement award vesting rights					one-third increments on each of the first three anniversaries of the award date
Share-based compensation, number of grants \| shares					3,253,000	2,929,250	2,205,500
Plan 2009
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement award vesting rights					one-third increments on each of the first three anniversaries of the award date
Contractual term of option granted					10 years
Unissued common stock reserved for grants \| shares					6,943,882
Plan 2009 \| Restricted Stock Units (RSUs) \| Non-management Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, number of grants \| shares	17,682	17,682	19,296	34,483
Fair value of units granted	$ 88,000	$ 180,000	$ 170,000	$ 170,000
Performance-Based Awards Granted On March 1, 2018 \| Restricted Stock, Performance-Based Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement award vesting rights, percentage		200.00%

Accounting for Stock-Based Compensation - Schedule of Share-based Compensation Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Effect on income before income taxes	$ (20)	$ (25)	$ (13)
Effect on net income	$ (15)	$ (20)	$ (10)

Accounting for Stock-Based Compensation - Schedule of Share-based Payment Awards, Stock Options, Valuation Assumptions (Details) - Employee Stock Option	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility			73.50%
Expected volatility, minimum	84.30%	84.30%
Expected volatility, maximum	87.50%	88.90%
Expected term			6 years
Risk-free interest rate			1.00%
Risk-free interest rate, minimum	1.50%	0.30%
Risk-free interest rate, maximum	1.60%	0.90%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	3 years	3 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	6 years	6 years

Accounting for Stock-Based Compensation - Schedule of Share-based Compensation, Stock Options, Activity (Details) - Employee Stock Option - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Shares	2,301,753	1,817,525	1,110,134
Granted, Shares	760,000	749,250	946,500
Exercised, Shares	(56,500)	(65,499)	(18,166)
Forfeited and cancelled, Shares	(173,502)	(199,523)	(220,943)
Ending Balance, Shares	2,831,751	2,301,753	1,817,525
Exercisable, Shares	1,298,412
Beginning of Period, Weighted Average Exercise Price	$ 6.77	$ 8.77	$ 16.90
Granted, Weighted Average Exercise Price	10.18	8.81	4.93
Exercised, Weighted Average Exercise Price	4.97	5.03	4.99
Forfeited and Cancelled, Weighted Average Exercise Price	13.41	33.14	33.52
End of Period, Weighted Average Exercise Price	7.32	$ 6.77	$ 8.77
Exercisable, Weighted Average Exercise Price	$ 5.64
Weighted Average Remaining Contractual Term	7 years 9 months 18 days
Exercisable, Weighted Average Remaining Contractual Term	7 years

Accounting for Stock-Based Compensation - Schedule of Share-based Compensation, Restricted Stock, Activity (Details) - Restricted Stock - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Unvested Shares	4,995,314	4,555,735	3,857,402
Granted, Shares	3,253,000	2,929,250	2,205,500
Vested, Shares	(2,561,575)	(2,312,328)	(1,123,329)
Forfeited, Shares	(145,674)	(177,343)	(383,838)
Ending Balance, Unvested Shares	5,541,065	4,995,314	4,555,735
Beginning of Period, Weighted Average Grant Date Fair Value	$ 6.30	$ 4.84	$ 5.47
Granted, Weighted Average Grant Date Fair Value	8.95	8.16	4.90
Vested, Weighted Average Grant Date Fair Value	5.70	4.68	5.84
Forfeited, Weighted Average Grant Date Fair Value	8.89	6.33	8.58
End of Period, Weighted Average Grant Date Fair Value	$ 8.53	$ 6.30	$ 4.84

Accounting for Stock-Based Compensation - Schedule of Share-based Compensation, Restricted Stock Units, Activity (Details) - Restricted Stock Units (RSUs) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Unvested Shares	486,598	613,739	541,576
Granted, Shares	176,820	173,664	310,347
Vested, Shares	(151,058)	(300,805)	(238,184)
Ending Balance, Unvested Shares	512,360	486,598	613,739
Beginning of Period, Weighted Average Grant Date Fair Value	$ 6.17	$ 4.89	$ 5.13
Granted, Weighted Average Grant Date Fair Value	9.66	8.81	4.93
Vested, Weighted Average Grant Date Fair Value	5.63	5.09	5.47
End of Period, Weighted Average Grant Date Fair Value	$ 7.54	$ 6.17	$ 4.89

Acquisitions, Divestitures and Closures - Acquisitions - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Physician Practices, Clinics, Ambulatory Surgery Centers and Other Ancillary Businesses
Acquisitions and Divestitures [Line Items]
Business acquisition, cost of acquired entity, purchase price	$ 9	$ 3	$ 1

Acquisitions, Divestitures and Closures - Schedule of Divestitures (Details) - Item	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
AllianceHealth Seminole
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	32
Effective Date	Jul. 01, 2022
Lea Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		84
Effective Date		Jan. 01, 2021
Tennova Healthcare - Tullahoma
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		135
Effective Date		Jan. 01, 2021
Tennova Healthcare - Shelbyville
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		60
Effective Date		Jan. 01, 2021
Northwest Mississippi Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		181
Effective Date		Feb. 01, 2021
Alliance Health Midwest
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		255
Effective Date		Apr. 01, 2021
Berwick Hospital Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			90
Effective Date			Dec. 01, 2020
Brownwood Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			188
Effective Date			Oct. 27, 2020
Abilene Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			231
Effective Date			Oct. 27, 2020
San Angelo Community Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			171
Effective Date			Oct. 24, 2020
Bayfront Health St. Petersburg
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			480
Effective Date			Oct. 01, 2020
Hill Regional Hospital
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			25
Effective Date			Aug. 01, 2020
St. Cloud Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			84
Effective Date			Jul. 01, 2020
Northern Louisiana Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			130
Effective Date			Jul. 01, 2020
Shands Live Oak Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			25
Effective Date			May 01, 2020
Shands Starke Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			49
Effective Date			May 01, 2020
Southside Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			300
Effective Date			Jan. 01, 2020
Southampton Memorial Hospital
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			105
Effective Date			Jan. 01, 2020
Southern Virginia Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			80
Effective Date			Jan. 01, 2020

Acquisitions, Divestitures and Closures - Divestitures - Additional Information (Details) - Item	Nov. 30, 2020	Dec. 31, 2022
Greenbrier Valley Medical Center \| Ronceverte, West Virginia
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		122
Plateau Medical Center \| Oak Hill, West Virginia
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		25
Biloxi Mississippi To Memorial Properties Inc
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	153
Agreement date	Oct. 12, 2020
Biloxi Mississippi To Memorial Properties Inc \| Merit Health Biloxi
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Ownership Interest percentage by parent	50.00%

Acquisitions, Divestitures and Closures - Schedule of Balance Sheet Items Classified as Held for Sale (Details) $ in Millions	Dec. 31, 2022 USD ($)
Acquisitions Divestitures And Closures [Abstract]
Other current assets	$ 6
Other assets, net	132
Accrued liabilities	$ (4)

Acquisitions, Divestitures and Closures - Closures - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2020 USD ($)	Sep. 30, 2022 Item	Sep. 30, 2020 Item
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charge of long-lived assets sold	$ 71
Shorepoint Health Venice \| Venice, Florida
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds \| Item			312
Impairment charge of long-lived assets sold	29
First Hospital Wyoming Valley (Psychiatric) \| Wilkes-Barre, Pennsylvania
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds \| Item			149
Impairment charge of long-lived assets sold	$ 15
Shands Lake Shore Regional Medical Center
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charge recorded on the sale or closure of hospitals		$ 3
Shands Lake Shore Regional Medical Center \| Lake City Florida
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds \| Item				99

Acquisitions, Divestitures and Closures - Other - Additional Information (Details) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2022 USD ($) Item	Dec. 31, 2022 USD ($) Item
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment of long-lived assets sold		$ 71
AllianceHealth Clinton
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charge recorded on the sale or closure of hospitals		$ 1
AllianceHealth Clinton \| Clinton, Oklahoma
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds \| Item	56	56
AllianceHealth Woodward \| Woodward, Oklahoma
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds \| Item	87	87
Impairment of long-lived assets sold	$ 8

Goodwill and Other Intangible Assets - Schedule of Goodwill (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill [Roll Forward]
Goodwill	$ 6,980	$ 7,033	$ 7,033
Accumulated impairment losses	(2,814)	(2,814)	(2,814)
Goodwill	4,166	4,219	$ 4,219
Goodwill acquired as part of acquisitions during current year	11	5
Goodwill allocated to hospitals divested or held-for-sale	$ (64)	$ (5)

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

Goodwill and Other Intangible Assets - Goodwill - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	$ 4,166,000,000	$ 4,219,000,000	$ 4,219,000,000
Impairment of goodwill	$ 0	$ 0	$ 0

- Definition

+ References + Details

Goodwill and Other Intangible Assets - Intangible Assets - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired during the year	$ 0	$ 0
Finite-lived intangible assets, gross	4,000,000	1,000,000
Finite-Lived intangible assets, net	2,000,000
Net, intangible asset not subject to amortization	50,000,000	54,000,000
Gross carrying amount of capitalized software	968,000,000	992,000,000
Capitalized computer software, net	170,000,000	215,000,000
Capitalized computer software, development stage costs	82,000,000
Finite-Lived Intangible Assets, Except Capitalized Internal-Use Software
Finite Lived Intangible Assets [Line Items]
Amortization expense	$ 1,000,000	1,000,000	$ 1,000,000
Capitalized Internal Use Software, Significant System Conversions
Finite Lived Intangible Assets [Line Items]
Weighted-average amortization period	3 years
Capitalized Internal Use Software
Finite Lived Intangible Assets [Line Items]
Amortization expense	$ 85,000,000	108,000,000	$ 123,000,000
Amortization expense for 2023	66,000,000
Amortization expense for 2024	43,000,000
Amortization expense for 2025	26,000,000
Acquired finite-lived intangible asset, residual value	0
Amortization expense for 2026	20,000,000
Amortization expense for 2027	8,000,000
Amortization expense thereafter	7,000,000
Maximum
Finite Lived Intangible Assets [Line Items]
Finite-Lived intangible assets, net		$ 1,000,000
Maximum \| Finite-Lived Intangible Assets, Except Capitalized Internal-Use Software
Finite Lived Intangible Assets [Line Items]
Amortization expense for 2023	1,000,000
Amortization expense for 2024	1,000,000
Amortization expense for 2025	$ 1,000,000

Income Taxes - Schedule of Provision for (Benefit from) Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current:
Federal		$ (46)	$ (1)
State	$ 5	6	3
Total, Current	5	(40)	2
Deferred:
Federal	166	161	(162)
State	(1)	10	(25)
Total, Deferred	165	171	(187)
Total provision for (benefit from) income taxes for income	$ 170	$ 131	$ (185)

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Income Taxes - Schedule of Reconciliation between the Statutory Federal Income Tax Rate and the Effective Tax Rate (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Differences between the statutory federal income tax rate and the effective tax rate
Provision for (benefit from) income taxes at statutory federal rate, Amount	$ 73	$ 105	$ 89
State income taxes, net of federal income tax benefit, Amount	3	44	(15)
Net income attributable to noncontrolling interests, Amount	(28)	(29)	(20)
Change in valuation allowance, Amount	122	33	(267)
Nondeductible goodwill, Amount			41
Amended return adjustments, Amount		(22)
Nondeductible loss on divestiture, Amount			(15)
Other, Amount			2
Total provision for (benefit from) income taxes for income	$ 170	$ 131	$ (185)
Provision for (benefit from) income taxes at statutory federal rate, Percentage	21.00%	21.00%	21.00%
State income taxes, net of federal income tax benefit, Percentage	0.80%	8.70%	(3.60%)
Net income attributable to noncontrolling interests, Percentage	(8.00%)	(5.80%)	(4.70%)
Change in valuation allowance, Percentage	34.90%	6.80%	(63.20%)
Nondeductible goodwill, Percentage			9.80%
Amended return adjustments, Percentage		(4.40%)
Nondeductible loss on divestiture, Percentage			(3.40%)
Other, Percentage			0.30%
Provision for (benefit from) income taxes and effective tax rate for income, Percentage	48.70%	26.30%	(43.80%)

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Taxes [Line Items]
Effective income tax rate	48.70%	26.30%	(43.80%)
Operating loss carryforwards, valuation allowance	$ 829,000,000
Unrecognized benefit that would affect the effective tax rate	2,000,000
Income tax refunds (payments), net	$ (6,000,000)	$ (4,000,000)	$ (2,000,000)
Minimum
Income Taxes [Line Items]
Operating loss carryforwards, expiration date	Jan. 01, 2023
Maximum
Income Taxes [Line Items]
Operating loss carryforwards, expiration date	Dec. 31, 2042
Amount of interest and penalties included in liabilities for uncertain tax positions	$ 1,000,000
Federal
Income Taxes [Line Items]
Net operating loss and credit carryforwards	68,000,000
Operating loss carryforwards expected to be utilized	21,000,000
Valuation allowance increase (decrease)	$ 122,000,000	64,000,000
Federal \| Tax Year 2014, 2015 and 2018
Income Taxes [Line Items]
Open tax year	2014 2015 2018
State and Local Jurisdiction
Income Taxes [Line Items]
Net operating loss and credit carryforwards	$ 9,600,000,000
Operating loss carryforwards expected to be utilized	532,000,000
Valuation allowance increase (decrease)	$ (108,000,000)	$ (31,000,000)

Income Taxes - Schedule of Components of Deferred Income Taxes (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Assets
Net operating loss and credit carryforwards	$ 553	$ 833
Self-insurance liabilities	30	49
Long-term debt and interest	41	48
Accounts receivable	16	22
IRC Section 163(j) interest limitation	448	329
Accrued vacation	19	22
Accrued bonus	19	31
Other comprehensive income	6	5
Right-of-use liability	156	142
Stock-based compensation	5	4
Deferred compensation	51	64
Other	19	38
Total	1,363	1,587
Valuation allowance	(829)	(814)
Total Deferred Income Tax Assets, Net	534	773
Liabilities
Property and equipment	323	343
Prepaid expenses	31	30
Intangibles	148	144
Investments in unconsolidated affiliates	58	58
Other liabilities	9	9
Right-of-use assets	148	137
IRC Section 481(a) adjustments	122	191
Total Deferred Income Tax Liabilities, Gross	$ 839	$ 912

Income Taxes - Schedule of Reconciliation of the Total Amount of Unrecognized Tax Benefit (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Unrecognized tax benefit, beginning of year	$ 42	$ 45	$ 26
Gross increases — tax positions in current period	8	5	19
Reductions — tax positions in prior period		(8)
Unrecognized tax benefit, end of year	$ 50	$ 42	$ 45

Long-Term Debt - Schedule of Debt (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Debt and lease obligations	$ 11,635	$ 12,140
Less: Unamortized deferred debt issuance costs and note discount	(402)	(435)
Less: Current maturities	(21)	(31)
Total long-term debt	11,614	12,109
ABL Facility
Debt Instrument [Line Items]
Debt and lease obligations	53
Senior Notes \| Senior Notes at 6.875%, Due 2028
Debt Instrument [Line Items]
Debt and lease obligations	756	767
Senior Secured Notes \| Senior Secured Notes at 6.625%, Due 2025
Debt Instrument [Line Items]
Debt and lease obligations		1,462
Senior Secured Notes \| Senior Secured Notes at 8%, Due 2026
Debt Instrument [Line Items]
Debt and lease obligations	2,101	2,101
Senior Secured Notes \| Senior Secured Notes at 8%, Due 2027
Debt Instrument [Line Items]
Debt and lease obligations	700	700
Senior Secured Notes \| Senior Secured Notes at 5.625% due 2027
Debt Instrument [Line Items]
Debt and lease obligations	1,900	1,900
Senior Secured Notes \| Senior Secured Notes at 6%, Due 2029
Debt Instrument [Line Items]
Debt and lease obligations	900	900
Senior Secured Notes \| Senior Secured Notes 5.250%, Due 2030
Debt Instrument [Line Items]
Debt and lease obligations	1,535
Senior Secured Notes \| Senior Secured Notes at 4.75%, Due 2031
Debt Instrument [Line Items]
Debt and lease obligations	1,058	1,095
Junior-Priority Secured Notes \| Junior-Priority Secured Notes at 6.875%, Due 2029
Debt Instrument [Line Items]
Debt and lease obligations	1,386	1,775
Junior-Priority Secured Notes \| Junior-Priority Secured Notes at 6.125%, Due 2030
Debt Instrument [Line Items]
Debt and lease obligations	1,232	1,440
Finance Lease and Financing Obligations
Debt Instrument [Line Items]
Debt and lease obligations	380	398
Other
Debt Instrument [Line Items]
Debt and lease obligations	$ 36	$ 37

Long-Term Debt - Schedule of Debt (Parenthetical) (Details)					12 Months Ended
	Feb. 04, 2022	May 19, 2021	Feb. 09, 2021	Feb. 02, 2021	Dec. 31, 2022	Dec. 31, 2021	Nov. 19, 2019	Mar. 06, 2019
Senior Secured Notes \| Senior Secured Notes at 6.625%, Due 2025
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage					6.625%	6.625%
Debt instrument, maturity year					2025	2025
Senior Secured Notes \| Senior Secured Notes at 8%, Due 2026
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage					8.00%	8.00%		8.00%
Debt instrument, maturity year					2026	2026
Senior Secured Notes \| Senior Secured Notes at 8%, Due 2027
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage					8.00%	8.00%	8.00%
Debt instrument, maturity year					2027	2027
Senior Secured Notes \| Senior Secured Notes at 5.625% due 2027
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage					5.625%	5.625%
Debt instrument, maturity year					2027	2027
Senior Secured Notes \| Senior Secured Notes at 6%, Due 2029
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage					6.00%	6.00%
Debt instrument, maturity year					2029	2029
Senior Secured Notes \| Senior Secured Notes 5.250%, Due 2030
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	5.25%				5.25%	5.25%
Debt instrument, maturity year	2030				2030	2030
Senior Secured Notes \| Senior Secured Notes at 4.75%, Due 2031
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage			4.75%		4.75%	4.75%
Debt instrument, maturity year			2031		2031	2031
Senior Notes \| Senior Secured Notes at 6.625%, Due 2025
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	6.625%
Senior Notes \| Senior Notes at 6.875%, Due 2028
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage					6.875%	6.875%
Debt instrument, maturity year					2028	2028
Junior-Priority Secured Notes \| Junior-Priority Secured Notes at 6.875%, Due 2029
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage				6.875%	6.875%	6.875%
Debt instrument, maturity year				2029	2029	2029
Junior-Priority Secured Notes \| Junior-Priority Secured Notes at 6.125%, Due 2030
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		6.125%			6.125%	6.125%
Debt instrument, maturity year		2030			2030	2030

Long-Term Debt - 6.625% Senior Notes, Due 2025 - Additional Information (Details) - Senior Notes - Senior Notes at 6.875%, Due 2022 - USD ($)	12 Months Ended
	Dec. 31, 2020	Feb. 04, 2022
Debt Instrument [Line Items]
Debt instrument, offering date	Feb. 04, 2022
Debt instrument aggregate principal amount		$ 1,535,000,000
Debt instrument stated interest rate		6.625%

Long-Term Debt - 6.25% Senior Secured Notes, Due 2023 - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Extinguishment of debt amount	$ 645
Issuance of long-term debt	$ 1,535	$ 4,310	$ 4,262

Long-Term Debt - 8% Senior Secured Notes, Due 2026 - Additional Information (Details) - USD ($)			12 Months Ended
	Nov. 19, 2019	Mar. 06, 2019	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Extinguishment of debt amount			$ 645,000,000
Senior Secured Notes at 8%, Due 2026
Debt Instrument [Line Items]
Debt instrument aggregate principal amount	$ 500,000,000
Credit Facility, Term Loan H
Debt Instrument [Line Items]
Extinguishment of debt amount		$ 1,557,000,000
Senior Secured Notes \| Senior Secured Notes at 8%, Due 2026
Debt Instrument [Line Items]
Debt instrument, offering date			Mar. 06, 2019
Debt instrument aggregate principal amount	2,101,000,000	$ 1,601,000,000
Debt instrument stated interest rate		8.00%	8.00%	8.00%
Debt instrument redemption price percentage		108.00%
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount		40.00%
Debt instrument redemption description			plus a “make-whole” premium, as described in the indenture governing the 8% Senior Secured Notes due 2026.
Senior Secured Notes \| Senior Notes at 7.125%, Due 2020
Debt Instrument [Line Items]
Extinguishment of debt amount	$ 121,000,000

Long-Term Debt - Schedule of Early Redemption Prices on 8% Senior Secured Notes due 2026 (Details) - Senior Secured Notes at 8%, Due 2026 - Senior Secured Notes		12 Months Ended
	Mar. 06, 2019	Dec. 31, 2022
Debt Instrument Redemption Price Percentage	108.00%
Debt Instrument, Redemption, Period One
Debt Instrument Redemption Price Percentage		104.00%
Debt Instrument, Redemption Period, Start Date		Mar. 15, 2022
Debt Instrument, Redemption Period, End Date		Mar. 14, 2023
Debt Instrument, Redemption, Period Two
Debt Instrument Redemption Price Percentage		102.00%
Debt Instrument, Redemption Period, Start Date		Mar. 15, 2023
Debt Instrument, Redemption Period, End Date		Mar. 14, 2024
Debt Instrument, Redemption, Period Three
Debt Instrument Redemption Price Percentage		100.00%
Debt Instrument, Redemption Period, Start Date		Mar. 15, 2024
Debt Instrument, Redemption Period, End Date		Mar. 14, 2026

Long-Term Debt - 8% Senior Secured Notes, Due 2027 - Additional Information (Details) - Senior Secured Notes - Senior Secured Notes at 8% Due 2027 - USD ($)		12 Months Ended
	Nov. 19, 2019	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Debt instrument aggregate principal amount	$ 700,000,000
Debt instrument stated interest rate	8.00%	8.00%	8.00%
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount	40.00%
Debt instrument redemption description		plus a “make-whole” premium, as described in the indenture governing the 8% Senior Secured Notes due 2027.
Minimum period notice for redemption of debt	15 days
Maximum period notice for redemption of debt	60 days
Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument redemption price percentage	108.00%	102.00%
Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt instrument redemption price percentage	100.00%	104.00%

Long-Term Debt - Schedule of Early Redemption Prices on 8% Senior Secured Notes due 2027 (Details) - Senior Secured Notes at 8% Due 2027 - Senior Secured Notes		12 Months Ended
	Nov. 19, 2019	Dec. 31, 2022
Debt Instrument, Redemption, Period One
Debt Instrument Redemption Price Percentage	100.00%	104.00%
Debt Instrument, Redemption Period, Start Date		Dec. 15, 2022
Debt Instrument, Redemption Period, End Date		Dec. 14, 2023
Debt Instrument, Redemption, Period Two
Debt Instrument Redemption Price Percentage	108.00%	102.00%
Debt Instrument, Redemption Period, Start Date		Dec. 15, 2023
Debt Instrument, Redemption Period, End Date		Dec. 14, 2024
Debt Instrument, Redemption, Period Three
Debt Instrument Redemption Price Percentage		100.00%
Debt Instrument, Redemption Period, Start Date		Dec. 15, 2024
Debt Instrument, Redemption Period, End Date		Dec. 14, 2027

Long-Term Debt - 5.625% Senior Secured Notes, Due 2027 - Additional Information (Details) - Senior Secured Notes - USD ($)		12 Months Ended
	Dec. 28, 2020	Dec. 31, 2022
5⅝% Senior Secured Notes due 2027
Debt Instrument [Line Items]
Debt instrument, offering date		Dec. 28, 2020
Debt instrument, maturity date		Mar. 15, 2027
Debt instrument aggregate principal amount	$ 1,900,000,000
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount	40.00%
Debt instrument redemption description		plus a “make-whole” premium, as described in the indenture governing the 5⅝% Senior Secured Notes due 2027.
Minimum period notice for redemption of debt	15 days
Maximum period notice for redemption of debt	60 days
5⅝% Senior Secured Notes due 2027 \| Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument redemption price percentage	105.625%	101.406%
5⅝% Senior Secured Notes due 2027 \| Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt instrument redemption price percentage	100.00%	102.813%
6?% Senior Secured Notes due 2023
Debt Instrument [Line Items]
Debt instrument aggregate principal amount	$ 2,579,000,000

Long-Term Debt - Schedule of Early Redemption Prices on 5.625% Senior Secured Notes Due 2027 (Details) - 5⅝% Senior Secured Notes due 2027 - Senior Secured Notes		12 Months Ended
	Dec. 28, 2020	Dec. 31, 2022
Debt Instrument, Redemption, Period One
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%	102.813%
Debt Instrument, Redemption Period, Start Date		Dec. 15, 2023
Debt Instrument, Redemption Period, End Date		Dec. 14, 2024
Debt Instrument, Redemption, Period Two
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	105.625%	101.406%
Debt Instrument, Redemption Period, Start Date		Dec. 15, 2024
Debt Instrument, Redemption Period, End Date		Dec. 14, 2025
Debt Instrument, Redemption, Period Three
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage		100.00%
Debt Instrument, Redemption Period, Start Date		Dec. 15, 2025
Debt Instrument, Redemption Period, End Date		Dec. 14, 2027

Long-Term Debt - 6.875% Senior Notes, Due 2028 - Additional Information (Details) - USD ($) shares in Millions			12 Months Ended
	Dec. 07, 2020	Nov. 19, 2019	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Gain (loss) on early extinguishment of debt			$ 253,000,000	$ (79,000,000)	$ 317,000,000
Extinguishment of debt amount			$ 645,000,000
Senior Notes \| Senior Notes At 6.875% Due 2028
Debt Instrument [Line Items]
Debt instrument aggregate principal amount	$ 700,000,000	$ 1,700,000,000
Debt instrument stated interest rate		6.875%
Cash proceeds received in exchange offer		$ 0
Debt instrument, maturity date		Apr. 01, 2028
Minimum period notice for redemption of debt		15 days
Maximum period notice for redemption of debt		60 days
Debt instrument redemption description			plus a “make-whole” premium, as described in the indenture governing the 6⅞% Senior Notes due 2028.
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount		40.00%
Aggregate consideration from debt instrument exchanged for cash	$ 400,000,000
Debt instrument converted into shares of common stock	10
Gain (loss) on early extinguishment of debt	$ 205,000,000
Extinguishment of debt amount					226,000,000
Extinguishment of debt amount via tender offer					$ 7,000,000
Tender offer commencement date					Oct. 30, 2020
Tender offer expiration date					Nov. 30, 2020
Senior Notes \| Senior Notes At 6.875% Due 2028 \| Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt instrument redemption price percentage		100.00%
Senior Notes \| Senior Notes At 6.875% Due 2028 \| Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument redemption price percentage		106.875%

Long-Term Debt - Schedule of Early Redemption Prices on 6.875% Senior Notes Due 2028 (Details) - Senior Notes At 6.875% Due 2028 - Senior Notes	12 Months Ended
	Dec. 31, 2022
Debt Instrument, Redemption, Period Three
Debt Instrument Redemption Price Percentage	103.438%
Debt Instrument, Redemption Period, Start Date	Apr. 01, 2023
Debt Instrument, Redemption Period, End Date	Mar. 31, 2024
Debt Instrument, Redemption, Period Four
Debt Instrument Redemption Price Percentage	101.719%
Debt Instrument, Redemption Period, Start Date	Apr. 01, 2024
Debt Instrument, Redemption Period, End Date	Mar. 31, 2025
Debt Instrument, Redemption, Period Five
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Apr. 01, 2025
Debt Instrument, Redemption Period, End Date	Mar. 31, 2028

Long-Term Debt - 6% Senior Secured Notes, Due 2029 - Additional Information - (Details) - Senior Notes - USD ($) $ in Millions		12 Months Ended
	Dec. 28, 2020	Dec. 31, 2022
6% Senior Secured Notes due 2029
Debt instrument aggregate principal amount	$ 900
Debt instrument, maturity date	Jan. 15, 2029
Debt instrument stated interest rate	6.00%
Minimum period notice for redemption of debt	15 days
Maximum period notice for redemption of debt	60 days
Debt instrument redemption description		plus a “make-whole” premium, as described in the indenture governing the 6% Senior Secured Notes due 2029.
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount	40.00%
6% Senior Secured Notes due 2029 \| Debt Instrument, Redemption, Period One
Debt instrument redemption price percentage	100.00%
6% Senior Secured Notes due 2029 \| Debt Instrument, Redemption, Period Two
Debt instrument redemption price percentage	106.00%
6% Senior Secured Notes due 2029 and 5.625% Senior Secured Notes due 2027
Debt instrument, repurchase amount	$ 2,579

Long-Term Debt - Schedule of Early Redemption Prices on 6.0% Senior Notes Due 2029 (Details) - 6% Senior Secured Notes due 2029 - Senior Secured Notes	12 Months Ended
	Dec. 31, 2022
Debt Instrument, Redemption, Period One
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	103.00%
Debt Instrument, Redemption Period, Start Date	Jan. 15, 2024
Debt Instrument, Redemption Period, End Date	Jan. 14, 2025
Debt Instrument, Redemption, Period Two
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	101.50%
Debt Instrument, Redemption Period, Start Date	Jan. 15, 2025
Debt Instrument, Redemption Period, End Date	Jan. 14, 2026
Debt Instrument, Redemption, Period Three
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Jan. 15, 2026
Debt Instrument, Redemption Period, End Date	Jan. 14, 2029

Long-Term Debt - 5.250% Senior Secured Notes, Due 2030 - Additional Information (Details) - Senior Secured Notes - Senior Secured Notes at 5.25%, Due 2030 - USD ($) $ in Millions		12 Months Ended
	Feb. 04, 2022	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Debt instrument, offering date		Feb. 04, 2022
Debt instrument aggregate principal amount	$ 1,535
Debt instrument stated interest rate	5.25%	5.25%	5.25%
Debt instrument, maturity date		May 15, 2030
Debt instrument redemption price percentage	100.00%
Debt instrument redemption description		plus a “make-whole” premium, as described in the indenture governing the 5¼% Senior Secured Notes due 2030.
Minimum period notice for redemption of debt	10 days
Maximum period notice for redemption of debt	60 days
Debt instrument, maturity year	2030	2030	2030
Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt instrument, maturity date	May 15, 2025
Debt instrument redemption price percentage	105.25%	102.625%
Debt instrument redemption description		plus accrued and unpaid interest, if any. In addition, any time prior to May 15, 2025, but not more than once during each 12 month period
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount	40.00%
Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt instrument redemption price percentage	103.00%	101.313%
Debt instrument redemption description		plus accrued and unpaid interest, if any.
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount	10.00%
Redeem at Any Time and from Time to Time on or After May 15, 2025
Debt Instrument [Line Items]
Debt instrument stated interest rate	5.25%
Debt instrument redemption description		plus accrued and unpaid interest, if any, on the 4¾% Senior Secured Notes due 2031 redeemed, to, but excluding, the applicable date of redemption, if redeemed during the 12 month period beginning on February 15 of the years indicated below:
Debt instrument, maturity year	2030
Debt instrument optional redemption date	May 15, 2025
Minimum period notice for redemption of debt	10 days
Maximum period notice for redemption of debt	60 days

Long-Term Debt - Schedule of Early Redemption Prices on 5.250% Senior Notes Due 2030 (Details) - Senior Secured Notes at 5.25%, Due 2030 - Senior Secured Notes		12 Months Ended
	Feb. 04, 2022	Dec. 31, 2022
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption, Period One
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	105.25%	102.625%
Debt Instrument, Redemption Period, Start Date		May 15, 2025
Debt Instrument, Redemption Period, End Date		May 14, 2026
Debt Instrument, Redemption, Period Two
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	103.00%	101.313%
Debt Instrument, Redemption Period, Start Date		May 15, 2026
Debt Instrument, Redemption Period, End Date		May 14, 2027
Debt Instrument, Redemption, Period Three
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage		100.00%
Debt Instrument, Redemption Period, Start Date		May 15, 2027
Debt Instrument, Redemption Period, End Date		May 14, 2030

Long-Term Debt - 4.750% Senior Secured Notes, Due 2031 - Additional Information (Details) - Senior Secured Notes - USD ($) $ in Millions		12 Months Ended
	Feb. 09, 2021	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument Redemption Period Six
Debt Instrument [Line Items]
Debt instrument stated interest rate	4.75%
Debt instrument, maturity year	2031
Debt instrument redemption description	plus a “make-whole” premium, as described in the indenture governing the 4¾% Senior Secured Notes due 2031
Debt instrument optional redemption date	Feb. 15, 2026
Minimum period notice for redemption of debt	15 days
Maximum period notice for redemption of debt	60 days
Debt instrument redemption price percentage	100.00%
Senior Secured Notes at 4.75%, Due 2031
Debt Instrument [Line Items]
Debt instrument, offering date	Feb. 09, 2021
Debt instrument aggregate principal amount	$ 1,095
Debt instrument stated interest rate	4.75%	4.75%	4.75%
Debt instrument, maturity date	Feb. 15, 2031
Debt instrument, maturity year	2031	2031	2031
Debt instrument redemption description		The 4¾% Senior Secured Notes due 2031 bear interest at a rate of 4.750% per year payable semi-annually in arrears on February 15 and August 15, commencing on August 15, 2021.
Debt instrument optional redemption date	Feb. 15, 2026
Minimum period notice for redemption of debt	15 days
Maximum period notice for redemption of debt	60 days
Senior Secured Notes at 4.75%, Due 2031 \| Redeem up to 40% Principal Amount Prior to February 15, 2024
Debt Instrument [Line Items]
Debt instrument stated interest rate	4.75%
Debt instrument, maturity year	2031
Debt instrument optional redemption date	Feb. 15, 2024
Debt instrument redemption price percentage	104.75%
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount	40.00%
Senior Secured Notes at 4.75%, Due 2031 \| Redeem up to 10% Principal Amount Prior to February 15, 2026
Debt Instrument [Line Items]
Debt instrument redemption description	plus accrued and unpaid interest, if any. In addition, any time prior to February 15, 2026, but not more than once during each 12 month period
Debt instrument redemption price percentage	103.00%
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount	10.00%
Senior Secured Notes At8625 Due2024
Debt Instrument [Line Items]
Debt instrument stated interest rate	8.625%
Debt instrument, maturity year	2024
Debt instrument redemption date	Feb. 09, 2021

Long-Term Debt - Schedule of Early Redemption Prices on 4.750% Senior Notes Due 2031 (Details) - Senior Secured Notes - Senior Secured Notes at 4.75%, Due 2031	12 Months Ended
	Dec. 31, 2022
Debt Instrument, Redemption, Period One
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	102.375%
Debt Instrument, Redemption Period, Start Date	Feb. 15, 2026
Debt Instrument, Redemption Period, End Date	Feb. 14, 2027
Debt Instrument, Redemption, Period Two
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	101.583%
Debt Instrument, Redemption Period, Start Date	Feb. 15, 2027
Debt Instrument, Redemption Period, End Date	Feb. 14, 2028
Debt Instrument, Redemption, Period Three
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.792%
Debt Instrument, Redemption Period, Start Date	Feb. 15, 2028
Debt Instrument, Redemption Period, End Date	Feb. 14, 2029
Debt Instrument, Redemption, Period Four
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Feb. 15, 2029
Debt Instrument, Redemption Period, End Date	Feb. 14, 2031

Long-Term Debt - 6.875% Senior Secured Notes, Due 2029 - Additional Information (Details) - Junior-Priority Secured Notes - USD ($) $ in Millions		12 Months Ended
	Feb. 02, 2021	Dec. 31, 2022	Dec. 31, 2021
Junior-Priority Secured Notes at 6.875% Due 2029
Debt Instrument [Line Items]
Debt instrument, offering date	Feb. 02, 2021
Debt instrument aggregate principal amount	$ 1,775
Debt instrument stated interest rate	6.875%	6.875%	6.875%
Debt instrument, maturity date	Apr. 15, 2029
Debt instrument, maturity year	2029	2029	2029
Minimum period notice for redemption of debt	15 days
Maximum period notice for redemption of debt	60 days
Debt instrument redemption price percentage	100.00%
Debt instrument optional redemption date	Apr. 15, 2024
Debt instrument redemption description	plus a “make-whole” premium, as described in the indenture governing the 6⅞% Junior-Priority Secured Notes due 2029
Junior-Priority Secured Notes at 6.875% Due 2029 \| Debt Instrument, Redemption, Period Five
Debt Instrument [Line Items]
Debt instrument redemption price percentage	106.875%
Debt instrument optional redemption date	Apr. 15, 2024
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount	40.00%
Junior-Priority Secured Notes at 9.875% Due 2023
Debt Instrument [Line Items]
Debt instrument stated interest rate	9.875%
Debt instrument, maturity year	2023

Long-Term Debt - Schedule of Early Redemption Prices 6.875% Junior-Priority Secured Notes due 2029 (Details) - Junior-Priority Secured Notes at 6.875% Due 2029 - Junior-Priority Secured Notes	Feb. 02, 2021
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption, Period One
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	103.438%
Debt Instrument, Redemption Period, Start Date	Apr. 15, 2024
Debt Instrument, Redemption Period, End Date	Apr. 14, 2025
Debt Instrument, Redemption, Period Two
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	101.719%
Debt Instrument, Redemption Period, Start Date	Apr. 15, 2025
Debt Instrument, Redemption Period, End Date	Apr. 14, 2026
Debt Instrument, Redemption, Period Three
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Apr. 15, 2026
Debt Instrument, Redemption Period, End Date	Apr. 14, 2029

Long-Term Debt - 6.125% Junior-Priority Secured Notes, Due 2030 - Additional Information (Details) - Junior-Priority Secured Notes - Junior-Priority Secured Notes at 6.125% Due 2030 - USD ($) $ in Millions		12 Months Ended
	May 19, 2021	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Debt instrument, offering date	May 19, 2021
Debt instrument aggregate principal amount	$ 1,440
Debt instrument stated interest rate	6.125%	6.125%	6.125%
Debt instrument, maturity date	Apr. 01, 2030
Debt instrument, maturity year	2030	2030	2030
Debt instrument, frequency of periodic payment		The 6⅛% Junior-Priority Secured Notes due 2030 bear interest at a rate of 6.125% per year payable semi-annually in arrears on April 1 and October 1, commencing on October 1, 2021
Minimum period notice for redemption of debt	15 days
Maximum period notice for redemption of debt	60 days
Debt instrument redemption price percentage	100.00%
Debt instrument optional redemption date	Apr. 01, 2025
Debt instrument redemption description		plus a “make-whole” premium, as described in the indenture governing the 6⅛% Junior-Priority Secured Notes due 2030.
Redeem up to 40% Principal Amount Prior to May 15, 2024
Debt Instrument [Line Items]
Debt instrument redemption price percentage	106.125%
Debt instrument optional redemption date	May 15, 2024
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount	40.00%

Long-Term Debt - Schedule of Early Redemption Prices 6.125% Junior-Priority Secured Notes due 2030 (Details) - Junior-Priority Secured Notes at 6.125% Due 2030 - Junior-Priority Secured Notes	May 19, 2021
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption, Period One
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	103.063%
Debt Instrument, Redemption Period, Start Date	Apr. 01, 2025
Debt Instrument, Redemption Period, End Date	Mar. 31, 2026
Debt Instrument, Redemption, Period Two
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	101.531%
Debt Instrument, Redemption Period, Start Date	Apr. 01, 2026
Debt Instrument, Redemption Period, End Date	Mar. 31, 2027
Debt Instrument, Redemption, Period Three
Debt Instrument Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Apr. 01, 2027
Debt Instrument, Redemption Period, End Date	Mar. 31, 2030

Long-Term Debt - Summary of Extinguished Portion of Certain Series of Outstanding Notes (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Extinguishment Of Debt [Line Items]
Total principal amount of debt extinguished	$ 645
Senior Notes \| 6.875% Senior Notes due 2028
Extinguishment Of Debt [Line Items]
Total principal amount of debt extinguished	11
Senior Secured Notes \| Senior Secured Notes at 4.75%, Due 2031
Extinguishment Of Debt [Line Items]
Total principal amount of debt extinguished	37
Junior-Priority Secured Notes \| Junior-Priority Secured Notes at 6.875% Due 2029
Extinguishment Of Debt [Line Items]
Total principal amount of debt extinguished	389
Junior-Priority Secured Notes \| Junior-Priority Secured Notes at 6.125% Due 2030
Extinguishment Of Debt [Line Items]
Total principal amount of debt extinguished	$ 208

Long-Term Debt - Summary of Extinguished Portion of Certain Series of Outstanding Notes (Parenthetical) (Details)				12 Months Ended
	May 19, 2021	Feb. 09, 2021	Feb. 02, 2021	Dec. 31, 2022	Dec. 31, 2021
Senior Notes \| 6.875% Senior Notes due 2028
Extinguishment Of Debt [Line Items]
Debt instrument, interest rate, stated percentage				6.875%
Debt instrument, maturity year				2028
Senior Secured Notes \| Senior Secured Notes at 4.75%, Due 2031
Extinguishment Of Debt [Line Items]
Debt instrument, interest rate, stated percentage		4.75%		4.75%	4.75%
Debt instrument, maturity year		2031		2031	2031
Junior-Priority Secured Notes \| Junior-Priority Secured Notes at 6.875% Due 2029
Extinguishment Of Debt [Line Items]
Debt instrument, interest rate, stated percentage			6.875%	6.875%	6.875%
Debt instrument, maturity year			2029	2029	2029
Junior-Priority Secured Notes \| Junior-Priority Secured Notes at 6.125% Due 2030
Extinguishment Of Debt [Line Items]
Debt instrument, interest rate, stated percentage	6.125%			6.125%	6.125%
Debt instrument, maturity year	2030			2030	2030

Long-Term Debt - Other Debt - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt And Capital Lease Obligations [Abstract]
Pre-tax gain from early extinguishment of debt	$ 253	$ (79)	$ 317
After-tax gain (loss) from extinguishment of debt	$ 208	$ (116)	$ 352

Long-Term Debt - ABL Facility - Additional Information (Details) - USD ($)		12 Months Ended
	Nov. 22, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Interest paid on borrowings		$ 835,000,000	$ 778,000,000	$ 1,039,000,000
Amended and Restated ABL Credit Agreement
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$ 1,000,000,000.0
Line of credit facility, excess availability		852,000,000
Line of credit outstanding amount		53,000,000
Aggregate principal amount for springing maturity	350,000,000
Amended and Restated ABL Credit Agreement \| ABL Facility Customary Covenants
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$ 95,000,000
Debt instrument variable interest rate	10.00%
Amended and Restated ABL Credit Agreement \| Minimum
Debt Instrument [Line Items]
Line of credit facility, unused capacity, commitment fee percentage	0.25%
Amended and Restated ABL Credit Agreement \| Maximum
Debt Instrument [Line Items]
Line of credit facility, unused capacity, commitment fee percentage	0.375%
Amended and Restated ABL Credit Agreement \| Base Rate
Debt Instrument [Line Items]
Percentage of the maximum commitment of excess availability, one	0.75%
Percentage of the maximum commitment of excess availability, two	1.00%
Percentage of the maximum commitment of excess availability, three	1.25%
Amended and Restated ABL Credit Agreement \| Federal Reserve’s Secured Overnight Financing Rate
Debt Instrument [Line Items]
Percentage of the maximum commitment of excess availability, one	1.75%
Percentage of the maximum commitment of excess availability, two	2.00%
Percentage of the maximum commitment of excess availability, three	2.25%
Letter of Credit \| Amended and Restated ABL Credit Agreement
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$ 200,000,000
Line of credit outstanding amount		$ 83,000,000

Long-Term Debt - Schedule of Maturities of Long-Term Debt (Details) $ in Millions	Dec. 31, 2022 USD ($)
Debt Disclosure [Abstract]
2023	$ 21
2024	15
2025	10
2026	2,163
2027	2,609
Thereafter	7,219
Total maturities	12,037
Less: Deferred debt issuance costs	(391)
Less: Unamortized note discount	(11)
Total long-term debt	$ 11,635

Fair Value of Financial Instruments - Schedule of Estimated Fair Value of Financial Instruments, by Balance Sheet Grouping (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Assets:
Available-for-sale debt securities	$ 179	$ 178
Carrying Amount
Assets:
Cash and cash equivalents	118	507
Investments in equity securities	107	144
Available-for-sale debt securities	179	178
Trading securities	5	13
Carrying Amount \| Senior Notes \| Senior Notes at 6.875% Due 2028
Liabilities:
Notes payable, fair value disclosure	749	759
Carrying Amount \| Senior Secured Notes \| Senior Secured Notes at 8%, Due 2026
Liabilities:
Notes payable, fair value disclosure	2,083	2,078
Carrying Amount \| Senior Secured Notes \| Senior Secured Notes at 8% Due 2027
Liabilities:
Notes payable, fair value disclosure	693	692
Carrying Amount \| Senior Secured Notes \| Senior Notes at 6% Due 2029
Liabilities:
Notes payable, fair value disclosure	865	860
Carrying Amount \| Senior Secured Notes \| Senior Secured Notes at 4.75%, Due 2031
Liabilities:
Notes payable, fair value disclosure	1,053	1,090
Carrying Amount \| Senior Secured Notes \| Senior Secured Notes at 6.625%, Due 2025
Liabilities:
Notes payable, fair value disclosure		1,434
Carrying Amount \| Senior Secured Notes \| Senior Secured Notes at 5.625% due 2027
Liabilities:
Notes payable, fair value disclosure	1,833	1,819
Carrying Amount \| Senior Secured Notes \| Senior Secured Notes 5.250%, Due 2030
Liabilities:
Notes payable, fair value disclosure	1,448
Carrying Amount \| Junior-Priority Secured Notes \| Junior-Priority Secured Notes at 6.875% Due 2029
Liabilities:
Notes payable, fair value disclosure	1,282	1,625
Carrying Amount \| Junior-Priority Secured Notes \| Junior-Priority Secured Notes at 6.125% Due 2030
Liabilities:
Notes payable, fair value disclosure	1,164	1,352
Carrying Amount \| ABL Facility and Other Debt
Liabilities:
Notes payable, fair value disclosure	85	32
Estimated Fair Value
Assets:
Cash and cash equivalents	118	507
Investments in equity securities	107	144
Available-for-sale debt securities	179	178
Trading securities	5	13
Estimated Fair Value \| Senior Notes \| Senior Notes at 6.875% Due 2028
Liabilities:
Notes payable, fair value disclosure	389	758
Estimated Fair Value \| Senior Secured Notes \| Senior Secured Notes at 8%, Due 2026
Liabilities:
Notes payable, fair value disclosure	1,917	2,210
Estimated Fair Value \| Senior Secured Notes \| Senior Secured Notes at 8% Due 2027
Liabilities:
Notes payable, fair value disclosure	631	758
Estimated Fair Value \| Senior Secured Notes \| Senior Notes at 6% Due 2029
Liabilities:
Notes payable, fair value disclosure	751	966
Estimated Fair Value \| Senior Secured Notes \| Senior Secured Notes at 4.75%, Due 2031
Liabilities:
Notes payable, fair value disclosure	766	1,108
Estimated Fair Value \| Senior Secured Notes \| Senior Secured Notes at 6.625%, Due 2025
Liabilities:
Notes payable, fair value disclosure		1,517
Estimated Fair Value \| Senior Secured Notes \| Senior Secured Notes at 5.625% due 2027
Liabilities:
Notes payable, fair value disclosure	1,633	2,011
Estimated Fair Value \| Senior Secured Notes \| Senior Secured Notes 5.250%, Due 2030
Liabilities:
Notes payable, fair value disclosure	1,166
Estimated Fair Value \| Junior-Priority Secured Notes \| Junior-Priority Secured Notes at 6.875% Due 2029
Liabilities:
Notes payable, fair value disclosure	720	1,823
Estimated Fair Value \| Junior-Priority Secured Notes \| Junior-Priority Secured Notes at 6.125% Due 2030
Liabilities:
Notes payable, fair value disclosure	615	1,431
Estimated Fair Value \| ABL Facility and Other Debt
Liabilities:
Notes payable, fair value disclosure	$ 85	$ 32

Fair Value - Additional Information (Details)	12 Months Ended
Fair Value - Additional Information (Details)	Dec. 31, 2022 USD ($) Item	Dec. 31, 2021 USD ($) Item	Dec. 31, 2020 USD ($)
Fair Value Disclosures [Line Items]
Fair value, assets, level 1 to level 2 transfers, amount	$ 0	$ 0
Fair value, assets, level 2 to level 1 transfers, amount	0	0
Fair value, liabilities, level 1 to level 2 transfers, amount	0	0
Fair value, liabilities, level 2 to level 1 transfers, amount	0	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	$ 169,000,000	$ 125,000,000
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions \| Item	348	281
Other Investment Income
Fair Value Disclosures [Line Items]
Investment Income, Interest and Dividend	$ 6,000,000	$ 5,000,000	$ 6,000,000
Available-for-sale Securities
Fair Value Disclosures [Line Items]
Other than Temporary Impairment, Credit Losses Recognized in Earnings, Credit Losses on Debt Securities Held	$ 0

Fair Value - Schedule of Fair Value, Assets Measured on Recurring Basis (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale debt securities	$ 179	$ 178
Fair Value, Measurements, Recurring
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments in equity securities	107	144
Available-for-sale debt securities	179	178
Trading securities	5	13
Total assets	291	335
Fair Value, Measurements, Recurring \| Fair Value, Inputs, Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments in equity securities	107	144
Total assets	107	144
Fair Value, Measurements, Recurring \| Fair Value, Inputs, Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale debt securities	179	178
Trading securities	5	13
Total assets	$ 184	$ 191

Fair Value - Supplemental Information Regarding Available-for-Sale Debt Securities (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 201	$ 179
Gross Unrealized Gains		1
Gross Unrealized Losses	(22)	(2)
Estimated Fair Value	179	178
Government
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	107	83
Gross Unrealized Gains		1
Gross Unrealized Losses	(11)	(1)
Estimated Fair Value	96	83
Corporate
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	69	62
Gross Unrealized Losses	(9)	(1)
Estimated Fair Value	60	61
Mortgage and Asset-Backed Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	25	34
Gross Unrealized Losses	(2)
Estimated Fair Value	$ 23	$ 34

Fair Value - Contractual Maturities of Debt Securities (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Within 1 year, Amortized Cost	$ 13	$ 8
After 1 year and through year 5, Amortized Cost	74	61
After 5 years and through year 10, Amortized Cost	56	49
After 10 years, Amortized Cost	58	61
Within 1 year, Fair Value	13	8
After 1 year and through year 5, Fair Value	70	61
After 5 years and through year 10, Fair Value	48	49
After 10 years, Fair Value	$ 48	$ 60

Fair Value - Gross Realized Gains and Losses and Investment Income on Available-for-Sale Debt Securities (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Realized gains		$ 1	$ 2
Realized losses	$ (2)	$ (1)	$ (1)

Fair Value - Net Gains and Losses Recognized for Investments in Equity Securities (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Net (losses) and gains recognized during the year on equity securities	$ (28)	$ 20	$ 9
Available-for-sale Securities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Net (losses) and gains recognized during the year on equity securities	(2)	13	14
Held-to-maturity Securities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Unrealized (losses) and gains recognized during the year on equity securities held at the end of year	$ (26)	$ 7	$ (5)

Leases - Components of Lease Cost and Rent Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease cost	$ 211	$ 196	$ 203
Short-term rent expense	87	92	104
Variable lease cost	24	25	26
Sublease income	(5)	(5)	(6)
Total operating lease cost	317	308	327
Finance lease cost:
Amortization of ROU assets	13	9	10
Interest on finance lease liabilities	15	9	8
Total finance lease cost	$ 28	$ 18	$ 18

Leases - Supplemental Balance Sheet Information Related to Leases (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Operating Leases:
Operating Lease ROU Assets	$ 738	$ 668
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets, net of accumulated amortization of $1,392 and $1,216 at December 31, 2022 and 2021, respectively	Other assets, net of accumulated amortization of $1,392 and $1,216 at December 31, 2022 and 2021, respectively
Finance Leases:
Property and equipment	$ 9,639	$ 9,757
Less accumulated depreciation and amortization	(4,274)	(4,204)
Property and equipment, net	5,365	5,553
Current finance lease liabilities	$ 3	$ 8
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Current maturities of long-term debt	Current maturities of long-term debt
Long-term finance lease liabilities	$ 220	$ 233
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Long-term debt	Long-term debt
Finance Lease ROU Assets
Finance Leases:
Property and equipment	$ 273	$ 314
Less accumulated depreciation and amortization	(56)	(54)
Property and equipment, net	217	260
Finance Lease ROU Assets \| Land and Improvements
Finance Leases:
Property and equipment		8
Finance Lease ROU Assets \| Building and Improvements
Finance Leases:
Property and equipment	261	289
Finance Lease ROU Assets \| Equipment and Fixtures
Finance Leases:
Property and equipment	$ 12	$ 17

Leases - Supplemental Cash Flow and Other Information Related to Leases (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases	$ 204	$ 197	$ 188
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases	15	9	8
Cash paid for amounts included in the measurement of lease liabilities: Financing cash flows from finance leases	9	4	7
ROU assets obtained in exchange for new finance lease liabilities	42	166	22
ROU assets obtained in exchange for new operating lease liabilities	$ 195	$ 143	$ 150
Weighted-average remaining lease term: Operating leases	8 years	6 years	7 years
Weighted-average remaining lease term: Finance leases	31 years	30 years	19 years
Weighted-average discount rate: Operating leases	8.00%	8.10%	9.00%
Weighted-average discount rate: Finance leases	6.40%	6.30%	8.40%

Leases - Commitments Relating to Noncancellable Lease Obligations (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Operating Leases
2023	$ 205
2024	157
2025	126
2026	102
2027	76
Thereafter	385
Total minimum future payments	1,051
Less: Imputed interest	(298)
Total liabilities	753
Less: Current portion	(148)	$ (147)
Long-term liabilities	605	535
Finance Leases
2023	16
2024	16
2025	15
2026	16
2027	16
Thereafter	488
Total minimum future payments	567
Less: Imputed interest	(344)
Total liabilities	223
Less: Current portion	(3)	(8)
Long-term liabilities	220	$ 233
Financing Obligations
2023	13
2024	13
2025	13
2026	13
2027	14
Thereafter	75
Total minimum future payments	141
Less: Imputed interest	16
Total liabilities	157
Less: Current portion	(3)
Long-term liabilities	$ 154

Leases - Additional Information (Details) $ in Millions	Dec. 31, 2022 USD ($)
Leases [Abstract]
Operating lease right of use asset pending leases that have not yet commenced	$ 28

Employee Benefit Plans - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Defined Contribution Plan, Cost Recognized	$ 70,000,000	$ 65,000,000	$ 74,000,000
Liability for deferred compensation plans	127,000,000	175,000,000
Defined benefit plan, noncash settlement loss	0	$ 0	0
Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Accrued benefits liabilities	$ 2,000,000
Defined benefit plans and other post-retirement plans, weighted-average assumptions to determine net periodic cost, discount rates	2.80%	2.50%
Expected long-term rates of return on assets	4.30%	5.50%
Pension Plans, Defined Benefit [Member] \| Maximum
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit cost	$ 1,000,000	$ 1,000,000	1,000,000
Accrued benefits liabilities		1,000,000
Settlement charge		1,000,000
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Settlement Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Salaries and benefits
Deferred Compensation Plans Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Liability for deferred compensation plans	$ 46,000,000	81,000,000
Deferred Compensation Company-Owned Life Insurance Contracts [Member]
Defined Benefit Plan Disclosure [Line Items]
Liability for deferred compensation plans	135,000,000	167,000,000
Trust for Benefit of Employees [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan assets designated to pay benefits of the deferred compensation plans	181,000,000	248,000,000
Supplemental Employee Retirement Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit cost	11,000,000	11,000,000	$ 7,000,000
Accrued benefits liabilities	$ 91,000,000	$ 99,000,000
Defined benefit plans and other post-retirement plans, weighted-average assumptions to determine net periodic cost, discount rates	2.70%	2.70%
Defined benefit plans and other post-retirement plans, weighted-average assumptions to determine net periodic cost, rate of compensation increase	3.00%	3.00%

Stockholders' Deficit - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Equity [Abstract]
Capital stock, shares authorized	400,000,000
Common stock, shares authorized	300,000,000	300,000,000
Preferred stock, shares authorized	100,000,000	100,000,000
Common stock, par value per share	$ 0.01	$ 0.01
Preferred stock, par value per share	$ 0.01	$ 0.01
Preferred stock, shares outstanding	0
Amount available for dividend payments, stock repurchases at period end	$ 300

Stockholders' Deficit - Schedule of Impact of Noncontrolling Interest to Stockholders' Deficit (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Net income attributable to Community Health Systems,Inc. stockholders	$ 46	$ 230	$ 511
Net (decrease) increase in Community Health Systems,Inc. paid-in-capital for purchase of subsidiary partnership interests	(6)	17	3
Net transfers to the noncontrolling interests	(6)	17	3
Change to Community Health Systems, Inc. stockholders' deficit from net income attributable to Community Health Systems, Inc. stockholders and transfers to noncontrolling interests	$ 40	$ 247	$ 514

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

Earnings Per Share - Schedule of Components of Denominator for Computation of Basic and Diluted Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Effect of dilutive securities:
Weighted-average number of shares outstanding — basic	128,808,387	126,754,852	115,491,022
Restricted stock awards	842,055	2,803,938	905,903
Employee stock options	278,057	726,130	122,785
Other equity-based awards	131,820	312,490	24,851
Weighted-average number of shares outstanding — diluted	130,060,319	130,597,410	116,544,561

Earnings Per Share - Schedule of Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Employee stock options and restricted stock awards excluded from computation of earnings per share amount	4,406,764	774,981	2,821,511

Equity Investments - Additional Information (Details) $ in Millions		12 Months Ended				72 Months Ended
	Jul. 30, 2021 USD ($) Hospital	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2016	Dec. 31, 2022 USD ($)
Schedule Of Equity Method Investments [Line Items]
Proceeds from sale of unconsolidated minority equity interests			$ 110
Distribution of CoreTrust proceeds		$ 121
Gain from CoreTrust transaction		119
Equity method investment		155	129			$ 155
Equity in earnings of unconsolidated affiliates		14	$ 22	$ 10
CoreTrust Holdings, LLC [Member]
Schedule Of Equity Method Investments [Line Items]
Gain from CoreTrust transaction		$ 119
Home Care [Member]
Schedule Of Equity Method Investments [Line Items]
Disposal date		Dec. 31, 2016
Percentage of ownership interest sold					80.00%	20.00%
Equity method investment ownership percentage					80.00%
HealthTrust [Member]
Schedule Of Equity Method Investments [Line Items]
Equity method investment ownership percentage		13.30%				13.30%
Two Hospitals in Macon Georgia
Schedule Of Equity Method Investments [Line Items]
Disposal date			Jul. 30, 2021
Number of hospitals sold \| Hospital	2
Percentage of ownership interest sold	38.00%
Proceeds from sale of unconsolidated minority equity interests	$ 110
Pre tax gain on sale of investments			$ 39

Comprehensive Loss - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) ("AOCL") by Component (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income Loss [Line Items]
AOCL, Beginning Balance	$ (14)	$ (13)
Other comprehensive (loss) income before reclassifications	(6)
Amounts reclassified from AOCL	(1)	(2)
Other comprehensive loss	(7)	(2)	$ (4)
AOCL, Ending Balance	(21)	(14)	(13)
Change in Fair Value of Available for Sale Debt Securities
Accumulated Other Comprehensive Income Loss [Line Items]
AOCL, Beginning Balance	(2)	2
Other comprehensive (loss) income before reclassifications	(16)	(1)
Amounts reclassified from AOCL	(1)	(4)
Other comprehensive loss	(17)	(5)
AOCL, Ending Balance	(19)	(2)	2
Change in Unrecognized Pension Cost Components
Accumulated Other Comprehensive Income Loss [Line Items]
AOCL, Beginning Balance	(12)	(15)
Other comprehensive (loss) income before reclassifications	10	1
Amounts reclassified from AOCL		2
Other comprehensive loss	10	3
AOCL, Ending Balance	$ (2)	$ (12)	$ (15)

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References + Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

Comprehensive Loss - Schedule of Amounts Reclassified Out of AOCL (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Reclassification, net of tax	$ 1	$ 2
Pension Plans, Defined Benefit [Member]
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Reclassification, Total before tax	(1)	(2)
Reclassification, net of tax	(1)	(2)
Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member] \| Pension Plans, Defined Benefit [Member]
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Reclassification, Total before tax	$ (1)	$ (2)

Commitments and Contingencies - Additional Information (Details) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Commitments And Contingencies [Line Items]
Physician recruiting commitment, physician income guarantee period			12 months
Physician recruiting commitment, period of recoverability of physician income guarantee for noncommitment			3 years
Physician recruiting commitment, maximum potential future payments in excess of liability recorded	$ 6,000,000		$ 6,000,000
Malpractice Loss Contingency, Discount Rate			3.80%	1.80%	1.80%
Malpractice Loss Contingency, Accrual, Discounted	467,000,000	$ 533,000,000	$ 467,000,000	$ 533,000,000
Malpractice Loss Contingency, Accrual, Undiscounted	516,000,000	564,000,000	516,000,000	564,000,000
Malpractice Loss Contingency, Accrual, Discounted, Current	159,000,000	162,000,000	159,000,000	162,000,000
Expenses related to settlement of professional liability claim					$ 50,000,000
Recovery of full settlement amount					$ 50,000,000
Recovery from third-party insurers of professional liability claim		$ 22,000,000
Change in estimate reserve for professional liability claims			0	$ 0
Change in estimate for professional liability claims	$ 15,000,000		15,000,000
Professional and general liability self-insured claims reported prior to June 1, 2002, per occurrence [Member]
Commitments And Contingencies [Line Items]
Malpractice loss contingency, self-insured retention			1,000,000
Professional and general liability self-insured reported from June 1, 2002 through June 1, 2003, per occurrence [Member]
Commitments And Contingencies [Line Items]
Malpractice loss contingency, self-insured retention			2,000,000
Professional and general liability self-insured reported from June 1, 2003 and before June 1, 2005, per occurrence [Member]
Commitments And Contingencies [Line Items]
Malpractice loss contingency, self-insured retention			4,000,000
Professional and general liability self-insured claims reported on or after June 1, 2005, per occurrence [Member]
Commitments And Contingencies [Line Items]
Malpractice loss contingency, self-insured retention			5,000,000
Professional and general liability claims reported on or after June 1, 2014 [Member]
Commitments And Contingencies [Line Items]
Malpractice loss contingency, self-insured retention			10,000,000
Professional and general liability claims reported on or after June 1, 2003 [Member]
Commitments And Contingencies [Line Items]
Malpractice Insurance, Maximum Coverage Per Incident			95,000,000
Professional and general liability claims incurred and reported after January 1, 2008 [Member]
Commitments And Contingencies [Line Items]
Malpractice Insurance, Maximum Coverage Per Incident			145,000,000
Professional and general liability claims incurred and reported after June 1, 2010 [Member]
Commitments And Contingencies [Line Items]
Malpractice Insurance, Maximum Coverage Per Incident			195,000,000
Professional and general liability claims reported on or after June 1, 2015 [Member]
Commitments And Contingencies [Line Items]
Malpractice Insurance, Maximum Coverage Per Incident			216,000,000
Integrated professional liability claims reported on or after June1 2014 [Member]
Commitments And Contingencies [Line Items]
Malpractice Insurance, Annual Coverage Limit			50,000,000
Integrated occurrence claims reported on or after June 1, 2015 through June 1, 2020 [Member]
Commitments And Contingencies [Line Items]
Malpractice Insurance, Annual Coverage Limit			75,000,000
Integrated occurrence claims reported between June 1,2020 and June 1,2023 [Member]
Commitments And Contingencies [Line Items]
Malpractice Insurance, Annual Coverage Limit			75,000,000
Professional and general liability self-insured claims under certain policy terms until Company total aggregate coverage is met if first aggregate layer becomes fully utilized [Member]
Commitments And Contingencies [Line Items]
Malpractice loss contingency, self-insured retention			$ 10,000,000
Maximum
Commitments And Contingencies [Line Items]
Malpractice loss contingency, average lag period from occurrence to settlement			4 years
Malpractice loss contingency, settled claims as percent of total liability			7.00%
Malpractice loss contingency, self-insured retention			$ 15,000,000
Maximum \| Professional And General Liability Claims Incurred And Reported On Or After June 1, 2008 [Member]
Commitments And Contingencies [Line Items]
Malpractice loss contingency, self-insured retention			$ 15,000,000
Minimum
Commitments And Contingencies [Line Items]
Malpractice loss contingency, average lag period from occurrence to settlement			3 years
Malpractice loss contingency, self-insured retention			$ 10,000,000
Minimum \| Professional and general liability self-insured claims under certain policy terms until Company total aggregate coverage is met if first aggregate layer becomes fully utilized [Member]
Commitments And Contingencies [Line Items]
Malpractice loss contingency, self-insured retention			$ 15,000,000
Northwest Health – Starke [Member]
Commitments And Contingencies [Line Items]
Capital commitment, future period after acquisition for completing open capital improvement projects date			Sep. 30, 2026
Northwest Health – Starke [Member] \| Maximum
Commitments And Contingencies [Line Items]
Capital commitment, future period after acquisition for completing open capital improvement projects			5 years

Commitments and Contingencies - Schedule of Reconciliation of the Beginning and Ending Liability Balances in Connection with Probable Contingencies (Details) - Pending Litigation [Member] - Other Probable Contingencies [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Loss Contingency Accrual [Roll Forward]
Beginning Balance	$ 20	$ 11
Expense	8	11
Reserve for insured claim		(1)
Cash payments	(17)	(1)
Ending Balance	$ 11	$ 20

Subsequent Events - Additional Information (Details) - Greenbrier Valley Medical Center - Subsequent Event $ in Millions	Jan. 01, 2023 USD ($) Bed
Subsequent Event [Line Items]
Number of licensed beds \| Bed	122
Proceeds from sale of afiliates assets \| $	$ 85

Condensed Financial Information of Parent - Condensed Balance Sheets (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
ASSETS
Prepaid income taxes	$ 99	$ 94
Total current assets	3,082	3,479
Deferred income taxes	49	53
Other assets, net	2,007	1,913
Total assets	14,669	15,217
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Deferred income taxes	354	192
Other long-term liabilities	644	827
Total liabilities	15,403	16,027
Community Health Systems, Inc. stockholders’ deficit:
Preferred stock
Common stock	1	1
Additional paid-in capital	2,084	2,118
Accumulated other comprehensive loss	(21)	(14)	$ (13)
Accumulated deficit	(3,431)	(3,477)
Total Community Health Systems, Inc. stockholders’ deficit	(1,367)	(1,372)
Total liabilities and stockholders' deficit	14,669	15,217
Parent Company
ASSETS
Prepaid income taxes	99	94
Total current assets	99	94
Deferred income taxes	49	53
Total assets	148	147
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Intercompany payable	1,159	1,326
Deferred income taxes	354	192
Other long-term liabilities	2	1
Total liabilities	1,515	1,519
Community Health Systems, Inc. stockholders’ deficit:
Preferred stock
Common stock	1	1
Additional paid-in capital	2,084	2,118
Accumulated other comprehensive loss	(21)	(14)
Accumulated deficit	(3,431)	(3,477)
Total Community Health Systems, Inc. stockholders’ deficit	(1,367)	(1,372)
Total liabilities and stockholders' deficit	$ 148	$ 147

Condensed Financial Information of Parent - Condensed Statement of Income (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Condensed Income Statements Captions [Line Items]
Net operating revenues	$ 12,211	$ 12,368	$ 11,789
Operating costs and expenses:
Salaries and benefits	5,330	5,242	5,411
Supplies	1,975	2,042	1,963
Other operating expenses	3,336	2,958	2,957
Pandemic relief funds	(173)	(148)	(601)
Depreciation and amortization	534	540	558
Impairment and (gain) loss on sale of businesses, net	71	24	48
Total operating costs and expenses	11,390	10,966	10,663
Income from operations	821	1,402	1,126
Interest expense, net	858	885	1,031
Gain (loss) on early extinguishment of debt	253	(79)	317
Income before income taxes	349	499	422
Provision for (benefit from) income taxes	170	131	(185)
Net income	179	368	607
Less: Net income attributable to noncontrolling interests	133	138	96
Net income attributable to Community Health Systems, Inc. stockholders	46	230	511
Parent Company
Operating costs and expenses:
Equity in earnings of unconsolidated affiliates	(46)	(230)	(511)
Income before income taxes	46	230	511
Net income	46	230	511
Net income attributable to Community Health Systems, Inc. stockholders	$ 46	$ 230	$ 511

Condensed Financial Information of Parent - Condensed Statements of Comprehensive Income (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Condensed Statement Of Income Captions [Line Items]
Net income	$ 179	$ 368	$ 607
Equity in other comprehensive (loss) income of affiliates, net of income taxes:
Net change in fair value of interest rate swaps, net of tax			(1)
Net change in fair value of available-for-sale debt securities, net of tax	(17)	(5)	4
Amortization and recognition of unrecognized pension cost components, net of tax	10	3	(7)
Other comprehensive loss	(7)	(2)	(4)
Comprehensive income	172	366	603
Less: Comprehensive income attributable to noncontrolling interests	133	138	96
Comprehensive income attributable to Community Health Systems, Inc. stockholders	39	228	507
Parent Company
Condensed Statement Of Income Captions [Line Items]
Net income	46	230	511
Equity in other comprehensive (loss) income of affiliates, net of income taxes:
Net change in fair value of interest rate swaps, net of tax			(1)
Net change in fair value of available-for-sale debt securities, net of tax	(17)	(5)	4
Amortization and recognition of unrecognized pension cost components, net of tax	10	3	(7)
Other comprehensive loss	(7)	(2)	(4)
Comprehensive income	39	228	507
Comprehensive income attributable to Community Health Systems, Inc. stockholders	$ 39	$ 228	$ 507

Condensed Financial Information of Parent - Condensed Statement of Cash Flows (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net cash used in operating activities	$ 300	$ (131)	$ 2,178
Cash flows from investing activities:
Net cash provided by (used in) investing activities	(259)	(524)	177
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll tax withholding requirements	(8)	(5)	(1)
Net cash provided by financing activities	(430)	(514)	(895)
Net change in cash and cash equivalents	(389)	(1,169)	1,460
Cash and cash equivalents at beginning of period	118	507	1,676	$ 216
Parent Company
Cash flows from operating activities:
Net cash used in operating activities	(13)	(11)	(12)
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll tax withholding requirements	(8)	(5)	(1)
Changes in intercompany balances with affiliates, net	21	16	13
Net cash provided by financing activities	$ 13	$ 11	$ 12